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ABSTRACT 
A fraction of the body’s creatine and creatine-phosphate spontaneously degrades to 
creatinine, which is excreted by the kidneys.  In humans, this amounts to about 1-2 g per 
day and demands a comparable rate of de novo creatine synthesis.  This is a two-step 
process in which L-arginine:glycine amidinotransferase (AGAT) catalyzes the conversion 
of glycine and arginine to ornithine and guanidinoacetate (GAA); guanidinoacetate 
methyltransferase (GAMT) then catalyzes the SAM-dependent methylation of GAA to 
creatine.  AGAT is found in the kidney and GAMT in the liver, which implies an inter-
organ movement of GAA from the kidney to the liver.  We have studied the renal 
production of this metabolite in both rats and humans.  In control rats, [GAA] was 5.9 µM 
in arterial plasma and 10.9 µM in renal venous plasma for a renal A-V difference of –5.0 
µM.  In the rat, infusion of arginine or citrulline markedly increased renal GAA 
production but infusion of glycine did not.  Rats fed 0.4% creatine in their diet had 
decreased renal AGAT activity and mRNA, and arterial plasma [GAA] of 1.5 µM and a 
decreased renal A-V difference for GAA of –0.9 µM.  In humans, [GAA] was 2.4 µM in 
arterial plasma, with a renal A-V difference of -1.1 µM.  These studies show, for the first 
time, that GAA is produced by both rat and human kidneys in vivo. 
Creatine is essential for normal neural development; children with inborn errors of 
creatine synthesis or transport exhibit neurological symptoms such as mental retardation, 
speech delay, and epilepsy.  Creatine accretion may occur through dietary intake or de 
novo creatine synthesis.  The objective of this study is to determine how much creatine an 
infant must synthesize de novo.  We have calculated how much creatine an infant needs to 
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account for urinary creatinine excretion (creatine’s breakdown product) and new muscle 
lay-down.  To measure an infant’s dietary creatine intake, we measured creatine in 
mother’s milk and in various commercially available infant formulas.  Knowing the 
amount of milk/formula ingested, we calculated the amount of creatine ingested.  We 
have found that a breast-fed infant receives about 9% of the creatine needed in the diet 
and that infants fed cow’s milk-based formula receive up to 36% of the creatine needed.  
However, infants fed a soy-based infant formula receive negligible dietary creatine and 
must rely solely on de novo creatine synthesis.  This is the first time that it has been 
shown that neonatal creatine accretion is largely due to de novo synthesis and not through 
dietary intake of creatine.  This has important implications both for infants suffering from 
creatine deficiency syndromes and for neonatal amino acid metabolism.   
Approximately 1.7% of the body’s creatine pool is spontaneously converted to creatinine 
each day and excreted in the urine. This loss must be replaced by a combination of diet 
and synthesis.  During lactation there may be an additional requirement due to the 
provision of creatine to the milk.  Our objectives were (i) to quantify milk creatine in 
lactating rats, (ii) to determine the origin of milk creatine, (iii) to determine the activities 
of the enzymes of creatine synthesis in lactating rats and suckling pups and (iv) to 
quantify the origin of the creatine that accumulates in suckling rat pups. The origin of 
milk creatine was determined by administering 
14
C-creatine to lactating rats, followed by 
determination of its isotopic enrichment in milk and plasma.  These experiments indicate 
that the mammary gland extracts creatine from the circulation, rather than synthesising it. 
This was confirmed by our failure to find significant activities of the enzymes of creatine 
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synthesis in mammary glands. The provision of milk creatine requires an additional 35-
55% of creatine above the daily requirement by lactating mothers. However, there was no 
increased creatine synthesis by these dams, so that the additional creatine was largely 
provided by hyperphagia, as creatine is present in rat chow. There was substantial 
accumulation of creatine in the growing pups but only approximately 12 % was obtained 
from milk. The great bulk of creatine accretion was via de novo synthesis by the pups, 
which imposed a substantial metabolic burden on them. 
  
v 
 
DEDICATION 
 
This thesis is dedicated to the memory of Mrs. Beatrice Hall, a strong woman who truly 
loved her job and could work “like a Bayman with two woodstoves” to make a batch of 
“happy hepatocytes” in record time.  There was no problem too big for her to tackle.  She 
may have “sputtered” about technical difficulties but she always finished every job with 
precision.  She certainly had an influence on everyone she met; she was a devoted wife, a 
loving mother, a hard-working and dedicated scientist and a true friend.  She was my 
“mom away from home” and I miss her.  Bea, you will never be forgotten.  I wish you 
were here to read through these pages. 
  
vi 
 
ACKNOWLEDGEMENTS 
 
An enormous debt is owed to my co-supervisors, Drs. Sean and Margaret Brosnan.  You 
have provided much guidance in the creation of this project, a guidance that goes beyond 
expectation.  You have both provided academic and social support and I am thankful for 
you.  Many thanks to other co-workers at Memorial University of Newfoundland: Dr. 
Robert Bertolo (my supervisory committee member), Dr. Shobhitha Ratnam, Dr. Simon 
Lamarre, Dr. Robin da Silva, Dr. Enoka Wijekoon, Dr. Edward Randell, Mrs. Donna 
Hunt and Mr. Barry Walters. 
Financial support for this research has been provided by grants from the Canadian 
Institutes of Health Research and the Janeway Research Foundation.  The material in 
Chapter 2 is based on work supported in part by the Office of Research and 
Development, Department of Veterans Affairs. 
To Dr. David Craig and the Psychiatry Residency Program at Memorial University of 
Newfoundland, I thank you for the opportunity to complete this thesis while jointly 
completing my residency in psychiatry.  You have enabled me to achieve goals which I 
never dreamed possible.  
Last and certainly not least, I wish to extend a special thanks to my family and friends 
who have supported me in past endeavors and will continue to support me in the future.  
Russell, Samson and Emma, you have kept me grounded and in the moment.  You have 
always been understanding when job demands are high.  I appreciate our time together 
vii 
 
and hope you know that I cherish every moment.  My parents, Eric and Venus, you have 
supported me in every goal that I have set.  You have watched me meet many of these 
goals and I know that you will be there to watch me meet many more.  My brother, 
Adam, you have been a best friend to me and your down to earth opinion has always 
guided my decisions.  Thank you all so much for your support. 
  
viii 
 
TABLE OF CONTENTS 
Abstract          ii 
Dedication          v 
Acknowledgements         vi 
Table of Contents         viii 
List of Tables          xiv 
List of Figures         xv 
List of Abbreviations        xviii 
List of Appendices         xxi 
 
Chapter 1 –  Introduction and Overview      1 
1.1. Functions of Creatine and Creatine Phosphate    2 
1.1.1. The Energy Buffer Theory      3 
1.1.2. The Energy Shuttle Theory      4 
1.2. Creatine as a Sports Nutraceutical      7 
1.3. Need for Creatine Synthesis       12 
1.3.1. Creatine Balance       13 
1.4. Synthesis of Creatine        14 
1.4.1. Pathway of Creatine Synthesis     14 
1.4.1.1. L-Arginine:Glycine Amidinotransferase (AGAT)  15 
1.4.1.2.  Guanidinoacetate Methyltransferase (GAMT)  18 
1.4.2. Creatine Transporter       19 
1.4.3. Tissues Responsible for Creatine Synthesis    20 
ix 
 
1.4.4. Regulation of Creatine Synthesis     23 
1.5. Quantitative Aspects of Creatine Synthesis     25 
1.5.1. Demand for Amino Acids      26 
1.5.2. Creatine Synthesis makes a Large Demand for Amino Acids  
in Infants        28 
1.6. Mammary Gland Physiology       29 
1.6.1. Milk Production and Secretion     30 
1.7. Pathology – Creatine Deficiency Diseases     32 
1.7.1. L-Arginine:Glycine Amidinotransferase (AGAT) Deficiency 32 
1.7.2. Guanidinoacetate Methyltransferase (GAMT) Deficiency  33 
1.7.3. Creatine Transporter (SLC6A8) Deficiency    34 
1.8. Statement of Problem        35 
1.8.1. Pathway and Regulation of Creatine Synthesis   36 
1.8.2. Creatine Synthesis in the Neonate     36 
 
Co-authorship Statement        37 
 
Chapter 2 – Creatine Synthesis: production of guanidinoacetate by the  
rat and human kidney (published in Am J Physiol 293,  
F1799-F1804, 2007)       40 
2.1. Abstract         42 
2.2. Introduction         43 
2.3. Materials and Methods       45 
x 
 
2.4. Results          49 
2.5. Discussion         56 
2.6. Acknowledgements        61 
2.7. Grants          61 
2.8. References         61 
 
Chapter 3 –  Creatine and Guanidinoacetate Content of Human Milk  
and Infant Formulas: Implications for Creatine Deficiency  
Syndromes and Amino Acid Metabolism (published in  
Brit J Nutr, 110, 1075-1078, 2013)     66 
3.1. Abstract         68 
3.2. Introduction         69 
3.3. Experimental Methods       70 
3.4. Results and Discussion       71 
3.5. Acknowledgements        79 
3.6. References         79 
 
Chapter 4 –  Suckling Rat Pups Accumulate Creatine primarily via  
de Novo Synthesis rather than from Dam Milk (published  
in J Nutr 140, 1570-1573, 2010)     83 
4.1. Abstract         85 
4.2. Introduction         86 
4.3. Materials and Methods       87 
xi 
 
4.4. Results         91 
4.5. Discussion         93 
4.6. Acknowledgements        99 
4.7. Footnotes         100 
4.8. Literature Cited        100 
 
Chapter 5 –  General Discussion and Conclusions    104 
5.1. Renal Guanidinoacetate Production In Vivo     105 
5.2. Effect of Creatine Feeding on GAA Production    107 
5.3. Role of Substrate Supply in GAA Synthesis     108 
5.4. Importance of Creatine Intake to Infants     111 
5.5. Creatine Balance in Infants       112 
5.6. How much Creatine is Provided to the Infant via the Diet?   113 
5.6.1. Role of the Mammary Gland in Provision of Neonatal Creatine 113 
5.6.2. Role of Dietary Intake in Provision of Creatine in Formula-fed  
Infants         116 
5.7. Metabolic Burden of de Novo Creatine Biosynthesis in Infants  118 
5.8. Conclusions         122 
 
References          124 
 
xii 
 
Appendix A:  New Insights into Creatine Function and Synthesis  
(published in Adv Enzyme Regul 47, 252-260, 2007)   141 
A.1. Introduction         143 
 A.1.1. Creatine Function       143 
 A.1.2. Creatine Loss and Replacement     146 
 A.1.3. Creatine Synthesis and Transport     147 
 A.1.4. Inborn Errors of Creatine Synthesis and Transport   149 
 A.1.5. Creatine Synthesis in the Rat      151 
 A.1.6. Creatine Synthesis and Homocysteine    154 
  A.1.7. Perspective        156 
A.2. Summary         158 
A.3. Acknowledgements        158 
A.4. References         159 
 
Appendix B – Materials and Methods      163 
B.1. Chemicals         164 
B.2. Animal Handling        164 
B.2.1. Urine and Feces Collection      165 
B.3. Experimental Diets        165 
B.4. Tissue Preparation        165 
B.4.1. Plasma Preparation       167 
B.4.2. Kidney Preparation       167 
B.5. Plasma Analysis        167 
xiii 
 
B.5.1. Plasma Guanidinoacetate Analysis     169 
B.5.2. Plasma Creatine Analysis      170 
B.5.3. Plasma Creatinine Analysis      173 
B.5.4. Plasma Amino Acid Analysis      173 
B.6. Kidney Analysis        176 
B.6.1. L-Arginine:Glycine Amidinotransferase Activity   180 
B.6.2. RT-PCR Analysis of L-Arginine:Glycine Amidinotransferase 
 mRNA        181 
B.7. Urine Analysis        184 
B.8. Infant Formula Analysis       184 
B.9. Human Milk Collection and Analysis     186 
B.10. Human Umbilical Cord Blood Collection and Analysis   186 
B.11. Lactating Rat Studies        187 
B.11.1. In vivo GAA production, milk and plasma creatine concentration, 
 and renal AGAT activity      188 
B.11.2. Hepatic GAMT Activity      188 
B.11.3. Determination of Creatine Specific Radioactivity   191 
B.11.4. Creatine Content of Adult Tissues and Pups    192 
B.12. Statistical Analysis        192 
 
  
xiv 
 
LIST OF TABLES 
 
Chapter 2 -  Creatine Synthesis: production of guanidinoacetate  
by the rat and human kidney 
2.1. Renal Metabolism of Guanidinoacetate (GAA) and Creatinine  
in Humans         53 
2.2. Plasma Amino Acid Levels following Infusion of Various  
Substrates in Rats        54 
   
Chapter 3 –  Creatine and Guanidinoacetate Content of Human Milk  
and Infant Formulas: Implications for Creatine  
Deficiency Syndromes and Amino Acid Metabolism 
3.1. Creatine and Guanidinoacetate Concentrations in Various Infant  
Formulas         73 
 
Chapter 4 –  Suckling Rat Pups Accumulate Creatine primarily via  
de Novo Synthesis rather than from Dam Milk 
4.1. Renal GAA Output in Lactating and Virgin Rats    95 
 
Appendix B – Materials and Methods 
B.1. Experimental Diet Composition      166 
B.2. Prime and Infusate Concentrations      168 
B.3. Infant Formula Information       185 
xv 
 
LIST OF FIGURES 
 
Chapter 1 -  Introduction 
1.1. The Energy Shuttle Theory of Creatine Function    6 
1.2. Creatine Synthesis        16 
1.3. Creatine Biosynthesis and Proposed Interorgan Metabolism   22 
 
Chapter 2 –  Creatine Synthesis: production of guanidinoacetate by the  
rat and human kidney 
2.1. Effect of Creatine Feeding on Renal Guanidinoacetate (GAA)  
Production and L-Arginine:Glycine Amidinotransferase (AGAT)  
Activity and mRNA Expression in Rats     50 
2.2. Creatinine Excretion vs. Guanidinoacetate (GAA) Production  
by the Kidneys of Rats fed the control (creatine-free) diet   52   
2.3. Total Renal Production of Guanidinoacetate (GAA) in Rats Infused  
with Various Substrates       55 
 
Chapter 3 –  Creatine and Guanidinoacetate Content of Human Milk  
and Infant Formulas: Implications for Creatine Deficiency  
Syndromes and Amino Acid Metabolism 
3.1. Concentrations of Creatine and Guanidinoacetate (GAA) in Human  
Milk and Plasma        72 
3.2.  Creatine (Cr) Synthesis       77 
xvi 
 
 
Chapter 4 –  Suckling Rat Pups Accumulate Creatine primarily via  
de Novo Synthesis rather than from Dam Milk 
4.1. Isotopic Enrichment of Creatine in Plasma and Milk of 4 Lactating  
Rats          92 
4.2. Arterial (A) and Venous (V) Plasma GAA Concentrations and  
Renal A-V Differences in Lactating and Virgin Females   94 
4.3. Total Body Creatine Content in Rat Pups at d 10, 15 and 20 of Age  96 
 
Appendix A: New Insights into Creatine Function and Synthesis 
A.1. Mitochondrial-Cytoplasmic Interactions in Creatine Function  144 
A.2. Pathway of Creatine Synthesis      148 
A.3. Inter-Organ Pathway for Creatine Synthesis in the Rat   152 
A.4. Effect of Dietary GAA and Creatine Supplementation on Total  
Plasma Homocysteine and Methionine Levels    155 
 
Appendix B – Materials and Methods 
B.1. Sample Chromatogram of GAA as measured via HPLC   171 
B.2. Standard Curve of GAA detection via HPLC    172 
B.3. Standard Curve of Creatine detection via Spectrophotometry  174 
B.4. Standard Curve of Creatinine detection via Cayman Chemical kit  175 
B.5. Sample Chromatogram of Amino Acids as measured via HPLC  177 
B.6. Amino Acid Standard Curves       178 
xvii 
 
B.7. Dependence of L-arginine:glycine Amidinotransferase Activity on  
Amount of Kidney and Incubation Time     182 
B.8. Standard Curve of Ornithine detection by 6% Ninhydrin   183 
B.9. Dependence of Guanidinoacetate Methyltransferase Activity on  
Amount of Protein and Incubation Time     190 
  
xviii 
 
LIST OF ABBREVIATIONS: 
 
A – arterial 
 
AGAT – L-arginine:glycine amidinotransferase 
 
ANOVA – analysis of variance 
 
ASL – argininosuccinate lyase 
 
ASS – argininosuccinate synthase 
 
A-V – arteriovenous or arterial - renal venous difference 
 
BBB – blood-brain barrier 
 
BCSFB – blood-cerebrospinal fluid barrier 
 
bp – basepairs 
 
CK – creatine kinase 
 
CNS – central nervous system 
 
CPEC – choroid plexus epithelial cells 
 
CPS 1 – carbamylphosphate synthetase 1 
 
Cys - cysteine 
 
EEG - electroencephalogram 
 
FAD – flavin adenine dinucleotide 
 
GAA – guanidinoacetic acid 
 
GAMT – guanidinoacetate Methyltransferase 
 
GBq - gigaBecquerel 
 
GI - gastrointestinal 
 
g - gram 
 
Hcy – homocysteine 
xix 
 
 
HPLC – high performance liquid chromatography 
 
i.p. – intraperitoneal 
 
i.v. – intravenous 
 
kBq - kiloBecquerel 
 
kDa – kiloDalton 
 
Keq – equilibrium constant 
 
kJ – kilojoules 
 
Km – Michaelis-Menten constant 
 
M – molar 
 
mBq – milliBacquerel 
 
MCEC – microcapillary endothelial cells 
 
mL - milliliter 
 
mM - millimolar 
 
mol - mole 
 
MS – methionine synthase 
 
MTHFR – methylene tetrahydrofolate reductase 
 
N – number of subjects 
 
nm - nanometers 
 
NADH – nicotinamide adenine dinucleotide 
 
NADPH – nicotinamide adenine dinucleotide phosphate 
 
NCAA – National Collegiate Athletic Association 
 
OD – optical density 
 
xx 
 
PBS – phosphate buffered saline 
 
PCA – perchloric acid 
 
PCR – polymerase chain reaction 
 
PEP – phosphoenolpyruvate 
 
PITC – phenyl isothiocyanate 
 
RT-PCR – reverse transcription-polymerase chain reaction 
 
SAH – S-adenosylhomocysteine 
 
SAM – S-adenosylmethionine 
 
SHMT – serine hydroxymethyltransferase 
 
TEA – triethanolamine 
 
TFA – trifluoroacetic acid 
 
uL – microlitre 
 
uM – micromolar 
 
um - micrometer 
 
UV – ultraviolet 
 
V – renal venous 
 
Vol – volume 
 
wt - weight 
 
x g – times the gravitational force 
  
xxi 
 
LIST OF APPENDICES 
 
Appendix A: New Insights into Creatine Function and Synthesis   141 
Appendix B: Materials and Methods       163  
  
 1 
 
 
 
 
 
 
 
 
 
 
CHAPTER 1 
INTRODUCTION AND OVERVIEW 
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1.1. FUNCTIONS OF CREATINE AND CREATINE PHOSPHATE 
 
The name “creatine” stems from the Greek word kreas, meaning flesh, as creatine was 
first discovered in muscle tissue.  Creatine is a small zwitterion that contains a guanidino 
group that can be phosphorylated to yield creatine-phosphate.  The phosphorylation of 
creatine is catalyzed by creatine kinase (CK) and occurs via the transfer of the γ-
phosphoryl group of ATP to creatine to yield creatine-phosphate and ADP [Walker, 1979; 
Wyss & Kaddurah-Daouk, 2000].  Creatine and creatine-phosphate occur in much higher 
cellular concentrations than ATP or ADP.  The hydrolysis of creatine-phosphate to form 
creatine and ATP has a standard free energy change of -45 kJ/mol at pH 7.0.  If we 
compare this standard free energy change to that of ATP hydrolysis (-31.8 kJ/mol) it is 
easy to see that the cytosolic phosphorylation potential of tissues containing the 
creatine/creatine-phosphate/CK system may be maintained at a higher level than in 
tissues devoid of the phosphagen system [Wyss & Kaddurah-Daouk, 2000].  
 
Because the creatine/creatine-phosphate/CK phosphagen system plays an important role 
in energy storage and transmission [Balsom et al., 1994; Schulze, 2003; Walker, 1979; 
Wyss & Kaddurah-Daouk, 2000], it is understandable that tissues which contain high 
levels of creatine are those which have high or variable rates of ATP usage.  For example, 
skeletal muscle, cardiac muscle, spermatozoa, and photoreceptors of the retina contain 
high amounts of creatine [Christensen et al., 1994; Kushmerick et al., 1992; Wallimann et 
al., 1986a; Wallimann et al., 1986b].  Intermediate levels of creatine are found in brain, 
intestine, brown adipose tissue, endothelial cells, macrophages, seminal vesicles, and 
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seminal vesicular fluid [Berlet et al., 1976; Delanghe et al., 1989; Lee et al., 1988; Loike 
et al., 1992; Loike et al., 1986; Navon et al., 1985;  Windischbauer et al., 1994].  Low 
levels are found in kidney, liver, lung, spleen, blood cells, serum, and white adipose tissue 
[Berlet et al., 1976; Delanghe et al., 1989; Wyss & Kaddurah-Daouk, 2000]. 
 
There are two proposed mechanisms by which the creatine/creatine-phosphate/CK 
phosphagen system acts to aid in energy storage and transmission.  The first mechanism 
is known as the “temporal energy buffer” and the second, as the “spatial energy buffer”, 
or the Energy Buffer Theory vs. the Phosphocreatine Energy Shuttle [Bessman & Geiger, 
1981; Wallimann et al., 1992].  It is important to realize that these mechanisms are not 
mutually exclusive and both are physiologically relevant, though each may be more 
important in different cells.   
 
1.1.1. The Energy Buffer Theory 
 
Local ATP, ADP, and AMP concentrations, as well as the ATP/ADP ratio, act as key 
regulators that influence many fundamental metabolic processes.  Therefore, it would not 
be appropriate to allow the intracellular concentrations of ATP to decrease during work 
[Wallimann et al., 1992].  To avoid this dilemma, many cells or tissues contain large 
quantities of phosphagens such as creatine/creatine-phosphate.  CK works to replenish 
ATP from the large pools of creatine-phosphate through the following reaction: 
ADP + creatine-phosphate ↔ ATP + creatine + H+ 
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During short activation of tissues which have high or variable rates of ATP usage, ATP 
levels do not significantly change even though cellular pools of ATP are quite small (2-5 
mM) [Infante & Davies, 1965; Mommaerts & Wallner, 1967; Seraydarian, 1980].  
Creatine-phosphate potentially plays an important role as an energy buffer in fast-twitch, 
glycolytic muscles.  Because cytosolic CK activity is high in these muscles, its reaction 
can remain in a near-equilibrium state over several seconds, keeping ATP and ADP 
concentrations relatively constant.  In this way, the creatine/creatine-phosphate/CK 
system “buffers” the cytosolic phosphorylation potential that is crucial for the proper 
function of a variety of cellular ATPases [Wyss and Kaddurah-Daouk, 2000]. 
 
1.1.2. The Energy Shuttle Theory 
 
There are at least four isoforms of CK: muscle (M)-CK, brain (B)-CK, and two 
mitochondrial (Mi)-CK isoforms.  These isoforms are expressed in a tissue-specific 
manner [Wallimann et al., 1992].  The presence of different isoforms and locations of the 
enzyme suggests that there are different metabolic roles for each isoform, leading to the 
energy shuttle theory of creatine-phosphate.  The energy shuttle theory implies that 
creatine-phosphate acts as an energy carrier between sites of energy production 
(mitochondria) and sites of energy utilization in the cytoplasm [Greenhaff, 2001; 
Wallimann et al., 1992].  Bessman and Geiger [1981] suggest that the energy shuttle 
theory is central to aerobic muscle mechanics. 
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A key factor in the energy shuttle theory is the subcellular localization of the various 
isoforms of CK.  For clarification, let us imagine an arbitrary aerobic muscle cell.  The 
mitochondrial isoform of CK is located at contact points between the inner and outer 
mitochondrial membranes.  ATP produced by oxidative phosphorylation is readily 
converted to creatine-phosphate in the presence of creatine.  Creatine-phosphate can 
diffuse from the mitochondrion to the major cellular sites of ATP utilization, such as 
myofibrils, sarcoplasmic reticulum or plasma membranes [Wallimann et al., 1992].  Once 
ADP is phosphorylated to ATP by a cytosolic isoform of CK, creatine is free to diffuse 
back toward the mitochondrion.  It has been postulated that creatine-phosphate (MW 211) 
and creatine (MW 131) would diffuse faster through the cytosol than their larger 
counterparts, ATP (MW 507) and ADP (MW 427) [Ellington, 2001].  However, the 
differences in free concentration in the cytosol likely play a more important role (ATP, 3-
5 mM; ADP, 20-40 µM; creatine-phosphate 20-35 mM; creatine, 5-10 mM) [Wallimann 
et al., 1992].  In particular, the very low concentration of ADP may limit the rate of its 
diffusion, relative to that of creatine.  Figure 1.1 illustrates the concept of the energy 
shuttle theory.  Slow-twitch, oxidative, or cardiac muscle would likely employ the energy 
shuttle function as this would allow higher endurance.  It is worth mentioning again that 
the energy shuttle theory and the energy buffer theory are not mutually exclusive. 
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Figure 1.1: The Energy Shuttle Theory of Creatine Function. Creatine-phosphate 
acts as an energy carrier between sites of energy production (mitochondria) and sites of 
energy utilization in the cytoplasm.  Produced for this thesis by Adam Samson. 
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1.2. CREATINE AS A SPORTS NUTRACEUTICAL 
 
Upon commencement of high-intensity exercise the ATP demand of working muscles 
may increase to several hundred-fold higher than that at rest [Balsom et al., 1994].  
Initially, ATP hydrolysis is buffered by creatine/creatine-phosphate but creatine-
phosphate levels are depleted after about 10 seconds [Balsom et al., 1994; Wyss & 
Kaddurah-Daouk, 2000].  After the initial 10 seconds, other sources of ATP generation 
such as glycolysis and, then, mitochondrial oxidative phosphorylation are called into play 
[Balsom et al., 1994; Wyss & Kaddurah-Daouk, 2000].  Availability of creatine-
phosphate may be a limiting factor in muscle force maintenance [Balsom et al., 1994].  It 
is this idea that has led to the popularity of creatine as a sports nutraceutical.   
 
In 1992, Harris et al. first reported that dietary creatine is absorbed and that when creatine 
supplementation is carried over a period of time there are increases in muscle total 
creatine content.  Since this time creatine has become one of the most popular of the 
nutraceutical supplements used by athletes.  It has also proved to be profitable for the 
supplement industry [Volek & Rawson, 2004].  In 1996 it was estimated that 80% of the 
athletes competing in the Olympic Games were using or had been using creatine [Paddon-
Jones et al., 2004].  In 1998 creatine sales in the United States were estimated at $100 
million [Paddon-Jones et al., 2004].  In 1999, an estimated 2.5 million kg of creatine were 
consumed, and it was reported that 28% of NCAA Division I athletes used creatine 
[Racette, 2003].  A 2001 survey of 1349 high school football players indicated that 30% 
had used creatine [Racette, 2003].  These statistics reveal that creatine is an extremely 
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popular sports supplement and it is being used by a variety of athletes, from Olympic 
athletes to high school children.  This last point warrants research into the long-term 
effects of creatine supplementation, especially in terms of adolescent development. 
 
The typical supplement regimen followed by athletes involves a “loading phase” of 20-30 
g of creatine/day (generally divided into 5-7.5 g doses taken 4 times daily) for 5 days 
followed by a “maintenance phase” of 2-5 g of creatine/day [Racette, 2003; Wyss & 
Kaddurah-Daouk, 2000].  Plasma creatine concentration peaks approximately 1 hour after 
a single 5 g dose.  Intramuscular stores increase within 48 hours and at the end of the 
loading phase total intramuscular creatine content is increased by approximately 20%, 
depending on initial creatine levels [Rawson et al., 2002].  An alternative regimen for 
supplementation involves 3 g of creatine/day for 28 days.  At the end of 28 days the same 
final creatine concentrations are reached as with the 5 day loading period.  To aid in 
uptake of creatine, creatine monohydrate powder is dissolved in a carbohydrate solution.  
Green et al. [1996] showed that creatine dissolved in carbohydrate solution increased 
total muscle creatine stores by >25%, that is 60% more than when creatine was ingested 
alone.  Steenge et al. [1998] reported that insulin, whose secretion was increased by 
carbohydrate ingestion, enhanced muscle creatine accumulation.  In addition, they found 
that insulin’s effect required quite high insulin concentrations.  They suggested that an 
insulin-mediated augmentation of sodium-dependent creatine transport is responsible for 
the increased creatine uptake. 
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There seems to be no justification for taking higher doses of creatine because the capacity 
of muscle fibers to store creatine-phosphate is limited and excess creatine is excreted in 
the urine as either creatine or creatinine.  Upon cessation of supplementation, total 
intramuscular creatine concentrations return to basal levels after approximately 4 weeks 
[Racette, 2003].  Creatine uptake is stimulated by exercise, as demonstrated by Harris et 
al. [1992] by single leg exercises.  The exercised leg had appreciably higher muscle 
creatine levels than that of the unexercised, contralateral leg. 
 
Since creatine-phosphate only buffers ATP levels for approximately 10 seconds after the  
onset of intense exercise [Balsom et al., 1994; Wyss & Kaddurah-Daouk, 2000], it seems 
likely that increasing creatine-phosphate stores in muscle would aid in short, high-
intensity, repetitive exercise with little or no benefit for endurance-type exercise [Racette, 
2003; Kreider, 2003].  Therefore, creatine’s effects in athletic performance tend to be 
sport-specific with greatest benefit observed for bench press, leg press, squats, and 
jumping; minimal or no benefit was observed for swimming sprints, or tennis stroke 
power or precision [Racette, 2003].  For many types of exercise it is unclear what benefit 
creatine imposes upon athletic performance as results vary from one study to the next.  
For example, a meta-analysis of 96 creatine supplementation studies [Branch, 2003] 
found that creatine supplementation had minimal effectiveness in improving jumping, 
running and swimming performance.  However, the findings supported the effectiveness 
of creatine supplementation in increasing total and lean body mass, and performance in 
high-intensity, short duration, repetitive exercises such as weight-lifting repetitions and 
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resistance.  They concluded that the effect size is small and variable, highlighting the 
inconsistent effects of creatine supplementation for all variables and populations studied.   
 
There are three proposed mechanisms of action of creatine supplementation: 1) greater 
ATP availability to meet the high ATP demand during anaerobic exercise; 2) faster 
creatine-phosphate resynthesis during recovery from intense exercise; and 3) depressed 
degradation of adenine nucleotides and depressed accumulation of lactic acid during 
exercise.  These mechanisms may allow force or power to be maintained longer, thereby 
enhancing athletic performance.  Faster creatine-phosphate resynthesis could be 
beneficial during repeated exercise bouts with little recovery time in between [Racette, 
2003; Wyss & Kaddurah-Daouk, 2000]. 
 
The one side-effect that is common to almost all studies carried out on creatine 
supplementation is weight gain.  Depending upon the sport, weight gain can be 
considered as either positive or negative.  For example, a gymnast would consider weight 
gain a hindrance while a weightlifter/bodybuilder would value it as long as the weight 
represented muscle.  A number of suggestions have been made as to how creatine 
supplementation causes weight gain but, as yet, the mechanism is largely unknown.  
Creatine is an osmolyte whose storage requires water [Paddon-Jones et al., 2004; Racette, 
2003; Volek & Rawson, 2004; Wyss & Kaddurah-Daouk, 2000].  It has also been shown 
that creatine supplementation causes increases in glycogen storage in rat skeletal muscle 
[Eijnde et al., 2001].  In addition, increased water may cause cellular swelling which is 
known to enhance anabolism [Häussinger et al., 1999; Krause et al., 1996] and increase 
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cellular protein content.  Creatine seems to have no effect on protein synthesis but has 
been reported to decrease whole-body protein breakdown [Louis et al., 2003; Volek & 
Rawson, 2004].   
 
Other, less desirable side-effects that have occasionally been reported include mild 
asthmatic symptoms, gastrointestinal distress, muscle cramps, muscle strains, heat 
intolerance, rash, dyspnea, vomiting, diarrhea, nervousness, anxiety, fatigue, migraine, 
myopathy, polymyositis, seizures, and atrial fibrillation [Wyss & Kaddurah-Daouk, 
2000].  A study by Greenwood et al. [2003] suggested that incidences of dehydration, 
muscle cramping or injury in athletes taking creatine were similar or lower than that 
among athletes not taking creatine.  Kreider et al. [2003] studied long-term effects of 
creatine supplementation and its effect upon clinical markers of health.  They found no 
adverse effect of creatine intake on markers of health status in athletes undergoing 
intensive training, in comparison to athletes who do not take creatine.  It should be noted 
that the study only lasted 21 months and there were no follow-ups.  It has also been 
postulated that creatine supplementation may improve brain performance, indicating that 
research should extend to other areas of performance outside of athletic performance [Rae 
et al., 2003]. 
 
Based upon these conflicting results on the effects of creatine supplementation, it is safe 
to say that more research needs to be conducted in this area.  The basis for the conflicting 
results has been investigated by Greenhaff et al. [1994] and Syrotuik & Bell [2004].  Both 
studies suggest that non-responders may explain much of the variability in results.  A 
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non-responder is defined as any person who ingests 20 g of creatine/day for 5 days and 
has an increase in total resting muscle creatine of less than 10 mmol/kg dry weight 
muscle [Syrotuik & Bell, 2004].  It is suggested that 20-30% of the population may be 
non-responders [Greenhaff et al., 1994].  Rawson et al. [2002] showed that subjects who 
have high initial muscle creatine levels respond less than those with low initial muscle 
creatine.  This observation may account for many of the non-responders.  More research 
needs to be conducted in the area of creatine supplementation; in particular, an 
examination with regard to any long-term effects on health is needed. 
 
1.3. NEED FOR CREATINE SYNTHESIS 
 
Creatine and creatine-phosphate spontaneously degrade to creatinine in an irreversible 
manner [Bloch & Schoenheimer, 1939; Borsook & Dubnoff, 1947].  At pH 7.0-7.2 and 
38ºC, about 1.1% of creatine and 2.6% of creatine-phosphate are degraded per day, 
amounting to 1.7% of the total body creatine pool per day [Crim et al., 1976; Hoberman 
et al., 1948; Perrone et al., 1992].  The conversion of creatine to creatinine is favored by 
low pH and high temperature [Cannan & Shore, 1928; Edgar & Shiver, 1925].  Recently 
the turnover of the total creatine pool has been estimated by an entirely different approach 
and yielded a very similar result [Kan et al., 2006].  In this study, a healthy male 
volunteer ingested 20 g per day, for 5 days, of 11% 
13
C-4-creatine.  The signal intensity 
of the combined creatine and creatine-phosphate peak in the subject’s calf muscle was 
then monitored over time by in vivo 
13
C-NMR. The signal intensity decreased at a rate of 
1.6 ± 0.5% per day, essentially the same as the previous estimate of 1.7% per day.  
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Creatinine has no known function in the body and is quantitatively excreted in the urine 
[Wyss & Kaddurah-Daouk, 2000].  Since approximately 95% of the total body pool of 
creatine in humans occurs in skeletal muscle [Balsom et al., 1994; Harris et al., 1974; 
Harris & Lowe, 1995], it is not surprising that urinary excretion of creatinine correlates 
with body muscle mass [Myers & Fine, 1913].  A 70 kg male, containing approximately 
120 g of total creatine, excretes about 2 g per day of creatinine [Walker, 1979].  The 
creatine lost must be replaced either by diet, by de novo synthesis, or by a combination of 
both. 
  
1.3.1. Creatine Balance 
 
To estimate creatine synthesis, one must first calculate the amount of creatine degraded, 
and then subtract from this the amount of creatine ingested, taking into account 
bioavailability of orally ingested creatine.  Harris et al. [2002] showed that dietary 
creatine is readily absorbed whether provided in solution, in meat or in solid (pill) form.  
Although ingestion of the creatine in meat and solid form gave lower peak concentrations, 
this was compensated for by an extended absorption time, such that the areas under the 
curve of plasma concentration over time were comparable.  The bioavailability of oral 
creatine, determined in adults who ingested 
2
H-creatine, has been estimated to be 
approximately 80% [MacNeil et al., 2005].  The mechanism for intestinal absorption of 
creatine is unclear, although mRNA for a creatine transporter has been identified in the 
GI tract [Persky et al., 2003].  Since creatine bears some similarity to basic amino acids, it 
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is possible that some creatine absorption may occur via the transporter for these amino 
acids [Persky et al., 2003].   
 
Stead et al. [2006] have estimated that in 20-59 year-olds, dietary creatine provides 
approximately 50-60% of the daily requirement.  If we go back to our example of the 70 
kg male, this means that about 1-1.2 g of creatine is received via the diet.  Therefore, 40-
50%, or 0.8-1.0 g, must be acquired via de novo creatine biosynthesis.  A more recent 
paper by Kasumov et al. [2009] examined the kinetics of creatine synthesis in a healthy 
adult using infusion of [1-
13
C]glycine.  The rate of creatine synthesis in a healthy 70 kg 
male was 1.85 g/day; this is of the same order of magnitude as previous estimates.  We 
must bear in mind that this estimate was obtained using a single human subject who was 
placed on a weight maintenance diet containing at least 70 g of protein per day for 7 days 
prior to study initiation.  It is unclear how much creatine was provided by this diet.  
Finally, it should be emphasized that creatine is only found in animal tissues.  
Vegetarians, and in particular vegans, will ingest little or no creatine and will need to 
provide all of their creatine by endogenous synthesis. 
 
1.4. SYNTHESIS OF CREATINE 
 
1.4.1. Pathway of Creatine Synthesis 
 
The biological synthesis of creatine is a very simple process, involving just two 
enzymatic steps.  The first step involves two amino acids: arginine and glycine.  The 
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amidino group of arginine is transferred to glycine by L-arginine:glycine 
amidinotransferase (AGAT) to form ornithine and guanidinoacetic acid (GAA) [Bloch & 
Schoenheimer, 1941; Wyss & Kaddurah-Daouk, 2000].   
Arginine + Glycine → Ornithine + GAA  [Step 1] 
GAA is methylated by guanidinoacetate methyltransferase (GAMT) using S-
adenosylmethionine (SAM) as methyl donor to form creatine and S-
adenosylhomocysteine (SAH) [du Vigneaud et al., 1940; Cantoni & Vignos, 1954].   
GAA + SAM → SAH + creatine  [Step 2] 
See Figure 1.2 for a complete diagram of creatine synthesis from arginine, glycine and 
methionine.  
 
1.4.1.1.  L-Arginine:Glycine Amidinotransferase (AGAT) 
 
AGAT (EC 2.1.4.1) catalyzes the reversible transfer of the amidino group of arginine to 
glycine to form ornithine and GAA.  This reaction was first demonstrated by Bloch and 
Schoenheimer [1941] in rats fed diets containing various 
15
N-labelled compounds, 
including glycine, arginine and GAA.  Arginine and glycine were the only “natural” 
amino acids that produced a large amount of labeled creatine, each supplying nitrogen to 
different parts of the creatine molecule.  Labeled GAA also produced significant amounts 
of labeled creatine but since GAA is not a normal constituent of food, but can be found in 
small quantities in normal urine and tissues, it was correctly suggested to be an 
intermediate in the creatine synthesis pathway.  
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Figure 1.2: Creatine Synthesis.  L-arginine:glycine amidinotransferase (AGAT) first 
catalyzes the transfer of an amidino group from arginine (Arg) to glycine (Gly), 
producing ornithine (Orn) and guanidinoacetate (GAA).  Next, guanidinoacetate 
methyltransferase (GAMT) transfers a methyl group from S-adenosylmethionine (SAM) 
to GAA, producing S-adenosylhomocysteine (SAH) and creatine.  The asterisk indicates 
point of methylation.  Boxes are drawn to indicate transfer of common groups, as well as 
methylation. 
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AGAT has been localized to the outer surface of the inner mitochondrial membrane in the 
rat kidney and pancreas [McGuire et al., 1984; Walker, 1979].  There may also be some 
cytosolic AGAT [Tormanen, 1990], however, which could arise as a result of alternative 
splicing of AGAT mRNA [Humm et al., 1997a].   
 
Gross et al. [1986] reported that there are at least two isoforms of AGAT, designated as 
α- and β-forms in rat and human tissues.  These are known to exist as dimeric molecules 
with subunit molecular weights of 42,000-44,000 Daltons, giving a total molecular weight 
for the functioning enzyme between 82,600 and 89,000 Daltons [Gross et al., 1986; Gross 
et al., 1988; McGuire et al., 1980].  There is a 94-95% amino acid sequence homology 
between rat, pig and human AGAT [Humm et al., 1994].   
 
Humm et al. [1997b] and Fritsche et al. [1999] used x-ray crystallography to gain insight 
into the mechanism of AGAT action.  The enzyme appears to work using a double-
displacement (Ping-Pong, bi-bi) mechanism whereby arginine binds first, ornithine is 
released and then glycine binds [Fritsche et al., 1999].  A conformational change takes 
place upon binding of substrate, arginine, which switches the enzyme from a closed to an 
open state.  The amidino group of arginine is transiently attached to Cys 407 and the 
product, ornithine, leaves before glycine binds and accepts the amidino group to form 
GAA.  The binding of glycine does not cause any structural change in the enzyme.   
 
The optimum pH for GAA formation is 7.2-7.5 while that for arginine formation is 8.5.  
The Michaelis-Menten constant, Km, for arginine was determined to be 1.3-2.8 mM, and 
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1.8-3.1 mM for glycine [Gross et al., 1986; McGuire et al., 1980; Walker, 1979] and the 
Ki for ornithine to be 0.25 mM [Fritsche et al., 1999].   
 
Maximum velocity (Vmax) values at 37ºC for human, rat α-, and rat β-AGAT were 
determined to be 0.5, 0.39, and 0.37 µmol ornithine formed per minute per mg protein, 
respectively [Gross et al., 1986; McGuire et al., 1980], while that of hog was determined 
to be 1.2 µmol ornithine formed per minute per mg protein [Conconi & Grazi, 1965]. 
 
Amino acids other than those involved in creatine synthesis may act as substrates for 
AGAT in the test tube.  Other amidino group donors include homoarginine, 3-
guanidinopropionate, 4-guanidinobutyrate, hydroxyguanidine and canavanine.  Other 
amidino group acceptors include β-alanine, 3-aminopropionate, 4-aminobutyrate, 1,4-
diaminobutylphosphonate, glycylglycine, hydroxylamine and canaline [Ennor & 
Morrison, 1958; Pisano et al., 1963; Walker, 1979].  No physiological role has been 
proposed for any of these compounds as alternative substrates for AGAT.  
 
1.4.1.2.    Guanidinoacetate Methyltransferase (GAMT) 
 
GAMT (EC 2.1.1.2) catalyzes the irreversible methylation of GAA by SAM to produce 
creatine and SAH.  The methylation occurs on the amidino group which originates from 
arginine [Wyss & Kaddurah-Daouk, 2000].  Borsook and Dubnoff [1940] were the first to 
show, in vitro, that the methyl group donated to GAA to form creatine was from 
methionine.  It was later shown by Cantoni and Vignos [1954] that the immediate methyl 
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donor is SAM.  Takata et al. [1994] have proposed that the GAMT reaction occurs via an 
ordered Bi Bi mechanism, in which SAM is the first reactant to bind. 
 
In mammals, GAMT activity is highest in liver [Van Pilsum et al., 1972; Walker, 1979; 
Xue et al., 1988].  The pancreas, testis and kidney have intermediate levels of activity, 
while low levels have been found in skeletal and cardiac muscle, neuroblastoma cells, 
fibroblasts and spleen [Daly, 1985; Van Pilsum et al., 1972; Walker, 1979; Wyss & 
Kaddurah-Daouk, 2000; Xue et al., 1988]. 
 
Im et al. [1979] and Ogawa et al. [1983] have reported that GAMT from pig and rat liver 
functions as a monomeric protein with a molecular weight of 26,000-31,000 Daltons.  It 
catalyzes an irreversible reaction with a Km for SAM of 49 µM, and GAA of 23-27 µM 
[Im et al., 1979; Takata et al., 1991; Walker, 1979]. 
 
1.4.2. Creatine Transporter 
The creatine transporter (SLC6A8) is a member of the SLC6 family of transporters.  
SLC6A8 activity has electrogenic properties because, in addition to creatine, it co-
transports two sodium and one chloride ion [Chen et al., 2004; Guimbal & Kilimann, 
1993; Valayannopoulos et al., 2013].  Because of inadequate methodologies for the 
extraction and purification of the creatine transporter, the exact biochemical nature of the 
protein remains elusive.  There are no clear identification and sequence data currently 
available [Speer et al., 2004].  It is believed that, in addition to the high efficiency 
plasmalemma creatine transporter, there is a creatine uptake mechanism present in the 
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mitochondrion that has lower affinity and high Km [Speer et al., 2004].  Speer et al. 
[2004] reported that mitochondrial creatine transport likely occurs by unspecific 
transport, possibly by an amino acid transporter. 
 
Speer et al. [2004] speculate that the genuine creatine transporter protein is approximately 
60-65 kDa in size, depending upon the tissue and the species.  Creatine uptake appears to 
be regulated by a variety of mechanisms including changes in intracellular and 
extracellular creatine content, phosphorylation and glycosylation.  Competitive inhibitors 
of the transporter include β-guanidinopropionic acid, arginine and lysine.  The activity of 
the creatine transporter can also be modulated by the SH-modifying reagent, N-
ethylmaleimide and the protonophoric uncoupler, p-trifluoromethoxyphenylhydrazone.   
 
1.4.3. Tissues Responsible for Creatine Synthesis 
 
Van Pilsum et al. [1972] found that in mammals, the highest AGAT activity was found in 
the kidney although appreciable activity was also found in the liver of some species.  For 
example, livers of cow, pig, monkey and human seem to have high amounts of AGAT, 
whereas livers of rat, mouse, dog, cat and rabbit were reported to have low levels or no 
AGAT [Pisano et al., 1963; Van Pilsum et al., 1963; Van Pilsum et al., 1972; Walker, 
1979].  Experiments were conducted by da Silva et al. [2009], using rat hepatocytes 
incubated with 
15
N-ammonium chloride, as well as methionine and glycine.  It was found 
that labeled urea was produced at a linear rate under all substrate conditions but not 
labeled creatine.  Thus, it was concluded that rat hepatocytes are not capable of the entire 
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creatine synthetic pathway.  It is not known whether the liver of humans is capable of 
creatine synthesis from arginine and glycine, but the presence of appreciable AGAT 
activity there would make it feasible.   
 
Liver contained the highest activity of GAMT in all mammalian species examined [Van 
Pilsum et al., 1972].  Because of this and because of the fact that creatine biosynthesis is 
reduced in nephrectomized rats [Goldman & Moss, 1959; Levillain et al., 1995], it has 
been postulated that creatine biosynthesis is an interorgan process whereby GAA is 
synthesized from arginine and glycine by AGAT in the kidney and released into the 
bloodstream to be taken up by the liver and converted to creatine by GAMT.  Creatine is 
then released into the bloodstream to be taken up by other tissues, such as skeletal and 
cardiac muscle, where it is required (see Figure 1.3 for diagrammatic representation).   
 
More recently, Braissant et al. [2007] have demonstrated creatine synthesis in vitro by 
various types of cerebral cells.  Although cerebral creatine synthesis is not important for 
maintaining the total body creatine pool, it is probably necessary for CNS use.  It is well-
known that the brain is protected from various blood components via two main barriers, 
the blood-brain barrier (BBB) and the blood-cerebrospinal fluid barrier (BCSFB).  The 
BBB is the largest barrier between the brain and surrounding periphery.  It is made up of 
tightly connected, non-fenestrated, microcapillary endothelial cells (MCEC).  There is 
tight regulation of exchange through the BBB.  Exchange is regulated by 1) pericytes and 
 
 
 22 
 
 
 
 
Figure 1.3: Creatine Biosynthesis and Proposed Interorgan Metabolism.  GAA, 
guanidinoacetate; SAM, S-adenosylmethionine; SAH, S-adenosylhomocysteine.  1. L-
Arginine:glycine amidinotransferase (AGAT); 2. Guanidinoacetate methyltransferase 
(GAMT). 
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astrocytes on the abluminal side of MCEC and 2) pericytes and astrocytic feet that 
compose an extracellular matrix that sheaths the MCEC.  The BCSFB is located in the 
lateral, third and fourth brain ventricles.  It is composed of choroid plexus epithelial cells 
(CPEC) that form apical tight junctions between one another.  The main functions of the 
BCSFB include the secretion of CSF and regulated exchanges between CSF and blood 
[Braissant, 2012]. 
 
The creatine transporter is expressed by neurons and oligodendrocytes, including MCEC 
at the BBB; it is not expressed by astrocytes, particularly the astrocytic feet that line the 
BBB [Braissant et al., 2001; Ohtsuki et al., 2002; Tachikawa et al., 2004].  This may 
account for the findings of inefficient transport of creatine from periphery to CNS as 
reported by Perasso et al. [2003].  Braissant [2012] suggests that the brain may be 
responsible for much of its own creatine supply through endogenous creatine synthesis.  
This synthesis appears to be an intercellular process, as the expression of AGAT and 
GAMT is dissociated in most regions of the brain.  Therefore, a transporter would be 
needed for transport of GAA from AGAT- to GAMT-expressing cells to complete 
creatine synthesis [Braissant, 2012]. 
 
1.4.4. Regulation of Creatine Synthesis 
 
The regulation of creatine biosynthesis is usually thought to occur during the production 
of GAA, at the level of AGAT [Walker, 1979].  It seems that GAMT does not become 
rate-limiting for creatine biosynthesis unless AGAT activity is highly stimulated [Wyss & 
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Kaddurah-Daouk, 2000].  AGAT activity has been shown to be regulated by circulating 
creatine levels, dietary deficiency, hormonal factors and disease [Derave et al., 2004; 
Funahashi et al., 1981; Guthmiller et al., 1994; Van Pilsum & Wahman, 1960].  An 
increase in serum levels of creatine results in a decrease in AGAT enzyme activity, 
enzyme protein amount and mRNA expression [Derave et al., 2004; Guthmiller et al., 
1994; Walker, 1979; Wyss & Kaddurah-Daouk, 2000].  Fasting may have a similar effect 
on creatine biosynthesis [Shindo et al., 1986].  During fasting, plasma creatine levels 
increase and this may be the cause of decreased GAA levels, observed in tissues (but not 
plasma) [Zhao et al., 2002].  Both thyroxine and growth hormone are believed to be 
involved in the maintenance of AGAT levels, as both thyroidectomy and 
hypophysectomy decrease rat kidney AGAT activity.  AGAT activities are restored upon 
injection of thyroxine or growth hormone, respectively [Guthmiller et al., 1994; McGuire 
et al., 1980].  AGAT activity is also decreased by vitamin E deficiency, and by 
streptozotocin-induced diabetes [Funahashi et al., 1981; Van Pilsum & Wahman, 1960].  
Fitch et al. [1961] have shown that vitamin E deficiency increases serum creatine levels, 
suggesting that the increased creatine is responsible for the decrease in AGAT activity.  
The effect of streptozotocin-induced diabetes on AGAT activity may not be a result of the 
altered hormonal state since administration of insulin does not restore original AGAT 
activity [Funahashi et al., 1981]. 
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1.5. QUANTITATIVE ASPECTS OF CREATINE SYNTHESIS 
 
A consideration of the quantitative aspects of creatine synthesis is revealing.  This is best 
calculated from the rates of creatinine loss (about 1.7% of the total body creatine pool per 
day [Wyss & Kaddurah-Daouk, 2000]).  Since most of the body’s creatine and creatine-
phosphate are found in muscle, creatinine excretion is directly related to lean body mass.  
Creatinine excretion is, therefore, dependent on age and sex (which are related to lean 
body mass).  In general we excrete between 1.5 and 2 g of creatinine per day.  This means 
that approximately 1.5 to 2 g of creatine needs to be acquired by the body each day. 
 
Muscle meats, including fish, and dairy products are the sole sources of dietary creatine.  
Some creatine will be available from the diet to humans who ingest a typical mixed diet 
that includes meat and dairy foods.  It has been calculated (using published data on the 
creatine content of cooked foods, as well as the USDA tables of food consumption in the 
US, and published data on the bioavailability of food creatine) that a maximum of about 
0.5 g of creatine may be available in the diet [Brosnan & Brosnan, 2007].  This means 
that about 1.0 to 1.5 g of creatine per day will have to be synthesized to maintain creatine 
balance.  Vegans would have to synthesize 1.5 to 2 g of creatine per day.  These numbers 
are in agreement with Kasumov et al. [2009] who used a [1-
13
C]glycine infusion to 
measure creatine synthesis in a healthy adult.  They estimated a synthesis of 1.85 g of 
creatine per day in a single subject.   
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1.5.1. Demand for Amino Acids 
 
Walser [1983] and Visek [1986] were the first to consider the burden that creatine 
synthesis in adults imposes on amino acid metabolism.  They calculate that a typical, 70 
kg, 18-29 year-old male, synthesizing about 1.65 g of creatine per day, requires 0.18 
mmol of arginine per kg body weight per day (and also 0.18 mmol per kg body weight 
per day of glycine and of methyl groups) just for creatine synthesis.  This amounts to 2.2 
g of arginine which is about 50% of the arginine ingested by an individual with a typical 
North American protein intake of 80 g per day.  Thus, creatine synthesis constitutes an 
enormous potential sink for arginine and the other amino acids required for its synthesis.  
Creatine synthesis was suggested by Mudd and Poole [1975] as the dominant user of 
methyl groups, amounting to about 70% of all SAM utilization in adults. 
 
More recently, Brosnan et al. [2011] have re-examined the metabolic burden that creatine 
synthesis plays on each of the amino acids involved including glycine, arginine and 
methionine.  They concluded that due to dietary intake and readily available endogenous 
synthesis, creatine synthesis does not make a great demand on glycine availability.  In the 
neonatal piglet, they estimated that creatine synthesis required about 12% of dietary 
glycine [Brosnan et al., 2009].  These estimates are fairly straightforward because 
creatine synthesis utilizes the entire glycine molecule.  Based on data accumulated by Wu 
et al. [2004] on the amino acid composition of piglets at term, Brosnan et al. [2009] have 
calculated that the glycine incorporated into creatine in the neonatal piglet is equivalent to 
about 2.7% of the net glycine incorporated into protein.  Thus, they concluded that 
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creatine synthesis imposes a minor burden on glycine provision.  However, Melendez-
Hevia et al. [2009] have argued that humans may have limited capacity for glycine 
synthesis.  As a result, the availability of glycine for creatine synthesis in humans clearly 
needs further investigation. 
 
Ornithine, which is generated by AGAT during creatine synthesis, has one of two 
possible fates; 1) oxidation, as initiated by ornithine aminotransferase, or 2) reconversion 
to arginine.  The latter process requires three enzymes: carbamoylphosphate synthetase 1 
(CPS 1), argininosuccinate synthase (ASS) and argininosuccinate lyase (ASL).  ASS and 
ASL are highly expressed in the kidney [Dhanakoti et al., 1990].  However, CPS 1 is 
more limited in distribution, mainly found in liver and small intestine and absent from the 
kidney [Goping et al., 1992].  Ornithine aminotransferase is expressed in significant 
amounts in the kidney, primarily in the proximal tubules [Levillain et al., 2000] where 
renal AGAT is also found [McGuire et al., 1986].  The issue may be debated, but it seems 
plausible that, in the kidney, the ornithine produced by AGAT may be readily catabolized 
rather than recycled back to arginine [Brosnan et al., 2011]. 
 
The synthesis of creatine also requires a methyl group, donated from SAM.  Methyl 
groups may be obtained by SAM from dietary sources such as methionine, betaine, or 
choline via betaine, or produced endogenously via methylneogenesis.  Methylneogenesis 
requires three successively active enzymes; serine hydroxymethyltransferase (SHMT), 
methylene tetrahydrofolate reductase (MTHFR), and methionine synthase (MS) and is 
dependent upon vitamin B status [Brosnan et al., 2011].  For example, MTHFR is 
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dependent upon NADPH (niacin/vitamin B3) as a reductant, contains FAD 
(riboflavin/vitamin B2) as a prosthetic group, and produces methylene-tetrahydrofolate 
(folate/vitamin B9).  MS also requires methylcobalamin (vitamin B12) as a prosthetic 
group.  Brosnan et al. [2011] have estimated that creatine synthesis may consume about 
40% of the SAM available for all bodily methyltransferase reactions.  Clearly this 
imposes an appreciable burden on methionine metabolism and methyl balance. 
 
1.5.2. Creatine Synthesis Makes a Large Demand for Amino Acids in Infants 
 
Because of the expanding tissue mass in infants, the burden of creatine synthesis on 
amino acid metabolism is expected to be greater than in adults.  From 6-12 weeks of age, 
breastfed infants weigh an average of 5.7 kg [Motil et al., 1997] and excrete about 62 mg 
of creatinine per day [Coulthard et al., 2000].  This would total 434 mg of creatinine 
excreted per week or 3.8 mmol of creatinine.  These same infants ingest an average of 
143 ml of milk per kg per day and gain an average of 0.2 kg body weight per week [Motil 
et al., 1997].  Half of this weight gain is lean body mass and at least half of this is muscle 
[Motil et al., 1997].  This amounts to a gain of 50 g of muscle per week.  According to 
Eriksson [1980], the skeletal muscle content of creatine-phosphate in infants of this age is 
between 12 and 22 mmol per kg wet wt, with a mean value of 17 mmol per kg wet wt.  
Data regarding creatine concentration or total creatine content of infant muscle are scarce.  
However, if a ratio of 3 is applied for the concentrations of creatine-phosphate:creatine, 
which is common in adult human muscle [Kemp et al., 2007], an estimate of creatine 
concentration in infant skeletal muscle of 6 mmol per kg wet wt is obtained.  This implies 
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a total muscle creatine concentration of 23 mmol per kg wet wt for human infants aged 6-
12 weeks. 
 
Applying the above estimates of infant muscle total creatine content with an increase in 
muscle mass of 50 g per week, it can be calculated that 0.46 mmol of creatine is required 
each week for the expanding muscle mass.  Therefore, creatine accretion should be about 
0.46 mmol per week to account for muscle deposition and 3.8 mmol per week to account 
for creatinine loss, for a total creatine accretion of 4.26 mmol per week (0.48 g per week).  
To what extent this burden is borne by the infant or by the mother and its implication for 
amino acid metabolism was determined in this thesis. 
 
1.6. MAMMARY GLAND PHYSIOLOGY 
 
The mammary gland, characteristic of mammals, is an exocrine gland which produces 
milk for the sustenance of young offspring.  During late pregnancy and immediately 
following birth, the mammary gland secretes colostrum (also known as first milk) which 
contains high concentrations of antibodies, carbohydrates and protein and low 
concentrations of fat.  True milk secretion begins a few days after birth and contains 
higher concentrations of fat than does colostrum [Fetherston et al., 2001]. 
 
The number of mammary glands varies widely in different mammals.  Humans have one 
pair of mammary glands whereas the rat has six ventrolateral pairs of mammary glands, 
each with its own nipple, that form subcutaneous sheets of tissue that extend from the 
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cervical to the inguinal regions [Howard & Gusterson, 2000; Masso-Welch et al., 2000].  
During the reproductive cycle, the mammary gland undergoes many cycles of 
proliferation, differentiation and apoptosis.  The mammary gland can be viewed as two 
compartments: 1) the adipose stroma, which is composed mainly of adipocytes and 
fibroblasts, and surrounds 2) the parenchyma, which is composed of a system of 
branching ducts and alveoli [Masso-Welch et al., 2000].  During the first half of 
pregnancy, the epithelial parenchymal cells proliferate causing the formation of branching 
ducts and alveolar buds, which is accompanied by increased tissue vascularization.  The 
majority of differentiation occurs during the second half of pregnancy when the 
proportion of parenchymal ductal and alveolar cells increases dramatically [Masso-Welch 
et al., 2000]. 
 
1.6.1. Milk Production and Secretion 
 
Milk is synthesized by the epithelial cells, secreted into the alveolar lumen and then 
transported by milk collecting ducts to the surface of the nipple.  Mammary glands are 
fully capable of producing milk by about 20 weeks of gestation.  Milk secretion is 
prevented until parturition by the high circulating levels of estrogen and progesterone 
during the latter half of gestation.  Delivery of the placenta at parturition causes an abrupt 
decline in estrogen and progesterone and milk secretion is no longer inhibited [Sherwood, 
2001]. 
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The two main hormones responsible for maintaining lactation include: 1) prolactin, which 
promotes secretion of milk through its action on the alveolar epithelium, and 2) oxytocin, 
which aids in forced milk expulsion from the lumen of the alveoli into the ducts.  
Stimulation of sensory nerve endings in the nipple sends action potentials through the 
spinal cord and up to the hypothalamus.  The hypothalamus then signals the posterior 
pituitary to release oxytocin.  Stimulation of the nipple most often occurs through 
suckling by the infant [Sherwood, 2001]. 
 
Oxytocin causes contraction of the myoepithelial cells that surround each alveolus to 
bring about milk ejection or “let down”.  Milk ejection will continue as long as the 
suckling stimulus is present.  Without the stimulation by oxytocin, the milk present in the 
alveoli will not be released.  Conditioning can also result in oxytocin release.  For 
example, an infant’s cry can sometimes trigger milk ejection.  On the other hand, 
hypothalamic stimulation through physiological stress can inhibit milk ejection [Dewey, 
2001, Sherwood, 2001]. 
 
Suckling by the infant also triggers prolactin secretion.  Prolactin is secreted by the 
anterior pituitary and is controlled by two hypothalamic molecules.  The first is prolactin 
inhibiting hormone (PIH) which is now known to be dopamine, a neurotransmitter.  PIH 
is the predominant influence on prolactin throughout a female’s life, keeping levels of 
prolactin low.  During lactation, a second hormone comes into play, prolactin releasing 
hormone (PRH) which causes prolactin to be secreted from the anterior pituitary.  
Prolactin is then available to stimulate the alveolar epithelium to secrete milk in order to 
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replenish what is lost through ejection [Sherwood, 2001].  In this way, suckling 
concurrently stimulates both milk production and ejection, ensuring that milk synthesis 
meets the needs of the infant.  The more the infant suckles, the more milk is ejected and 
then the more milk is produced, preparing the mammary glands for the next feeding. 
 
1.7. PATHOLOGY – CREATINE DEFICIENCY DISEASES 
 
The synthesis of creatine requires two enzymes, AGAT and GAMT, and the uptake of 
creatine into tissues requires a creatine transporter, SLC6A8.  The disorders of creatine 
metabolism can be divided into two main categories: disorders of creatine synthesis and 
disorders of cellular creatine transport [Stromberger et al., 2003].  The clinical 
characteristics of the disorders in creatine metabolism principally result from cerebral 
creatine depletion; these characteristics include mental retardation and speech delay and 
may include seizures.  Surprisingly, although children with inborn errors in creatine 
metabolism may be hypotonic, cardiomyopathies or skeletal myopathies are not 
commonly reported although muscle tissue may be creatine-depleted [Stromberger et al., 
2003]. 
 
1.7.1. L-Arginine:Glycine Amidinotransferase (AGAT) Deficiency 
 
AGAT deficiency (McKusick 602360) has an autosomal recessive pattern of inheritance 
[Battini et al., 2006; Stromberger et al., 2003].  Mental retardation and speech delay are 
common clinical characteristics and epileptic episodes that are responsive to antiepileptic 
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drugs are also common [Stromberger et al., 2003].  Plasma creatine levels may be within 
the normal range but cerebral creatine levels are depleted.  Levels of GAA in the plasma 
are characteristically low.  Treatment with oral creatine monohydrate almost completely 
restores cerebral creatine levels and causes significant improvement in highly abnormal 
developmental scores [Stromberger et al., 2003].  In a case report by Battini et al. [2006], 
oral creatine supplementation begun early in life allowed normal growth patterns and 
normal developmental quotients at the age of 18 months, whereas untreated relatives had 
already begun to show symptoms of the disease at this age [Battini et al., 2006].  If 
treatment is administered early in development, AGAT deficiency may be considered a 
treatable metabolic disorder. 
 
1.7.2. Guanidinoacetate Methyltransferase (GAMT) Deficiency 
 
GAMT deficiency (McKusick 601240) follows an autosomal recessive inheritance 
pattern and leads to a lack of creatine and an accumulation of GAA [Schulze, 2003; 
Stromberger et al., 2003].  GAMT deficiency can be classified as mild, intermediate, or 
severe, with severe phenotypes exhibiting abnormal signal intensities of the basal ganglia 
on EEG, extrapyramidal movement disorder, untreatable epilepsy and early global 
developmental delay.  The mild phenotype presents with mental retardation, autistic 
behavior and speech delay and the intermediate phenotype presents with symptoms on a 
severity level between the severe and mild phenotypes [Stromberger et al., 2003].  A 
number of mutations located on various exons of the GAMT gene have been reported to 
cause GAMT deficiency.  GAMT-deficient patients have intracellular depletion of 
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creatine and creatine-phosphate and extracellular depletion of creatine and creatinine.  
Oral supplementation of creatine monohydrate has been found to alleviate depleted 
creatine concentrations, extrapyramidal symptoms, delayed developmental progress and 
epilepsy.  Soon after GAMT deficiency was discovered, no patient had achieved a normal 
developmental level and all patients lacked active speech even with treatment [Schulze, 
2003; Stromberger et al., 2003].  In 2006, Schulze et al. published a case study in which a 
child with GAMT deficiency was diagnosed early because of an older affected sibling.  
This child was provided with creatine, an arginine-restricted diet and benzoate to reduce 
glycine levels via the formation of hippuric acid.  The arginine-restricted diet and 
benzoate work together to reduce the substrates of AGAT, consequently reducing the 
synthesis of GAA.  Fourteen months following treatment, the child was normal 
developmentally and showed no symptoms of GAMT deficiency [Schulze et al., 2006]. 
 
1.7.3. Creatine Transporter (SLC6A8) Deficiency 
 
Creatine transporter deficiency (SLC6A8, McKusick 300036) is an X-linked disorder that 
is clinically characterized by mental retardation, speech delay and antiepileptic-
responsive epileptic episodes.  Extracellular creatine concentrations may be low or 
elevated while intracellular creatine concentrations are depleted [Stromberger et al., 2003; 
Valayannopoulos et al., 2013].  Urinary creatinine excretion may be normal while 
creatine excretion is elevated thereby causing an increase in the creatine:creatinine 
excretion ratio, usually the first diagnostic marker for creatine transporter deficiency 
[Valayannopoulos et al., 2012].  Since the problem is with creatine transport and not with 
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synthesis, creatine supplementation is not an effective treatment of the disorder and does 
not replenish cerebral creatine levels [Stromberger et al., 2003].  Studies by Fons et al. 
[2008] found that oral supplementation with arginine as a precursor of creatine also failed 
to improve the neurological status in patients with creatine transporter deficiency.  In 
2010, Fons et al. tried supplementation with a lipophilic creatine-derived compound, 
creatine ethyl ester, which also failed to replenish brain creatine content or neurological 
status.  Braissant et al. [2011] pointed out that even though the brain may be able to 
synthesize its own creatine, the synthesis appears to be an intercellular process and the 
creatine transporter is still needed to transport the precursors from one cell type to 
another.  Therefore, the endogenous creatine synthesis pathway would remain deficient in 
the CNS of patients with creatine transporter deficiency syndromes because GAA cannot 
be transported from AGAT- to GAMT-expressing cells because of the lack of a 
functional creatine transporter. 
 
1.8. STATEMENT OF PROBLEM 
 
The overall problems addressed in this thesis concern (i) the pathway and regulation of 
creatine synthesis in rats and, to a limited extent, humans, and, (ii) the way in which 
neonatal animals, including humans, accumulate creatine, as well as the metabolic burden 
imposed by this accumulation.  
 
 36 
 
1.8.1. Pathway and Regulation of Creatine Synthesis 
 
One of the principal questions addressed concerns the inter-organ synthesis of creatine.  
Does the rat kidney, in vivo, produce guanidinoacetate and release it to the plasma?  This 
is addressed, quantitatively, by means of measurements of arterio-venous differences 
together with renal blood flow.  Response of renal GAA production to creatine ingestion 
is examined.  As well, the extent that renal GAA production accounts for the need for 
creatine, as measured by renal creatinine excretion, is determined. 
 
1.8.2. Creatine Synthesis in the Neonate 
 
We have quantified creatine accretion in suckling rat pups and determined the extent to 
which this creatine is provided in mother’s milk.  We used an isotopic approach to 
characterize the origin of milk creatine, whether it be produced by the mammary gland or 
excreted from plasma. 
 
We have measured creatine and guanidinoacetate in human milk and in commercial infant 
formulas and determined the total dietary intake of creatine by the infant.  From these 
data, together with the estimates of total creatine accretion by the growing infant, we have 
determined the extent to which the infant and the mother bear the burden for providing 
creatine.  We have then discussed the metabolic burden, in the context of other aspects of 
metabolism.  
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CHAPTER 2 
CREATINE SYNTHESIS: PRODUCTION OF GUANIDINOACETATE BY 
THE RAT AND HUMAN KIDNEY IN VIVO 
Am J Physiol Renal Physiol 293: F1799-F1804, 2007 
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2.1. ABSTRACT 
A fraction of the body’s creatine and creatine phosphate spontaneously degrades to 
creatinine, which is excreted by the kidneys.  In humans, this amounts to about 1-2 g per 
day and demands a comparable rate of de novo creatine synthesis.  This is a two-step 
process in which L-arginine:glycine amidinotransferase (AGAT) catalyzes the conversion 
of glycine and arginine to ornithine and guanidinoacetate (GAA); guanidinoacetate 
methyltransferase (GAMT) then catalyzes the SAM-dependent methylation of GAA to 
creatine.  AGAT is found in the kidney and GAMT in the liver, which implies an 
interorgan movement of GAA from the kidney to the liver.  We have studied the renal 
production of this metabolite in both rats and humans.  In control rats, [GAA] was 5.9 µM 
in arterial plasma and 10.9 µM in renal venous plasma for a renal A-V difference of –5.0 
µM.  In the rat, infusion of arginine or citrulline markedly increased renal GAA 
production but infusion of glycine did not.  Rats fed 0.4% creatine in their diet had 
decreased renal AGAT activity and mRNA, an arterial plasma [GAA] of 1.5 µM and a 
decreased renal A-V difference for GAA of –0.9 µM.  In humans, [GAA] was 2.4 µM in 
arterial plasma, with a renal A-V difference of -1.1 µM.  These studies show, for the first 
time, that GAA is produced by both rat and human kidneys in vivo. 
 
Keywords: L-arginine:glycine amidinotransferase (AGAT), transamidinase, amino acid 
metabolism  
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2.2. INTRODUCTION 
Creatine and creatine phosphate act to buffer the cytosolic ATP/ADP ratio in tissues that 
have high and variable rates of ATP usage (e.g. skeletal and cardiac muscle).  Creatine 
kinase catalyzes the reversible transfer of the γ-phosphate group of ATP to the guanidino 
group of creatine to yield ADP and creatine phosphate. 
ATP   +   Creatine   ↔   ADP   +   Creatine Phosphate  [Equation 1] 
In skeletal muscle, creatine kinase activity is high, keeping its reaction at near-
equilibrium.  This keeps the ADP and ATP concentrations fairly constant and buffers the 
cytosolic phosphorylation potential (18, 27, 28).  Energy storage and transmission by the 
creatine kinase system is hypothesized to work in two ways: as a temporal buffer and as a 
spatial buffer.  The temporal energy buffer theory is best exemplified during episodes of 
high energy use, such as muscle contraction.  As soon as ATP is hydrolyzed it must be 
replenished.  The high-energy phosphate of creatine phosphate is transferred to ADP to 
regenerate ATP.  This leads to an accumulation of creatine that must be rephosphorylated 
during recovery from exercise.  The spatial energy buffer theory implies that creatine 
phosphate acts as an energy carrier, working to transport high-energy phosphate from 
sites of synthesis (mitochondria) to sites of ATP utilization in the cytosol (27). 
 
There is a need for creatine replacement due to the spontaneous, irreversible conversion 
of creatine and creatine phosphate to creatinine (3).  Creatinine is not used by the body 
and is excreted in the urine.  Approximately 1.7% of the body’s total creatine pool 
(creatine and creatine phosphate) is converted to creatinine per day (28).  In a young 70 
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kg male, this amounts to a loss of about 2 g of creatine per day (21).  This creatine has to 
be replenished by the dietary intake of creatine and by de novo creatine synthesis. 
 
De novo creatine synthesis is a very simple process, involving just two enzymes.  The 
first enzyme is L-arginine:glycine amidinotransferase (AGAT).  AGAT catalyzes the 
transfer of a guanidino group from arginine to glycine to form ornithine and 
guanidinoacetate (GAA) (26).  This is believed to be the regulated step of creatine 
biosynthesis.  The second enzyme in the pathway is guanidinoacetate methyltransferase 
(GAMT).  This enzyme catalyzes the transfer of a methyl group from S-
adenosylmethionine (SAM) to GAA to form S-adenosylhomocysteine (SAH) and creatine 
(26).  There are high activities of AGAT in the kidneys and of GAMT in the livers of 
various species (26).  Such tissue enrichment has suggested that creatine synthesis is an 
inter-organ process whereby GAA, produced by the kidney, is released into the 
circulation and is methylated to creatine in the liver.  Creatine is then released from the 
liver and into the circulation where it can be taken up, via a specific transporter, by 
various tissues.  However, this hypothesis has not been tested in vivo. 
 
The regulation of creatine biosynthesis is usually thought to occur at the level of AGAT 
(26).  An increase in serum levels of creatine results in a decrease in AGAT enzyme 
activity, enzyme level and mRNA expression in rat kidney (14). 
 
In the current study we investigate the production of GAA, in vivo, by human and rat 
kidneys.  We have also used the rat to study the regulation of renal GAA production.  We 
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have investigated the effects of creatine supply as well as substrate supply on renal GAA 
production.  This study has provided novel insights into the acute and chronic regulation 
of creatine synthesis. 
 
2.3. MATERIALS AND METHODS 
Chemicals and other reagents:  Chemicals and the Hypersil ODS C18 reverse-phase 
HPLC column were purchased from Sigma (Oakville, ON, Canada).  Diet components 
were purchased from MP Biomedicals (Montreal, QC, Canada).  The Pico-Tag column 
for the measurement of free amino acids, Centricon 3000 molecular weight cut-off spin 
columns and other filters were supplied by Millipore (Barrerica, MA, USA).  Creatine 
kinase was bought from Roche (QC, Canada) and Dulbecco’s phosphate-buffered saline 
from Invitrogen Canada Inc. (Burlington, ON, Canada).  A one-step RT-PCR kit was 
purchased from Qiagen (Mississauga, ON, Canada), and β-actin amplimer set primers 
were purchased from BD Biosciences Clontec (Palo Alto, CA, USA).  
Phenylisothiocyanate was provided by Pierce Biotechnology, Inc. (Rockford, IL, USA). 
 
Human Subjects:  Seven healthy subjects [44 years of age (SD 14), body mass index 27.9 
kg/m
2 
(SD 4.1)] were studied after the protocol had been approved by The University of
 
Rochester Institutional Review Board and informed written consent had been obtained.  
None of the subjects were vegetarians or followed a creatine-restricted diet.  Renal net 
balance measurements were performed as previously described (16).  Briefly, subjects 
were admitted to the University of Rochester General Clinical Research Center between 
6:00 and 7:00 pm on the evening prior to experimentation.  A standard meal (10 kcal/kg; 
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50% carbohydrate, 35% fat, 15% protein) was consumed between 6:30 and 8:00 pm after 
which subjects were required to fast until completion of the experiment.  At 
approximately 8:00 am the following morning, an infusion of para-aminohippuric acid 
was started for measurement of renal blood flow.  Between 8:00 and 9:00 am, a renal vein 
was catheterized, under fluoroscopy, through the right femoral vein and the position of 
the catheter tip ascertained by injection of a small amount of iodinated contrast material.  
At approximately 9:00 am, a dorsal hand vein was cannulated and kept in a 
thermoregulated Plexiglas box at 65ºC for sampling arterialized venous blood.  Starting at 
approximately 10:00 am, three blood samples were obtained simultaneously from the 
dorsal hand vein for determination of guanidinoacetate and creatinine concentrations.  
 
Animals:  The study was conducted in accordance with the Guidelines of the Canadian 
Council on Animal Care and was approved by Memorial University of Newfoundland’s 
Institutional Animal Care Committee.  Male Sprague-Dawley rats were purchased from 
Memorial University of Newfoundland’s breeding colony and were fed ad libitum and 
had free access to water.  The control diet, AIN-93G (17), is creatine-free while the 
creatine supplementation diet was a modified version of it.  For the creatine 
supplementation diet, 4.0 g/kg creatine monohydrate replaced 4.0 g/kg cornstarch.  Rats 
were placed on these diets for a period of two weeks.  Prior to the initiation of each 
experimental period, animals were allowed to become accustomed to the AIN-93G 
powdered diet for a period of 3-5 days.  At the beginning of the feeding study rats 
weighed about 200 g; at the end of the feeding period, control rats and creatine-fed rats 
weighed an average of about 400 g.  All animals were exposed to a 12-hour light: 12-hour 
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dark cycle, with the light cycle commencing at 8 am.  All procedures were conducted 
during the 12-hour light cycle.  
 
Tissue preparation:  Animals were anaesthetized with 65 mg/kg sodium pentobarbital 
(i.p.).  Following a midline abdominal incision and opening of the abdominal cavity, the 
renal vein was cleaned of connective tissue and blood flow was measured using a T206 
small animal blood flow meter (Transonic Systems Inc., Ithaca, NY, USA).  Arterial and 
venous blood samples were taken across the kidney.  Kidneys were removed and 
immediately placed in ice-cold 50 mM potassium phosphate buffer (pH 7.4), except for a 
small sample which was retained for RT-PCR analysis.   
 
Infusion experiments:  The femoral vein was cleaned to allow delivery of the 0.8 mL 
priming injection and the jugular vein was cannulated with PE50 tubing to allow delivery 
of infusate.  A tongue restrainer was placed in the animal’s mouth to prevent suffocation.  
The abdominal cavity was then opened, the T206 probe placed on the renal vein, the 
priming injection given and the infusion pump was set to deliver 0.037 mL/minute 
through the jugular vein for 20 minutes.  Blood flow was measured during the entire 20 
minute infusion.  At 20 minutes, both arterial and venous blood samples were taken 
across the kidney.  Priming injections for the different experimental conditions were 0.8 
mL of either 0.9% NaCl, 200 mM arginine, 100 mM citrulline, 200 mM glycine, or 200 
mM alanine.  Infusions, for each condition, were either 0.9% NaCl, 60 mM arginine, 30 
mM citrulline, 60 mM glycine, or 60 mM alanine, respectively.  All amino acid solutions 
were made isotonic with saline. 
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Creatine, guanidinoacetate, creatinine, and L-arginine:glycine amidinotransferase 
assays:  For creatine measurement, aliquots of the plasma samples were deproteinized by 
adding 50% vol/vol 0.6 M perchloric acid, kept on ice for 20 minutes and centrifuged at 
20 000 x g for 5 minutes to sediment proteins.  The supernatant was neutralized with 20% 
potassium hydroxide and creatine was measured as described by Lowry and Passonneau 
(12).  For GAA measurement, the plasma samples were diluted 4-fold with PBS, and 
centrifuged through a Centricon spin filter at 10 000 x g for 30 minutes to remove large 
proteins.  Filtered plasma was used for GAA analysis via HPLC according to the method 
of Carducci et al. (6).  Creatinine was measured by Clinical Laboratories, Health Sciences 
Center (St. John’s, NL, Canada).  Renal AGAT activity was measured as described by 
Van Pilsum et al. (25). 
 
Reverse Transcriptase/ Polymerase Chain Reaction (RT-PCR) analysis of AGAT mRNA:  
RNA was prepared from the kidney samples using a rapid guanidinium thiocyanate 
method as described by Chomczynski and Sacchi (7).  2 g of RNA were reverse 
transcribed using a one-step reverse transcription kit and amplified by 21 cycles.  An 
upstream primer (5'-ATGCTACGGGTGCGGTGT-3') and downstream primer (5'-
ATAATTGACCTGTATGCGCGG-3') were designed from the rat kidney AGAT 
sequence.  The primers were used to amplify a 599-bp PCR fragment.  A 768-bp 
fragment of rat β-actin gene was co-amplified using amplimer set primers.  PCR products 
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were separated on a 1.5% agarose gel.  Ethidium bromide-stained gels were visualized by 
UV illumination and quantified by densitometry. 
 
Amino acid analysis:  Plasma samples were deproteinized by mixing 200 µL plasma, 200 
µL internal standard (norleucine), and 1.0 mL 5% trifluoroacetic acid in methanol.  
Samples were centrifuged at 20 000 x g for 5 minutes so as to sediment proteins.  The 
supernatant was poured off, frozen in liquid nitrogen and freeze-dried overnight.  Amino 
acid analysis was as described by Bidlingmeyer et al. (2). 
 
Statistical analysis:  All data are presented as mean (standard deviation).  In studies with 
only two groups, Student’s paired or unpaired (depending upon appropriateness) t-test 
was used to identify significant differences.  One-way ANOVA followed by Newman-
Keuls post-hoc tests was used in studies involving three or more experimental groups.  A 
P value of <0.05 was taken as significant.  GraphPad Software Prism 3.0 was used for all 
statistical analyses.  
 
2.4. RESULTS 
Renal GAA Production and its Chronic Regulation.  Figure 1A shows that rat kidneys 
produce GAA and release it into the renal vein; on the control diet, GAA concentration in 
renal venous plasma was about 9 µM, compared with 5 µM in arterial plasma.  Creatine 
supplementation for two weeks massively decreased both the arterial GAA concentrations 
(by 72%) and renal A-V differences (by 81%).  Renal AGAT activity was decreased by 
86% upon creatine supplementation (Figure 2.1B).  Densitometric quantitation of renal  
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Figure 2.1: Effect of Creatine Feeding on Renal Guanidinoacetate (GAA) 
Production and L-Arginine:Glycine Amidinotransferase (AGAT) Activity and 
mRNA Expression in Rats.  Bars represent means and vertical lines standard deviations 
of 6 observations.  Different superscripts indicate statistical differences (P<0.05).  A. 
Plasma GAA concentrations and renal A-V differences.  A negative A-V difference 
represents renal output.  B. Renal AGAT activity.  C. Renal AGAT mRNA.  Lane 1, MW 
standards; lanes 2 and 3, control diet; lanes 4 and 5, creatine supplementation.  
Densitometric quantitation of AGAT mRNA, normalized for β-actin. 
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AGAT mRNA, when normalized for β-actin, shows a 41% decrease in its abundance 
upon feeding creatine. 
 
So as to determine the extent to which renal GAA production could account for total 
creatine synthesis, we measured, simultaneously, the A-V differences for GAA and 
creatinine across rat and human kidneys.  This is based on the fact that creatinine 
clearance via the kidneys reflects creatine loss by conversion to creatinine and, therefore, 
of the need for creatine replacement.  There was no significant difference between renal 
GAA production and creatinine loss in rats (Figure 2.2).  In humans, however, renal 
GAA production only amounted to about 11-12% of renal creatinine excretion under both 
fed and fasted conditions (Table 2.1). 
 
Acute Regulation of Renal GAA Production by Substrate Concentrations.  We examined 
the effects of acute increases in the amino acid substrates for GAA synthesis.  We 
employed two control groups, rats infused either with NaCl or with alanine. The 
experimental groups were infused with glycine or arginine.  We also infused rats with 
citrulline, which is converted to arginine in kidneys (9).  We measured renal GAA 
production, by measuring both renal plasma flow and A-V differences, after 20 minutes 
of infusion.  Glycine infusion increased the circulating levels of this amino acid by about 
50% (Table 2.2) but there was no increase in renal GAA production (Figure 2.3).  
Arginine infusion increased the plasma levels of this amino acid by about 300% (Table 
2.2); renal GAA production was increased by about 150% (Figure 2.3).  Citrulline  
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Figure 2.2: Creatinine Excretion vs. Guanidinoacetate (GAA) Production by the 
Kidneys of Rats fed the control (creatine-free) diet.  Bars represent means and vertical 
lines standard deviations of 10 observations.   
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Table 2.1: Renal Metabolism of Guanidinoacetate (GAA) and Creatinine in 
Humans.  All values are expressed as mean (standard deviation) of 7 observations.  An 
asterisk indicates that the arteriovenous (A-V) difference is significantly different from 
zero (P<0.01). 
     Guanidinoacetate            Creatinine 
 Fed Fasted Fed Fasted 
Arterial plasma 
concentration (µM) 
2.4 (0.8) 2.5 (0.4) 76 (13) 75 (12) 
Renal A-V 
difference (µM) 
-1.5 (0.9)* -1.5 (0.8)* 14 (8.1)* 11 (9.6)* 
Renal flux 
(µmoles/minute) 
-1.1 (0.5) -1.0 (0.6) 10 (5.2) 8.3 (5.1) 
 
 
 
 
 
 
 
 
 
 
Table 2.2: Plasma Amino Acid Levels following Infusion of Various Substrates in Rats.  All values are expressed as mean 
(standard deviation) of 6 observations.  An asterisk indicates statistical differences from the saline control in each vertical column 
(P<0.05). 
Infusion Glycine  
(µM) 
Arginine  
(µM) 
Citrulline  
(µM) 
Alanine  
(µM) 
Methionine  
(µM) 
Ornithine 
(µM) 
NaCl 268 (66) 111 (51) 85 (31) 566 (133) 42 (9) 93 (21) 
Glycine 413 (29)* 79 (28) 71 (17) 482 (46) 44 (22) 95 (30) 
Arginine 235 (44) 433 (219)* 92 (21) 516 (67) 40 (23) 315 (134)* 
Citrulline 244 (50) 98 (77) 347 (201)* 424 (58) 33 (9) 154 (53) 
Alanine 335 (84)* 93 (70) 101 (18) 925 (133)* 52 (10) 91 (33) 
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Figure 2.3: Total Renal Production of Guanidinoacetate (GAA) in Rats Infused with 
Various Substrates.  Bars represent means and vertical lines standard deviations of 6 
observations.  Different superscripts indicate statistical differences (P<0.05). 
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 infusion, which did not increase plasma arginine levels (Table 2.2), almost doubled renal 
GAA production (Figure 2.3). 
 
2.5. DISCUSSION 
The present study makes a number of novel contributions to our knowledge of creatine 
synthesis and its regulation: 
(i) the rat kidney produces GAA, in vivo, 
(ii) renal GAA production, in vivo, responds acutely to increased arginine levels 
but not to increased glycine levels, 
(iii) citrulline, converted to arginine in the renal tubules, is immediately available 
for GAA synthesis; however, creatine ingestion does not down-regulate 
intestinal citrulline production, 
(iv) creatine ingestion markedly decreases renal GAA production in the rat, 
(v) in rats fed a creatine-free diet, renal GAA production in vivo equals creatinine 
loss in the urine, 
(vi) human kidneys also produce GAA but, unlike in the rat, this is not the major 
source of GAA for creatine synthesis. 
In addition, we confirm that creatine ingestion decreases both renal AGAT activity and 
mRNA level. 
 
Since creatinine excretion is a measure of creatine and creatine phosphate breakdown and 
therefore, of the need for creatine replacement, our data on the equivalence of renal GAA 
production and creatinine excretion indicates that the kidney is the major organ for the 
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production of GAA in the rat.  Borsook and Dubnoff (4) had pointed out that the activity 
of renal AGAT is more than sufficient to supply the body’s creatine need.  However, 
measurements of enzyme activity under optimal conditions cannot be extrapolated to the 
in vivo situation; the present data provide definitive information on the in vivo situation.  
It cannot, however, be concluded that the kidney is the sole site of GAA production in the 
rat.  AGAT activity has been reported in rat kidney, pancreas, brain, spleen, and testes 
(24).  Horner (11) studied transamidination in nephrectomized rats and found that GAA 
synthesis was not entirely ablated; indeed extrarenal transamidination, in this situation, 
may be considerable.  Although we have shown that the rat kidney is the major organ 
involved in GAA production in vivo, extrarenal transamidination may be important in 
terms of local roles within tissues or in times of renal dysfunction. 
 
The situation in humans, however, is quite different as renal GAA production accounts 
for only about 11-12% of daily creatine loss as measured by creatinine excretion.  Thus, 
almost 90% of daily creatine replenishment occurs without renal involvement.  As our 
human subjects were not on a creatine-free diet, this creatine replenishment occurs via a 
combination of diet and de novo synthesis.  Stead et al. (21) have estimated that in 20-59 
year-olds on a typical western diet, about 50% of the creatine need can be provided by the 
diet.  If we take this into consideration, renal GAA production in a human may account 
for approximately 20% of total GAA synthesis.  The kidney, therefore, does not appear to 
be the major organ involved in GAA production in humans although it clearly plays a 
role.  An earlier study by Sandberg et al. (19) also reported GAA production by human 
kidneys, in vivo.  Again, GAA production amounted to only 25% of the renal creatinine 
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loss.  Although these data agree, in general, with our results, it should be appreciated that 
the GAA concentrations reported in this 1953 study are probably not reliable as they are 
5-fold those found by modern analytical techniques (8). 
 
We report that feeding a 0.4% creatine diet for a period of two weeks causes a down-
regulation of renal AGAT activity and mRNA expression as well as a decrease in in vivo 
renal GAA production in the rat.  The down-regulation of AGAT activity by creatine and 
GAA feeding has been previously shown by Van Pilsum (23) and in our lab by Stead et 
al. (20).  The effect of GAA is believed to be due to the conversion of GAA to creatine 
and the action of creatine to down-regulate the enzyme.  Our findings on the decreased 
levels of renal AGAT mRNA brought about by creatine feeding, confirm those of 
McGuire et al. (14).  These data suggest that AGAT activity may be regulated at the 
pretranslational level.  However, the decrease in renal AGAT mRNA expression is not as 
large as the decrease in renal AGAT activity (41% vs. 86%, respectively) suggesting that 
an additional mechanism may play a role. 
 
We also report, for the first time, that feeding a creatine-containing diet decreases GAA 
production by rat kidneys, in vivo.  Intake of a diet containing 0.4% creatine decreases 
renal GAA production by 81% and lowers plasma GAA values by 72%.  A recent study 
conducted by Derave et al. (8) showed that feeding creatine to humans for a period of 20 
weeks lowered plasma GAA levels in a dose-dependant manner: by 50% during the 
loading phase (20 g creatine per day) and by 30% during the maintenance phase (5 g 
creatine per day).   
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Our experiments also shed light on the acute regulation of renal GAA synthesis by 
increased provision of the amino acid substrates, glycine and arginine.  Increased 
provision of glycine had no effect on GAA production whereas provision of arginine did.  
These experiments are best interpreted in terms of the kinetic properties of AGAT and the 
renal concentrations of the substrates.  The Km of the rat kidney AGAT for glycine is 
reported to be 2.4-2.8 mM; that for arginine is 3.0-3.1 mM (15).  We have reported the rat 
renal levels of glycine and arginine to be 1320 and 170 nmol/g, respectively (5); this 
translates to average intracellular concentrations of about 2.5 mM and 0.32 mM, 
respectively for glycine and arginine.  Given that the cell glycine concentration is close to 
AGAT’s Km and that the infusion only raised the circulating glycine concentration by 
about 50% one may expect, at most, an increase of about 25% in GAA production.  An 
increase of this magnitude was observed but was not statistically significant.  On the other 
hand, cellular arginine concentration is well below the Km value of AGAT for this amino 
acid.  The infusion increased circulating arginine concentration four-fold so that, 
assuming that changes in cellular arginine concentration parallel the plasma levels and 
applying the Michaelis-Menten equation, we may anticipate an increased GAA 
production of about 3-fold.  This is remarkably close to the 2.7-fold increase that we 
observed.  The close agreement between the observed and calculated rates may be, to 
some degree, fortuituous given the nature of the assumptions we were obliged to make.  
Nevertheless, it does serve to highlight the sensitivity of renal GAA synthesis to ambient 
arginine concentration.  That GAA synthesis in humans is also markedly sensitive to 
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arginine concentration is suggested by a report of low plasma GAA concentration in 
children with urea cycle defects that may be normalized by the provision of arginine (1).   
 
Finally, we draw attention to our finding that renal GAA production was doubled by the 
infusion of citrulline even though there was no increase in circulating arginine 
concentration.  This result is attributable to the conversion of citrulline to arginine by the 
renal tubules.  We have already shown that this process is very sensitive to circulating 
citrulline concentration in the rat (9).  Renal arginine synthesis occurs in the cells of the 
proximal tubule (10) as does GAA synthesis (13, 22).  Therefore, arginine synthesized in 
these cells becomes immediately available as a substrate for GAA synthesis.  This 
indicates that citrulline synthesis (which occurs in the gut) may contribute in part to 
creatine synthesis.  It also suggests that gut citrulline synthesis may be regulated by 
ingestion of creatine.  To test this hypothesis, we measured gut citrulline flux in rats fed 
the 0.4% creatine diet.  We found, however, that the need for creatine synthesis does not 
drive intestinal citrulline synthesis, which was not altered in the creatine-fed rats (data not 
shown). 
 
In summary, this study has shown, for the first time, that GAA is produced by rat kidneys, 
in vivo.  We have also shown that the human kidney produces GAA.  Creatine-feeding 
downregulates renal AGAT activity and mRNA expression as well as in vivo production 
of GAA by the rat kidney.  Provision of the substrate glycine was without effect on renal 
GAA production in vivo; however, provision of the substrate arginine or citrulline, which 
is converted to arginine in the kidney, increased renal GAA production in the rat.   
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CREATINE AND GUANIDINOACETATE CONTENT OF HUMAN 
MILK AND INFANT FORMULAS: IMPLICATIONS FOR CREATINE 
DEFICIENCY SYNDROMES AND AMINO ACID METABOLISM 
British J Nutr 110: 1075-1078, 2013 
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3.1. ABSTRACT 
Creatine is essential for normal neural development; children with inborn errors of 
creatine synthesis or transport exhibit neurological symptoms such as mental retardation, 
speech delay, and epilepsy.  Creatine accretion may occur through dietary intake or de 
novo creatine synthesis.  The objective of this study is to determine how much creatine an 
infant must synthesize de novo.  We have calculated how much creatine an infant needs to 
account for urinary creatinine excretion (creatine’s breakdown product) and new muscle 
lay-down.  To measure an infant’s dietary creatine intake, we measured creatine in 
mother’s milk and in various commercially available infant formulas.  Knowing the 
amount of milk/formula ingested, we calculated the amount of creatine ingested.  We 
have found that a breast-fed infant receives about 9% of the creatine needed in the diet 
and that infants fed cow’s milk-based formula receive up to 36% of the creatine needed.  
However, infants fed a soy-based infant formula receive negligible dietary creatine and 
must rely solely on de novo creatine synthesis.  This is the first time that it has been 
shown that neonatal creatine accretion is largely due to de novo synthesis and not through 
dietary intake of creatine.  This has important implications both for infants suffering from 
creatine deficiency syndromes and for neonatal amino acid metabolism.   
 
Key Words: arginine, methionine, methylation reactions 
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3.2. INTRODUCTION 
Creatine is essential for normal brain development.  We know this because infants with 
inborn errors in either creatine synthesis or transport develop a consistent series of 
neurological symptoms, including speech delay, mental retardation and epilepsy
(1,2,3)
.  
Nevertheless, the great bulk of the body’s creatine and creatine phosphate occurs in 
muscle, and it is clear that these molecules play critical roles in the buffering of ATP 
levels, the vectorial transport of high-energy phosphates and in the control of the 
production of reactive oxygen species by mitochondria
(4,5,6)
.  The skeletal muscle content 
of creatine plus creatine phosphate is of the order of 25-30 µmol/g wet weight.  The brain 
content of these molecules is perhaps half that of muscle
(7)
.  The total body content of 
creatine plus creatine phosphate is quite high, approximately 100 g in an adult human
(8)
.  
Creatine and creatine phosphate are spontaneously and irreversibly broken down to 
creatinine at a rate of 1.7% per day.  Creatinine is excreted in the urine.  Therefore, adults 
have a continuous need to replace the creatine, usually by a combination of diet and 
endogenous synthesis
(9)
.  In addition to the replacement of this creatine lost as creatinine, 
infants must also supply creatine to their expanding tissue mass.  There are only two ways 
in which a growing infant may acquire creatine; it is either provided in mother’s milk (or 
in infant formula) or is synthesized de novo by the infant.  The situation with formula-fed 
infants is more complex and depends upon the type of formula used.  The present study 
examines the creatine and guanidinoacetate (a metabolic precursor of creatine) content of 
mother's milk and various infant formulas, and estimates the degree to which diet or 
endogenous synthesis provides creatine to the growing infant.  The implications of the 
quantity of dietary creatine available to infants suffering from creatine-deficiency 
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syndromes as well as the burden that creatine synthesis places on an infant’s amino acid 
metabolism are discussed. 
 
3.3. EXPERIMENTAL METHODS 
Twenty healthy lactating women (31 ± 5 years of age) donated milk at either 1-2 weeks or 
5-6 weeks post-partum (10 subjects at each time-period).  The milk was collected at the 
Janeway Children’s Health and Rehabilitation Centre, St. John’s, using electronic breast 
pumps.  Blood was taken from these subjects by nurses at the Janeway Blood Collection 
Services.  None of the subjects were vegetarian.  All protocols were approved by both the 
Memorial University Human Investigation Committee and the Research Approval 
Committee of the Health Care Corporation of St. John’s.  Informed written consent was 
obtained before the collection of any human samples.  
 
Eight different types of infant formula were purchased from various department stores in 
St. John’s.  Formulas from six different lots of each type were purchased, except for 
Isomil, for which samples from only five different lots were available.  Each formula was 
reconstituted according to the manufacturers’ instructions and an aliquot of each infant 
formula, or human milk sample, was centrifuged at 4ºC at 150,000 g for 60 minutes so as 
to separate the aqueous phase.  Blood samples were collected with lithium-heparin and 
centrifuged at 4ºC at 3,000 g for 10 minutes to separate the plasma.  Samples of the 
aqueous phase of the milk and formula samples, and of the plasma samples, were 
deproteinized by the addition of 50% vol/vol of 0.6 M perchloric acid, kept on ice for 20 
minutes and centrifuged at 20,000 g for 5 minutes to sediment the proteins.  To 1.5 ml 
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aliquots of the resulting supernatants were added 25 µl of 50% potassium carbonate and 
20 µl of universal indicator before neutralization with 20% potassium hydroxide.  The 
deproteinized, neutralized samples were used for the measurement of creatine by the 
enzymatic method of Lowry and Passonneau
(10)
 and guanidinoacetate by the HPLC 
method of Carducci
 
et al.
(11)
. 
 
Data are represented as means ± standard deviations.  Statistical significance was 
determined by means of a one-way ANOVA followed by Newman-Keuls post-hoc test.  
A p value of <0.05 was taken to indicate statistical significance. 
 
3.4. RESULTS AND DISCUSSION 
Figure 3.1 shows the concentrations of creatine and guanidinoacetate in human milk and 
plasma.  Since there was no difference between the concentrations measured at 1-2 weeks 
or at 5-6 weeks post-partum, these data were combined.  Both plasma and milk contained 
appreciable concentrations (60-70 µM) of creatine but creatine was not more concentrated 
in milk than in plasma.  The circulating concentration of guanidinoacetate was much 
lower than that of creatine and was even lower still in milk.  It is clear, therefore, that 
milk is a source of creatine for the nursing infant but that guanidinoacetate is not supplied 
in significant quantities by this route. 
 
Table 3.1 shows the creatine and guanidinoacetate content of the infant formulas.  There 
were appreciable concentrations of creatine in all of the cows’ milk-based formulas; 
indeed, these were substantially higher than the concentrations found in human milk,  
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Figure 3.1: Concentrations of Creatine and Guanidinoacetate (GAA) in Human 
Milk and Plasma.  Bars represent means and vertical lines standard deviations of 5-20 
observations. Asterisk indicates statistical significance (P=0.004).  
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Table 3.1: Creatine and guanidinoacetate concentrations in various infant formulas.  
N=6 (except N=5 for Nestle Alsoy 1).  
 Creatine (uM)  Guanidinoacetate (uM) 
 Mean SD  Mean SD 
Similac (ready-to-use) 114 3  1.1 1.9 
Similac (concentrated) 119 7  3.0 4.3 
Isomil 13 2  1.9 1.2 
Enfalac 334 10  3.7 1.1 
Enfamil A+ 311 18  3.5 0.4 
Lactofree 10 2  ND 
ND Nestle Goodstart 159 5  
Nestle Alsoy 1 11 6  0.3 0.4 
SD, standard deviation. ND, values which could not be determined.  
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which is consistent with the very high creatine concentration (550 µM) that we measured 
in cow’s milk.  On the other hand, the creatine concentration of Isomil, Lactofree and 
Nestle Alsoy 1 were very low (10-13 µM).  Isomil and Alsoy 1 are soy-based.  Lactofree 
is made with modified cow’s milk ingredients and is intended for infants that suffer from 
lactose intolerance.  The concentration of guanidinoacetate in the infant formulas was 
very low. 
 
It is of interest to estimate the extent to which mother’s milk provides the nursing infant 
with the necessary creatine.  So as to do this we need to calculate creatine intake in 
mother’s milk as well as the accretion of creatine by the infant.  We have selected as our 
reference, breast-fed infants between 6 and 12 weeks of age.  These infants weigh an 
average of 5.7 kg, ingest an average of 143 ml of milk·kg
-1
·day
-1
 and gain an average of 
0.2 kg body weight per week
(12)
.  Since the muscle mass of infants of this age is about 
25% of body mass
(13)
, this amounts to a gain of 50 g of muscle per week.  These infants 
excrete an average of 62 mg of creatinine per day, or 3.8 mmol per week
(14)
.  From the 
data in Figure 3.1 we can calculate that these breast-fed infants ingest about 0.4 mmol of 
creatine per week.  There is no data on the bioavailability of creatine in infants.  
However, creatine bioavailability has been determined to be 79% in adult humans
(15)
.  In 
addition, it is known that the transporter responsible for creatine absorption is elevated in 
suckling rat pups
(16)
.  It is likely, therefore, that the bioavailability of milk creatine is very 
high in suckling infants. 
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The accretion of creatine by these infants can also be estimated.  First of all, it is 
necessary to replace the creatine lost to creatinine formation and excretion, 3.8 mmol per 
week.  In addition, it is necessary to provide creatine to the expanding muscle mass.  
According to Eriksson
(17)
, the skeletal muscle content of creatine phosphate in infants of 
this age is between 12 and 22 mmol·kg wet weight
-1
.  This gives a mean value of 17 
mmol·kg wet weight
-1
.  We were unable to find any recently published data on the 
creatine concentration or total creatine content of infant muscle.  However, applying a 
ratio of 3 for [creatine phosphate]/[creatine], which is common in adult human muscle
(18)
, 
we estimate [creatine] in infant skeletal muscle to be approximately 6 mmol·kg wet 
weight
-1
, for a total muscle creatine concentration of 23 mmol·kg wet weight
-1
.  This is 
somewhat lower than concentrations found in adult muscle, which is consistent with 
measurements of creatine in adult and infant muscle reported in the early 20
th
 Century
(19)
.  
However, since the methodology used in these early studies is not nowadays considered 
to be very reliable we have not employed them in our calculations.  Applying our new 
estimates of infant muscle creatine content with an increase in muscle mass of 50 g per 
week we calculate that 0.46 mmol of creatine per week is required for the expanded 
muscle mass.  Together with the 3.8 mmol of creatine lost as creatinine, we estimate that 
infants of this age require 4.26 mmol of creatine per week.  Since they only receive about 
0.4 mmol per week via milk, almost 90% of their creatine must be provided by de novo 
synthesis by the infant.  These findings are in accord with our study of creatine accretion 
in rat pups
(20)
 and piglets
(21)
 where we showed that milk provided, respectively, only 12% 
and 25% of total creatine accretion, the balance being provided by endogenous synthesis 
by the neonatal animal.  The high rate of endogenous creatine synthesis has important 
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implications both for infants suffering from creatine deficiency syndromes and for the 
infant’s amino acid metabolism. 
 
The fact that infants receive almost all of their creatine by endogenous synthesis is 
entirely consistent with the speed with which symptoms become apparent in infants 
suffering from genetic defects in creatine synthesis.  Symptoms become apparent at an 
early age, regardless of whether the defect is due to an enzyme or a transporter 
deficiency.  These symptoms include highly abnormal developmental scores, mental 
retardation, speech impairment and epileptic seizures
(1,2,3)
. 
 
It is important to analyze the metabolic burden that the synthesis of approximately 3.9 
mmol of creatine per week places on these infants.  Creatine synthesis takes place by 
means of a very simple pathway, employing only two enzymes, L-arginine:glycine 
amidinotransferase (AGAT), and guanidinoacetate methyltransferase (GAMT) [see 
Figure 3.2].  AGAT catalyzes a reaction between arginine and glycine, to produce 
guanidinoacetate (GAA) and ornithine: 
arginine + glycine → ornithine + GAA. 
 
GAMT uses S-adenosylmethionine (SAM) to methylate GAA to creatine and S-
adenosylhomocysteine (SAH): 
GAA + SAM → creatine + SAH. 
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Figure 3.2: Creatine (Cr) Synthesis.  L-Arginine:glycine amidinotransferase (AGAT) 
first catalyzes the transfer of an amidino group from arginine (Arg) to glycine (Gly) to 
produce ornithine (Orn) and guanidinoacetate (GAA).  Guanidinoacetate 
methyltransferase (GAMT) then catalyzes the methylation of GAA from S-
adenosylmethionine (SAM) to produce S-adenosylhomocysteine (SAH) and Cr.   
 78 
 
In this pathway, the entire glycine molecule is incorporated into creatine as well as a 
guanidino group from arginine and a methyl group from SAM. 
 
Using the data provided by Davis et al.
(22)
 on the amino acid composition of human milk, 
we calculate that 6-12 week old infants ingest an average of 14.3, 10, and 5.2 mmol per 
week respectively, of glycine, arginine, and methionine.  Therefore, creatine synthesis 
consumes 27% of dietary glycine.  However, glycine is a nonessential amino acid and 
may be produced endogenously by the infant.  Creatine synthesis also consumes 
guanidino groups corresponding to 39% of those in dietary arginine and methyl groups 
corresponding to 75% of those in dietary methionine.  AGAT converts arginine to 
ornithine and this ornithine may be reconverted to arginine by the combined actions of 
carbamoyl phosphate synthetase I (CPS-I), argininosuccinate synthetase and 
argininosuccinate lyase.  We are aware of no data on the rate of this reconversion in 
infants.  SAH, produced by GAMT, is hydrolyzed by SAH hydrolase to adenosine and 
homocysteine; the homocysteine may be remethylated to methionine either by methionine 
synthase or betaine:homocysteine methyltransferase.  We are aware of no data on the rate 
of remethylation in 6-12 week old infants.  However, Thomas et al.
(23)
 have shown that 
remethylation is quite active in newborn infants; therefore, it is likely that much of the 
SAM required for creatine synthesis is regenerated via the remethylation pathway. 
 
In sum, these calculations reveal that the great bulk of the nursing infant’s need for 
creatine must be met by endogenous synthesis and that this imposes a considerable 
metabolic burden on the growing infant, particularly with regard to amino acid 
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metabolism.  Formula-fed infants receiving cow’s milk-based formula receive 2-4 times 
as much creatine as nursing infants depending upon the formula of choice.  Therefore, the 
metabolic burden of endogenous creatine synthesis may be reduced yet remains an 
appreciable burden on amino acid requirements even in these infants. 
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CHAPTER 4 
SUCKLING RAT PUPS ACCUMULATE CREATINE PRIMARILY VIA 
DE NOVO SYNTHESIS RATHER THAN FROM DAM MILK 
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(used with permission from American Society for Nutrition) 
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4.1. ABSTRACT 
During lactation, there may be a higher need for creatine replacement due to the provision 
of creatine to the milk. Our objectives were to: 1) quantify the creatine concentration in 
rat milk; 2) determine the origin of milk creatine; 3) determine the activities of the 
enzymes of creatine synthesis in lactating rats and pups; and 4) quantify the origin of the 
creatine that accumulates in rat pups. The origin of milk creatine was determined in 4 
dams following the administration of 
14
C-creatine by measuring the isotopic enrichment 
of creatine in the milk and plasma. The activities of the 2 enzymes involved in creatine 
synthesis were compared in lactating and virgin females (n = 7). For all experiments, the 
litter size was standardized to 8 pups. The data indicated that the mammary gland extracts 
creatine from the circulation rather than synthesizing it. This was confirmed by our failure 
to find substantial activities of the enzymes of creatine synthesis in mammary glands. The 
provision of milk creatine requires an additional 35–55% of creatine above the daily 
requirement by lactating rat dams. However, there was no increased creatine synthesis by 
these dams; the additional creatine was largely provided by hyperphagia, because creatine 
is present in commercial rat diet. There was a substantial accumulation of creatine in the 
growing pups, but only ∼12% was obtained from milk. The great bulk of creatine 
accretion was via de novo synthesis by the pups, which imposed a substantial metabolic 
burden on them. 
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4.2. INTRODUCTION 
The creatine and creatine phosphate system serves as an important energy buffer and 
shuttle of high-energy phosphates from mitochondria to the cytoplasmic sites of ATP 
utilization. This system is confined to tissues that have a high and variable energy 
demand such as muscles and brain. The functions of creatine have recently been reviewed 
(1, 2). The synthesis of creatine is a very simple process, involving only 2 reactions and 
requiring 3 amino acids: arginine, glycine, and methionine (3). In the first reaction, 
arginine:glycine amidinotransferase (AGAT;
4
 EC 2.1.4.1) catalyses the transfer of the 
amidino group from arginine to the amino group of glycine to form guanidinoacetic acid 
(GAA) and ornithine. In the second reaction, GAA methyltransferase (GAMT; EC 
2.1.1.2) catalyses the transfer of a methyl group from S-adenosylmethionine to GAA, 
producing creatine and S-adenosylhomocysteine. The highest activities of AGAT are 
found in the kidney and pancreas, although lesser activities are found in the brain, testes, 
lung and spleen. The highest activities of GAMT are found in the liver, with lesser 
activities in pancreas and testes. We have shown that, in rats, the bulk of creatine is 
synthesized via an inter-organ process where GAA produced by the kidney is methylated 
in the liver (1) to form creatine that is released to the circulation, where it can be taken up 
by tissues via a specific transporter. Methylation of GAA by GAMT is a major consumer 
of labile methyl groups. As revealed by analyses of transmethylation fluxes, creatine 
synthesis is a major consumer of labile methyl groups and is thought to account for up to 
45% of the methyl flux in humans (4, 5). Creatine synthesis is regulated by 
pretranslational control of AGAT expression in kidney. Rats fed a creatine-supplemented 
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diet have a marked decrease in AGAT activity, AGAT protein amount, and mRNA 
expression in their kidneys (6–9).  
Under physiological conditions, creatine and creatine phosphate spontaneously and 
irreversibly break down to creatinine, which is subsequently lost in the urine (10). The 
daily loss of creatine to creatinine is estimated to be 1.7% of the total creatine pool (2). 
This creatine loss is replaced both by dietary creatine and de novo synthesis. Humans 
consuming a typical Western diet obtain ∼50% of their daily creatine provision from their 
diet and synthesize the other one-half (5). During lactation, there is an additional 
requirement for creatine due to the provision of creatine in the milk. Accordingly, the 
objectives of this study were to: 1) quantify the creatine content in rat milk and the 
additional burden it imposes on creatine synthesis; 2) determine the origin of creatine in 
milk; 3) determine the impact of lactation on the activities of the enzymes of creatine 
synthesis in rats; and 4) quantify the sources of creatine in suckling rat pups (milk or de 
novo synthesis). 
4.3. MATERIALS AND METHODS 
Chemicals and other supplies.  HPLC-grade methanol, Hypercarb HPLC columns, and 
Scintiverse E were purchased from Fisher Scientific. 
14
C-creatine (creatine [4-
14
C], with a 
specific radioactivity of 1.96 GBq·mmol
−1
) was obtained from American Radiolabeled 
Chemicals. Oxytocin was obtained from Hospira Healthcare. Ion exchange resin (AG 
50W-X8 200–400 mesh) was obtained from Bio-Rad. Unless otherwise stated, all other 
chemicals were purchased from Sigma.  
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Rats.  All animal experimentation was approved by Memorial University's Institutional 
Animal Care Committee in accordance with the Guidelines of the Canadian Council on 
Animal Care. Lactating Sprague-Dawley rats (337.4 ± 16.5 g) with their pups were 
provided by Memorial University's breeding colony. At d 10 postpartum, each litter was 
standardized to 8 pups; extra pups were randomly selected and killed by inhalation of 
halothane (Isoflo, Abbott Laboratories). Each litter was individually housed on a 12:12-h 
light-dark cycle and consumed Purina Rat Diet 5012
5
 ad libitum. Milk, blood, and various 
tissue samplings were conducted 14 d after parturition, which coincides with the peak of 
lactation (11). When required, size-matched virgin females were used as control. Rats 
were anesthetized with an intraperitoneal injection of 6 mg of sodium pentobarbital⋅100 g 
body weight
−1
.  
In vivo GAA production, creatine concentration, AGAT, and GAMT assay.  The renal 
GAA output was measured in lactating and virgin rats (n = 7) as described previously (7). 
Briefly, the renal vein was cleaned of connective tissue and blood flow was measured 
using a T206 small animal blood flowmeter (Transonic Systems). Flow rate was 
measured for 10 min, then arterial and venous blood samples were taken across the 
kidney. Kidney samples were immediately freeze-clamped and stored at −80°C. AGAT 
was assayed in kidney samples that were frozen for <1 wk, as previously described (12). 
GAMT was measured on fresh liver samples using the method of Ogawa et al. (13), 
except that creatine production was quantified by HPLC (14). Enzyme activities were 
expressed in nmol⋅min−1⋅g tissue−1.  
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We examined the origin of milk creatine (whether it is synthesized within the mammary 
gland or extracted by it from circulating plasma) by comparing the specific radioactivity 
of creatine in arterial blood and milk. This required the injection of lactating rats with 
14
C-creatine and sampling blood and milk after an equilibration period. The equilibration 
period was determined by pilot experiments (n = 3) in which the excretion of 
14
C in urine 
was monitored. Urinary 
14
C reached a plateau after 3 d; this plateau extended for at least 6 
d (not shown). The dams (n = 4) were injected i.v. in the caudal vein with 740.9 kBq 
14
C-
creatine prepared in 0.5 mL saline at d 11 and immediately returned to their pups. At d 
14, milk and blood samples were taken. One hour prior to milk collection, the pups were 
removed from the dam who was anesthetized and injected intraperitoneally with oxytocin 
(4 iu⋅kg body weight−1) to stimulate milk release. The nipples and surrounding fur were 
then thoroughly cleaned by rinsing with distilled water. Milk was collected using a 
vacuum milking system adapted from Rodgers (11). Typically, 3–4 mL of milk was 
collected from each dam in <10 min. The collected milk was immediately frozen in liquid 
nitrogen and kept at −80°C until further analysis. Immediately following milk collection, 
arterial blood was drawn from the dam's abdominal aorta into a heparinized syringe and 
centrifuged at 6000 × g at 4°C for 10 min. Plasma was removed and stored at −80°C until 
analysis.  
Determination of creatine specific radioactivity.  We used a modification of the HPLC 
method of Gu and Lim (15) to measure the creatine concentration; the eluate from the 
HPLC column was collected by fraction collection and the creatine peak counted in a 
liquid scintillation spectrometer. Milk and plasma samples (1 mL) were deproteinized by 
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the addition of 100 μL ice-cold trifluoroacetic acid, placed on ice for 10 min, and the 
precipitated protein pelleted at 10,000 × g for 10 min at 4°C. The supernatant was 
immediately applied to a Bond-Elut C18 solid-phase extraction cartridge (100 mg, 1 mL; 
Varian) and the eluate collected. The cartridge was washed with 1 mL dH2O and eluate 
was again collected. The pooled eluate was applied to a disposable chromatography 
column containing 2 mL of cation-exchange resin using sodium as a counterion. It was 
followed by two 3-mL water washes and this eluate was discarded. Creatine bound to the 
resin was eluted with 1 mL of 2 mol⋅L−1 ammonium hydroxide. This eluate was freeze-
dried and dissolved in 250 μL of the mobile phase immediately prior to HPLC analysis. A 
100-μL volume of the dissolved eluate was injected onto a porous graphitized carbon 
column (Hypercarb, 100.0 × 4.6 mm). The column was eluted isocratically with 1% 
trifluoroacetic acid and 2% methanol; the absorbance was monitored at 210 nm. Fractions 
were collected every 0.5 min for 15 min. All fractions were mixed with 10 mL of 
Scintiverse E and counted for 10 min on a LKB 1214 Rackbeta liquid scintillation counter 
(LKB). Creatine eluted at ∼4 min and the corresponding fractions were the only ones 
containing substantial quantities of radioactivity. The creatine concentration was 
referenced to a set of creatine standards (0–1 mmol⋅L−1) that was processed in parallel to 
the samples (including solid phase extraction and ion exchange chromatography). The 
creatine specific radioactivity was expressed as mBq·nmol
−1
.  
Creatine content of adult tissues and pups.  To determine whether rats’ total creatine pool 
becomes depleted during lactation, we measured the creatine concentration of muscle and 
brain (2 major pools of creatine) in lactating and virgin females (n = 4). Tissues were 
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homogenized in 150 mmol⋅L−1 sodium phosphate (pH 7.4). Rat pups were killed at d 10, 
15, and 20 (n = 6) by halothane inhalation and each pup was homogenized. The 
homogenates were allowed to stand for 30 min at room temperature to allow for the 
conversion of creatine phosphate to creatine. The total creatine content was measured by 
HPLC (15) and was reported as nmol⋅g−1 for adult tissues and μmol⋅animal−1 for the pups.  
Statistical analysis.  All data are presented as means ± SD. Lactating and virgin female 
rats were compared using Student's t test, or, when variances were heterogeneous, the 
Mann-Whitney U test. Plasma and milk samples of lactating rats were compared using 
paired t tests, and 1-way ANOVA and Tukey's post hoc test were used to compare 
enzyme activities among lactating rats, virgin rats, and pups. Differences were considered 
significant at P < 0.05. GraphPad Prism 3.0 was used for statistical analyses. 
4.4. RESULTS 
The creatine concentrations in milk and plasma from lactating rats were 273.7 ± 47.7 
μmol⋅L−1 and 150.0 ± 48.8 μmol⋅L−1, respectively. The isotopic enrichments of creatine in 
plasma and in milk did not differ (paired t test, P = 0.37) (Fig. 4.1), indicating that the 
bulk, if not all, of milk creatine is derived from the plasma. To further explore this, we 
measured the activities of the enzymes of creatine synthesis in the mammary gland. The 
activity of AGAT was below our limit of detection (<10 nmol⋅min−1⋅g−1) and the activity 
of GAMT was very low (0.19 ± 0.08 nmol⋅min−1⋅g−1) compared with that in liver (13.10 
± 4.11 nmol⋅min−1⋅g−1).  
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Figure 4.1:  Isotopic enrichment of creatine in plasma and milk of 4 lactating rats. 
Means did not differ. 
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The arterial plasma concentration of GAA was significantly lower in the lactating females 
than in the virgin controls; however, the renal arteriovenous difference did not differ 
between lactating and virgin females (Fig. 4.2). A quantitative analysis of renal GAA 
output (Table 4.1) confirmed that lactation was not accompanied by an increased renal 
GAA output. It is noteworthy that the plasma creatine concentration was significantly 
lower in the lactating females (Table 4.1). Renal AGAT (0.24 ± 0.04 nmol⋅min−1⋅g−1) and 
GAMT (12.47 ± 4.66 nmol⋅min−1⋅g−1) did not differ between lactating and virgin rats.  
The limb muscle (biceps femoris) creatine concentration did not differ between the 
groups (19.51 ± 0.79 μmol⋅g−1). Unexpectedly, however, the brain creatine concentration 
was higher in lactating females (15.24 ± 1.13 μmol⋅g−1) than in virgin females (12.85 ± 
1.12 μmol⋅g−1) (P = 0.02). The pups accumulated an average of 20.7 μmol⋅d−1 between d 
10 and 15 and 42.0 μmol⋅d−1 between d 15 and 20, resulting in total body creatine 
contents that increased progressively (Fig. 4.3). On d 14, the hepatic GAMT activity of 
pups (15.94 ± 3.50 nmol⋅min−1⋅g−1) did not differ from virgin or lactating rats, but renal 
AGAT activity was higher in pups (0.50 ± 0.16 nmol⋅min−1⋅g−1) compared with both 
groups of adult females (0.24 ± 0.04 nmol⋅min−1⋅g−1) (P = 0.03).  
4.5. DISCUSSION 
The importance of the provision of creatine to neonatal animals has been emphasized by 
the discovery of inborn errors of creatine synthesis and of the creatine transporter. These 
diseases result in a common spectrum of neurological disorders, including epilepsy,  
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Figure 4.2:  Arterial (A) and venous (V) plasma GAA concentrations and renal A-V 
differences in lactating and virgin females.  Values are means ± SD, n=7.  *Different 
from lactating, P<0.05. 
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Table 4.1:  Renal GAA output in lactating and virgin rats.  Values are expressed as 
means ± SD, n=7. *Different from virgin, P = 0.005. 
 
 
 
 
 
  
 Lactating rats Virgin rats 
Number of animals 7 7 
Total mass (g) 337.4 ± 15.2 355.3 ± 37.6 
Kidney mass (g) 3.1 ± 0.2 3.0 ± 0.1 
Hematocrit  0.42 ± 0.01 0.45 ± 0.02 
Blood flow (mL·min
-1
) 7.0 ± 1.0 8.7 ± 2.9 
Total renal blood flow (mL·min
-1∙100 g body mass) 4.2 ± 0.8 5.0 ± 1.8 
Renal GAA output (nmol·min
-1∙100 g body mass) 9.45 ± 3.59 8.41 ± 3.40 
Plasma creatine concentration (μmol·L-1) 160.0 ± 15.6* 231.3 ± 62.2 
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Figure 4.3:  Total body Creatine content in rat pups at d 10, 15 and 20 of age.  Bars 
are means ± SD, n=6.  Means with different letters differ, P<0.05.  
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speech delay, and mental retardation (1). Neonatal animals can obtain creatine by a 
combination of diet (milk) and de novo synthesis. There is little information on the origin 
of milk creatine. To address this question, we compared the simultaneous isotopic 
enrichment of 
14
C-creatine in the plasma and milk of lactating rats. We also assayed the 
activities of the enzymes of creatine synthesis in mammary gland. The data clearly 
demonstrate that mammary glands extract creatine from the circulating plasma and have 
little or no capacity for creatine synthesis. Furthermore, the lower plasma concentrations 
of creatine and GAA in the lactating mother compared with virgin females are consistent 
with a larger extraction of creatine from plasma. However, a portion of this decrease may 
be attributable to the increased plasma volume, from 8.1 to 9.6 mL⋅100 g−1 (16), in 
lactating compared with nonlactating rats. The creatine concentration in milk was almost 
twice that of the plasma, indicating that the mammary gland is capable of concentrating 
creatine.  
The creatine concentration of rat milk averaged 274 μmol⋅L−1 and the milk production of 
a female during the peak production period (13–16 d postpartum) is estimated to be ∼40 
mL⋅d−1 (17). Therefore, the daily output of creatine at peak lactation is ∼11 μmol. We can 
calculate the total creatine pool (creatine + creatine phosphate) of a 335 g female rat to be 
∼1.67 mmol, given a total muscle creatine concentration of 20 mmol⋅kg−1 and a relative 
muscle mass of 25%. The daily creatine loss to creatinine (1.7%⋅d−1) can be calculated to 
be ∼28 μmol⋅d−1. Therefore, during lactation, the need for creatine replacement would be 
∼40% higher than in the nonlactating rat. However, we found no evidence for increased 
endogenous creatine synthesis in lactation; the renal activity of AGAT, the renal 
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production of GAA, and the hepatic activity of GAMT were unchanged during lactation. 
In lactating rats, food consumption is 2–3 times that of nonlactating, nonpregnant females 
(18). We fed the rats a commercial diet that by our measurements contained 0.9 μmol 
creatine⋅g−1 . We suggest that hyperphagia alone is adequate to provide the creatine 
required to cover the additional needs of lactation.  
Our data show that the pup accumulates an average of 20.7 μmol creatine⋅d−1 between d 
10 and 15. Between these ages, milk intake increases from 7.46 to 10.31 g⋅pup−1⋅d−1 (19). 
We have employed an average milk intake of 8.9 g⋅pup−1⋅d−1. We therefore calculate a 
creatine intake of ∼2.4 μmol⋅d−1 of creatine between d 10 and 15 (this calculation is based 
on the assumptions that 1 g of milk = 1 mL, that the milk creatine concentration is 274 
μmol⋅L−1, and that milk creatine is 100% bioavailable). Accordingly, milk provides only a 
small fraction (∼12%) of the creatine needs of rat pups between d 10 and 15. This figure 
is even lower when creatine accretion is measured between d 15 and 20. Therefore, the 
bulk of creatine accretion must come from de novo synthesis. To determine whether this 
is feasible, we measured the activities of the enzymes of creatine synthesis in 15-d-old 
pups. Renal AGAT activity was higher in pups compared with the activity in adult 
animals. This increase in renal AGAT activity may be brought about by growth hormone, 
which induces the synthesis of AGAT by a pretranslational mechanism (20). The lack of 
increase of GAMT activity is consistent with previous findings that this enzyme is not 
limiting for the synthesis of creatine (1).  
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It is also instructive to compare the rates of creatine synthesis in the pups with their intake 
of amino acids, using the data of Davis et al. (19) on the amino acid composition of rat 
milk protein. Between d 10 and 15, the mean intakes of methionine, glycine, and arginine 
are calculated to be 87, 146, and 153 μmol⋅pup−1⋅d−1, respectively. In the same time 
period, creatine synthesis, calculated as the difference between creatine accretion and 
creatine intake, was 19.2 (20.7–1.5) μmol⋅d−1. Creatine synthesis requires a full molecule 
of glycine, the amidino group of arginine, and the methyl group of methionine. 
Accordingly, creatine synthesis consumes 13, 13, and 22% of dietary glycine, arginine, 
and methionine, respectively. We obtained very similar numbers in a previous study on 
piglets (1).  
In summary, our study showed that milk's creatine is extracted from circulating plasma by 
the mammary gland. We also showed that there is no apparent capacity for creatine 
synthesis in the rat mammary gland and that during lactation, the increased demand for 
creatine is primarily supported by hyperphagia when creatine is present in the food. In 
neonatal rats, the provision of creatine in the milk is not the primary source of creatine 
and pups must rely mostly on de novo synthesis. This finding highlights the burden that 
creatine synthesis imposes on methyl group metabolism and arginine metabolism in 
neonatal rats. 
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CHAPTER 5 
GENERAL DISCUSSION AND CONCLUSIONS 
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5.1.  RENAL GUANIDINOACETATE PRODUCTION IN VIVO 
 
A number of novel contributions to our knowledge of creatine synthesis and its regulation 
have been made through the course of the present research.  This is the first time that 
renal production of guanidinoacetate (GAA) has been shown in vivo in rodents.  We have 
also shown that in rats fed a creatine-free diet, renal GAA production in vivo equals 
creatinine loss in the urine.  We have shown that human kidneys also produce GAA but, 
unlike the rat, this is not the major source of GAA for creatine synthesis.   
 
Creatinine excretion is a measure of creatine and creatine-phosphate breakdown, and 
therefore, represents the need for creatine replacement in the adult animal.  Since it has 
been shown that renal GAA production was equivalent to renal creatinine excretion in the 
rat, we can conclude that the kidney is the major organ involved in the production of 
GAA in the rat.  In 1940, Borsook and Dubnoff pointed out that the activity of renal 
AGAT was more than sufficient to supply the body’s creatine need.  However, 
measurements of enzyme activity under optimal conditions cannot be extrapolated to the 
in vivo situation; the present data provide definitive information on the in vivo situation.  
It cannot, however, be concluded that the kidney is the sole site of GAA production in the 
rat.  AGAT activity has been reported in rat kidney, pancreas, brain, spleen, and testes 
[Van Pilsum et al., 1972].  In 1959, Horner studied GAA synthesis in nephrectomized 
rats.  He found that synthesis was not entirely ablated; and indeed extrarenal 
transamidination, in that situation, may be considerable.  Although we have shown that 
the rat kidney is the major organ involved in GAA production in vivo, extrarenal 
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transamidination may be important in terms of local roles within tissues or in times of 
renal dysfunction. 
 
Renal GAA production in humans was quite different from that found in rats.  In humans, 
the kidney’s production of GAA could only account for about 11-12% of daily creatine 
loss as measured by urinary creatinine excretion.  Thus, almost 90% of daily creatine 
replenishment occurs without renal involvement.  The human subjects used in the current 
research were not on a creatine-free diet and we know that creatine replenishment occurs 
via a combination of diet and de novo synthesis.  Stead et al. [2006] have estimated that 
in 20-59 year-olds on a typical western diet, about 50% of the creatine need can be 
provided by the diet.  If this is taken into consideration, renal GAA production in humans 
may account for approximately 20% of total GAA synthesis.  The kidney, therefore, does 
not appear to be the major organ involved in GAA production in humans although it 
clearly plays a role.  This is supported by reports of AGAT immunofluorescence in liver 
and pancreas [McGuire et al., 1986].   
 
In 1953, Sandberg et al. reported in vivo renal GAA production in humans.  This GAA 
production amounted to 25% of creatinine loss through renal excretion.  These data are in 
agreement with results obtained during the present studies.   However, it should be noted 
that concentrations of GAA reported in this 1953 study are 5-fold those found by modern 
analytical techniques and may not be reliable [Derave et al., 2004]. 
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5.2. EFFECT  OF CREATINE FEEDING ON GAA PRODUCTION 
 
This is the first time that renal GAA production has been shown to occur in the rat, in 
vivo.  Ingestion of a 0.4% creatine diet decreased renal GAA production by 81% and 
lowered plasma GAA concentrations by 72%.  Thus the present study also shows, for the 
first time, that creatine ingestion markedly decreases renal GAA production in vivo in the 
rat.   
 
A 0.4% creatine diet was fed to Sprague-Dawley rats for a period of two weeks.  After 
this two week period, there was a marked down-regulation of renal AGAT activity and 
mRNA expression as well as a decrease in renal GAA production in vivo, as compared to 
controls.  The down-regulation of AGAT activity by creatine and GAA feeding has been 
shown previously [Stead et al., 2001; Van Pilsum, 1971].  It is believed that the 
conversion of GAA to creatine, and therefore, an increase in creatine concentration, is 
what actually causes the down-regulation of AGAT during GAA feeding.  The present 
study has confirmed findings by McGuire et al. [1984], that creatine feeding can decrease 
levels of renal AGAT mRNA.  These data suggest that AGAT activity may be regulated 
at the pretranslational level.  However, the decrease in renal AGAT mRNA expression is 
not as large as the decrease in renal AGAT activity (41% vs. 86%, respectively) 
suggesting that there may be an additional postranslational mechanism(s) involved (e.g. 
feedback inhibition through allosteric regulation, etc.). 
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Derave et al. [2004] showed that feeding creatine to humans for a period of 20 weeks 
lowered plasma GAA levels in a dose-dependent manner: by 50% during the loading 
phase (20 g creatine per day) and by 30% during the maintenance phase (5 g creatine per 
day).  They did not determine the source of the GAA or the reason for the decrease in its 
concentration.  However, these data suggest that creatine ingestion may also down-
regulate creatine synthesis in humans. 
 
5.3. ROLE OF SUBSTRATE SUPPLY IN GAA SYNTHESIS 
 
Our experiments also addressed the acute regulation of renal GAA synthesis by increased 
provision of the amino acid substrates, glycine and arginine.  Increased provision of 
glycine had no effect on GAA production whereas provision of arginine did.  This is best 
interpreted in terms of the kinetic properties of AGAT and the renal concentrations of the 
substrates.  The Km of rat kidney AGAT for glycine is reported to be 2.4-2.8 mM; that for 
arginine is 3.0-3.1 mM [McGuire et al., 1980].  Brosnan et al. [1983] have reported the 
rat renal contents of glycine and arginine to be 1320 and 170 nmol/g, respectively. 
Assuming that these amino acids are evenly distributed in the kidney, we can estimate 
intracellular concentrations of about 2.5 mM and 0.32 mM, respectively for glycine and 
arginine.  Renal cellular glycine concentration would be close to the Km of that for 
AGAT.  The infusion of glycine, in the present study, only raised the circulating glycine 
concentration by about 50%.  Keeping both of these facts in mind, an increased glycine 
concentration of 50% under these conditions would, at most, increase renal GAA 
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production by 25%.  An increase in the mean GAA production of this magnitude was 
observed but was not statistically significant.   
 
Our estimated renal cellular arginine concentration is well below the Km value of AGAT 
for this amino acid.  In the present study, the circulating arginine concentration increased 
four-fold during infusion so that, assuming that changes in cellular arginine concentration 
parallel the plasma levels and applying the Michaelis-Menten equation, we may anticipate 
an increased GAA production of about 3-fold.  This is remarkably close to the 2.7-fold 
increase that was observed.  Given the nature of the assumptions made, the close 
agreement between the observed and calculated rates may be somewhat fortuitous.  
Regardless, the current experiments have highlighted the sensitivity of renal GAA 
synthesis to the ambient arginine concentration.  GAA synthesis in humans may also be 
markedly sensitive to arginine concentration, since Arias et al. [2004] have reported that 
provision of arginine to children with urea cycle defects normalized low plasma GAA 
concentrations. 
 
Renal GAA production was doubled by the infusion of citrulline, even though there was 
no increase in the circulating arginine concentration.  This result is attributable to the 
conversion of citrulline to arginine by the renal tubules.  Dhanakoti et al. [1990] have 
previously reported that arginine production in the rat is very sensitive to circulating 
citrulline concentrations.  Renal arginine synthesis occurs in the cells of the proximal 
tubule [Dhanakoti et al., 1992] as does GAA synthesis [McGuire et al., 1986; Takeda et 
al., 1992].  Therefore, arginine synthesized in these cells becomes immediately available 
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as a substrate for GAA synthesis.  This indicates that citrulline synthesis (which occurs in 
the gut) may contribute in part to creatine synthesis.  To test whether gut citrulline 
synthesis could be regulated by ingestion of creatine, gut citrulline flux was measured in 
rats fed a 0.4% creatine diet and compared to that of aged-matched AIN-93G-fed controls 
as described in Section B.3.  At the end of the 2 week feeding period, animals were 
anaesthetized, portal vein blood flow was measured and plasma was prepared from 
samples taken across the gut as described previously.  Plasma amino acids were analyzed 
as described in Section B.5.4. and gut citrulline production was calculated.  Intestinal flux 
of citrulline did not differ significantly between the groups (control 117 nmol/min/100 g 
body wt, creatine-treated 93 nmol/min/100 g body wt, n=12, P = 0.26).  Therefore, the 
need for creatine synthesis does not drive intestinal citrulline synthesis, as this was not 
altered in the creatine-fed rats 
. 
In 2011, Brosnan et al. examined the metabolic burden that creatine synthesis plays on 
each of the amino acids involved including glycine, arginine and methionine.  They 
concluded that creatine synthesis only imposes a minor burden on glycine provision.  
However, the availability of glycine for creatine synthesis in humans does need further 
investigation, as Melendez-Hevia et al. [2009] questioned the capacity for glycine 
synthesis in humans. 
 
Brosnan et al. [2011] estimated that dietary arginine availability averaged between 20-45 
mmol/day in young adults and that endogenous synthesis may represent an important 
supply of arginine for creatine synthesis.  The most revealing aspect of their calculations 
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was that creatine synthesis may consume about 40% of the S-adenosylmethionine 
available for all bodily methyltransferase reactions.  Taking this into consideration, 
clearly, creatine biosynthesis imposes an appreciable burden on methionine metabolism 
and methyl balance.  
 
5.4. IMPORTANCE OF CREATINE INTAKE TO INFANTS 
 
In contrast to the abundance of information on adults, we know very little about human 
neonatal creatine metabolism other than that it is a crucial issue.  There are examples of 
genetic defects in each of the three proteins responsible for creatine synthesis and 
distribution - AGAT, GAMT and the creatine transporter [Schulze, 2003; Stromberger et 
al., 2003].  The extraordinary finding is that, in each case, the principal symptoms are 
neurological, even though approximately 90 - 95% of the body’s creatine is found in 
muscles.  Regardless of which of these proteins is defective, the affected children 
displayed mental retardation, epilepsy and speech delay [Schulze, 2003; Stromberger et 
al., 2003].  The symptoms tend to be more severe in the children with GAMT deficiency, 
which has been attributed to an additional, specific effect of the accumulated GAA.  Early 
diagnosis of infants with the synthetic enzyme deficiencies is critical.  Case studies of the 
diagnoses of AGAT and GAMT deficiencies at birth and then subsequent 
supplementation with creatine showed remarkable success.  All developmental milestones 
were normal at 18 months [Battini et al., 2006; Schulze et al., 2006].  In the case of 
GAMT deficiency, arginine-restriction and treatment with benzoate to remove glycine as 
hippuric acid was employed, in addition to creatine supplementation, to prevent 
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accumulation of neurotoxic levels of GAA.  Clearly, creatine plays an unanticipated role 
in brain development.   
 
5.5.   CREATINE BALANCE IN INFANTS 
 
In addition to creatine replacement to account for urinary creatinine loss, growing infants 
need to deposit substantial quantities of creatine in muscle and brain during the course of 
normal growth and development of these tissues [Wyss & Kaddurah-Daouk, 2000].    In 
order to derive estimates of loss and accretion, a number of assumptions had to be made.  
First, an average creatine-phosphate concentration in infant skeletal muscle was used; this 
was obtained from Eriksson [1980].  Second, we could find no recently published data on 
either the creatine concentration or total creatine content of infant skeletal muscle; we 
were obliged to use the common ratio of creatine-phosphate:creatine concentrations for 
adult skeletal muscle [Kemp et al., 2007].    
 
Briefly, we calculated that 3.8 mmol of creatine are lost per week to creatinine excretion 
and 0.46 mmol of creatine is needed per week for expanding muscle mass.  Therefore, we 
estimated that an infant, 6-12 weeks of age, would need a total of 4.26 mmol of creatine 
per week (see Chapter 3). 
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5.6.   HOW MUCH CREATINE IS PROVIDED TO THE INFANT VIA THE DIET? 
 
As stated earlier, neonatal creatine accretion can occur in two ways, through dietary 
intake of creatine, de novo creatine biosynthesis, or both.  This thesis has provided data 
on the provision of creatine in the infant diet.  The provision of creatine in mother’s milk 
or various infant formulas has been quantified. We propose that accretion of creatine in 
the infant through biosynthesis creates an appreciable metabolic burden on amino acid 
metabolism.   
 
5.6.1. Role of the Mammary Gland in Provision of Neonatal Creatine 
   
It is of note that renal AGAT activity, renal GAA production and hepatic GAMT activity 
were not increased during lactation in the rat (Table 4.1).  However, during lactation, the 
need for creatine replacement would be 40% higher than in the nonlactating rat (see 
detailed calculations in Chapter 4). In lactating rats, food consumption is 2–3 times that 
of nonlactating, nonpregnant females [Cripps & Williams, 1975].  Hyperphagia alone was 
adequate to provide the creatine required to cover the additional needs of lactation, as the 
commercial diet used in the current study contained 0.9 µmol of creatine per g.  However, 
it is important to understand that the creatine content of commercial rat chow may vary 
from batch to batch, as the amount of fish and meat meal used to prepare the Purina Rat 
Chow 5012 changes from one lot to another depending upon availability and cost of the 
ingredients.  
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Previous studies showed that creatine occurs in milk, including human milk [Hülsemann 
et al., 1987].  However, there is little information on the origin of milk creatine.  To 
address this question, we compared the simultaneous isotopic enrichment of 
14
C-creatine 
in the plasma and milk of lactating rats. Activities of the enzymes involved in creatine 
synthesis were also measured in the mammary gland.  The isotopic enrichments of 
creatine in plasma and in milk of lactating rats did not differ.  In addition, activities of the 
enzymes required for creatine synthesis were negligible in the rat mammary gland as 
compared to the activities of these enzymes in organs known for creatine synthesis (e.g. 
AGAT activity in the rat kidney and GAMT activity in the rat liver).  Combined, these 
data demonstrate that the mammary gland must extract creatine from the circulating 
plasma and has little or no capacity for creatine synthesis.  
 
Plasma concentrations of creatine and GAA in the lactating rat were lower than those in 
virgin female controls.  This is consistent with the extraction of creatine from the plasma 
by mammary gland. The creatine concentration in rat milk was almost twice that of the 
plasma, indicating that the mammary gland of the rat is capable of concentrating creatine 
in the milk. A minor component of the decreased plasma creatine and GAA in lactating 
rats may be attributable to the increased plasma volume, from 8.1 to 9.6 mL per 100 g 
body wt, in lactating compared with nonlactating rats [Bond, 1958].   
 
The mean creatine concentration of rat milk was 274 μM.  The milk production of a 
female rat during the peak production period (between days 13–16 postpartum) is 
estimated to be 40 mL per day [Flint & Vernon, 1998]. From these data the daily output 
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of creatine at peak lactation can be calculated to be 11 μmol to be distributed to the entire 
litter.  From Figure 4.3 we can deduce that an average of 20.7 µmol of creatine is needed 
each day to account for the total creatine accumulation in the rat pup during peak 
lactation.  In Chapter 4 it was calculated that the 10-15 day old rat pup receives on 
average about 2.4 µmol of creatine per day from mother’s milk.  This is only a small 
fraction, about 12%, of the creatine need.  Therefore, the bulk of the rat pup’s creatine 
need must be accounted for by de novo synthesis.   
 
The role of the human mammary gland in providing creatine is not as well studied.  
Human milk contains a lower concentration of creatine than rat milk, about 70 µM.  The 
findings from Chapter 3 show that there is no difference between the milk and plasma 
creatine concentrations in lactating humans.  We assume that, like the rat, the human 
mammary gland does not have a significant role in the production of creatine but derives 
milk creatine from the plasma; however, we have no experimental data on the matter.  
GAA was also measured in mother’s milk because its presence would spare the infants’ 
glycine and arginine requirements for creatine synthesis.  Very little GAA was found in 
human milk.  In fact, the GAA concentration of human milk was lower than that of 
plasma.   
 
As discussed earlier, between 6-12 weeks of age, a human infant requires approximately 
4.26 mmol of creatine each week to account for the expanding muscle mass and creatine 
lost as creatinine.  In Chapter 3 it was calculated that these same infants receive only 0.4 
mmol of creatine per week from mother’s milk.  This means that de novo synthesis of 
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creatine must account for approximately 90% of the accreted creatine in human neonates.  
This high rate of endogenous creatine synthesis has important implications for the 
neonate’s amino acid metabolism, posing a substantial metabolic burden.  In conclusion, 
the mammary gland of both the human and the rat have a very limited role with regards to 
supplying the neonate with the creatine required for normal development.  It should be 
pointed out that a study of creatine metabolism in neonatal piglets came to the same 
conclusion (Brosnan et al., 2009) so it is likely to be a general feature of mammalian 
metabolism that neonatal animals are required to synthesize most of their creatine. 
 
Dickinson et al. [2013] reported that maternal dietary creatine supplementation during 
pregnancy increases the total creatine content of mouse fetal tissues but does not cause 
downregulation of AGAT expression in the neonatal mouse kidney.  However, AGAT 
gene expression was decreased in the brain.  They concluded that maternal creatine 
supplementation does not impair endogenous creatine synthesis in the key creatine 
synthesizing organs (kidney and liver) of the mouse neonate but local sites of creatine 
synthesis (e.g. brain) may be affected. 
 
5.6.2.  Role of Dietary Intake in Provision of Creatine in Formula-Fed Infants 
 
Table 3.1 lists the creatine and GAA concentrations of the various infant formulas.  The 
creatine concentrations vary from 334 µM to 10 µM, depending upon the brand and the 
type of milk base.  For example, cow’s milk-based formulas had much higher creatine 
 117 
 
concentrations than did soy-based formulas.  Formulas that claimed to be most similar to 
mother’s milk (Similac) had moderate levels of creatine.   
 
Using tables of recommended formula intake [Dietitians of Canada, 2008], a formula-fed 
infant could potentially receive, through the diet, up to 63% of the creatine needed (based 
on the creatine concentration of Enfalac and the maximum recommended intake for 12 
week old formula-fed infants).  Infants fed a soy-based infant formula would have to rely 
solely upon de novo creatine synthesis to meet their body’s need, as these formula-fed 
infants would be provided with less than 2% of the creatine needed for accretion.  
Therefore, the amount of creatine provided in the diet varies widely, depending upon the 
dietary source.  However, regardless of the dietary source, there is a large metabolic 
burden placed on a neonate by de novo synthesis of creatine to meet accretion 
requirements. 
 
GAA was measured in each of the infant formulas because its presence would spare the 
neonates’ glycine and arginine requirements for creatine synthesis.  The GAA 
concentration of each of the formulas tested was negligible.  Creatinine concentration was 
also measured in the various infant formulas.  It was significantly higher for both Enfalac 
(156 µM) and Enfamil A+ (176 µM) in comparison with the other infant formulas (from 
“not detectable” to 8 µM).  Creatinine concentrations of Similac Ready To Use, Similac 
Concentrated, and Lactofree were below the limits of detection.  These results are 
somewhat surprising because it may be expected that the creatinine content would reflect 
the creatine content, since creatinine is simply the non-enzymatic breakdown product of 
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creatine.  It is possible that the creatinine content of the various formulas reflects the 
processing procedures.  Either acidic conditions or high temperatures during the canning 
and sterilization process could speed up the degradation of creatine to form creatinine 
[Wyss & Kaddurah-Daouk, 2000].   This may explain the variations in both creatine and 
creatinine concentrations in milk-based formulas.  Infants ingesting Enfalac or Enfamil 
A+ might be expected to show elevated creatinine levels in plasma and urine, relative to 
infants on other formulas or on breast milk due to the increased intake of creatinine.  Such 
increased creatinine would not reflect on renal function. 
 
5.7. METABOLIC BURDEN OF DE NOVO CREATINE BIOSYNTHESIS IN INFANTS 
 
Creatine is synthesized, de novo, by the neonate from the amino acids glycine, arginine 
and methionine, as described above.  The quantities that need to be synthesized could 
become a very large drain on these three key amino acids.  In particular, it would 
represent an enormous drain on “labile methyl groups” and on arginine.   
 
Perhaps the supply of methyl groups for S-adenosylmethionine is of even more 
importance.  Creatine synthesis in adults uses about 40% of all S-adenosylmethionine-
derived methyl groups [Mudd et al., 2007; Stead et al., 2006].  Does it also use such a 
large proportion in infants?  Our study is an important step in understanding this question.  
We are just beginning to appreciate the importance of methyl group metabolism in 
developmental biology.  DNA methylation plays a crucial role in the epigenetic silencing 
of one of the X-chromosomes in females [Bestor, 2000].  Impairment of such 
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methylations, whether as a result of a deficiency of specific proteins required for DNA 
methylation [Neul & Zoghbi, 2004] or of folate deficiency [Scott et al., 1994] results in 
developmental disorders such as Rett syndrome and neural tube defects.  There has been a 
recent report of trials of “pro-methylation” dietary supplements in mice to ensure that the 
dietary supply of methyl groups is not limiting [Waterland, 2006; Waterland et al., 2006].  
Such dietary supplements have been successful in correcting two separate developmental 
anomalies in mice that are known to be caused by hypomethylation of epigenetic regions 
of specific genes. 
 
Infants suffering from genetic defects in creatine synthesis display symptoms at a very 
early age, consistent with our data that creatine accretion in neonates is almost entirely 
brought about by endogenous synthesis.  The symptoms of creatine deficiency appear 
early regardless of the manifestation of the disorder, be it an enzyme or transporter defect.  
These symptoms include abnormal developmental scores, mental retardation, speech 
impairment and epileptic seizures.   
 
In Chapter 3 it was calculated that neonates must synthesize approximately 3.9 mmol of 
creatine per week.  Since creatine synthesis requires the entire glycine molecule, a 
guanidino group from arginine and a methyl group from S-adenosylmethionine, creatine 
synthesis potentially consumes about 27% of dietary glycine, 39% of dietary arginine and 
up to 75% of dietary methionine.  These percentages are based on the amino acid 
composition of human milk as reported by Davis et al. [1994].   Infants fed cow’s milk-
based formulas may receive 2-4 times as much creatine in the diet as does the nursing 
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infant, depending upon the formula of choice.  In this case the metabolic burden of 
endogenous creatine synthesis may be reduced but yet an appreciable burden on amino 
acid metabolism remains even in these infants.    
 
Creatine synthesis is not thought to place an appreciable burden on glycine metabolism as 
this amino acid is synthesized in significant quantities [Brosnan et al., 2011].  The same is 
not true of arginine and methionine.  AGAT converts arginine to ornithine; through the 
combined actions of carbamoyl phosphate synthetase I, argininosuccinate synthetase and 
argininosuccinate lyase, this ornithine may be reconverted to arginine.  We are aware of 
no data on the magnitude of this reconversion in neonates.  However, to the extent that it 
occurs, it will minimize the potential net arginine loss brought about by creatine 
synthesis. The GAMT reaction produces S-adenosylhomocysteine as well as creatine.  
This S-adenosylhomocysteine is hydrolyzed by S-adenosylhomocysteine hydrolase to 
produce adenosine and homocysteine.  Homocysteine may either be irreversibly 
catabolised to cysteine by the transsulphuration pathway or it may be remethylated to 
methionine by either methionine synthase or betaine:homocysteine methyltransferase.  
Using [1-
13
C]methionine and [C
2
H3]methionine tracers, Thomas et al. [2008] measured 
remethylation in newborn infants, only days old. They reported that remethylation was 
even more active in infants than in adults, and they attributed this to a high rate of 
methyltransferase activity.  We agree with this characterization and suggest that creatine 
synthesis represents one of the major users of S-adenosylmethionine-derived methyl 
groups in this situation.  To our knowledge, rates of remethylation in 6-12 week old 
infants have not been reported in the current literature. 
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To add to our calculated metabolic burden of creatine synthesis, we must consider 
possible urinary loss of creatine.  The current literature does not seem to address urinary 
creatine excretion in the neonate.  Our own data involving 24 hour urine collection in 
adult rats found negligible amounts of urinary creatine excretion in comparison to 
creatinine excretion.  However, we did not measure urinary creatine excretion in our rat 
pups, nor in human neonates.  In 2004, Volongo et al. measured urinary creatine and 
GAA excretion in children and adolescents.  They analyzed 4 study groups based on age: 
< 1 year, 1-4 years, 5-11 years and 12-16 years.  They did not find any significant 
differences between the creatine and GAA excretion based on gender or upon these initial 
age groups.  Subsequently, they combined male and female results and analyzed the data 
based on the following age ranges: ≤4 years, 5-11 years and 12-16 years.  Unfortunately, 
there were few demographic details outlined in the paper.  The age ranges of the subjects 
ranged from 6 days to 16 years but it was not stated how many subjects were less than 1 
year of age and, more importantly for this study, how many neonatal subjects were 
recruited.  There were 70 subjects in the age group ≤4 years.  They found that GAA 
excretion ranged from 18-159 µmol per mmol of creatinine in children ≤4 years.  This 
amount is negligible when considering the effect it would have on the need for creatine 
replacement in neonates.  However, they found urinary creatine excretion to be 0.04-1.51 
mmol per mmol creatinine in these same children.  These numbers, if confirmed, would 
have significant implications for the rate of creatine replacement.  In fact, in some cases, 
the estimates calculated in Chapter 3 of the need for creatine replacement in neonates 
may be substantially underestimated. These considerations, however, only strengthen one 
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of our principal conclusions, that creatine biosynthesis places a substantial burden on an 
infants’ amino acid metabolism.  Indeed, the burden may be appreciably greater than our 
data suggest. 
 
When creatine synthesis rates were compared to the intake of amino acids in the rat pup, 
it was calculated that creatine synthesis could potentially consume 13, 13 and 22% of 
dietary glycine, arginine, and methionine, respectively.  These numbers were calculated 
based on data provided by Davis et al. [1993] regarding the amino acid composition of rat 
milk protein.  These numbers are very similar to those found in piglets [Brosnan & 
Brosnan, 2007].  It is clear that creatine biosynthesis places a significant burden on 
methyl group metabolism and arginine metabolism in neonatal rats.   
 
5.8. CONCLUSIONS 
  
This study has shown, for the first time, that GAA is produced by rat kidneys, in vivo.  It 
was also shown that the human kidney produces GAA.  Creatine feeding downregulates 
renal AGAT activity and mRNA expression as well as the in vivo production of GAA by 
the rat kidney.  Acute provision of additional glycine was without effect on renal GAA 
production in vivo; however, acute provision of arginine or citrulline, which is converted 
to arginine in the kidney, increased renal GAA production in the rat.   
 
The investigation of creatine balance in the adult human indicated that creatine synthesis 
imposes a considerable metabolic burden on each of the amino acids involved [Brosnan et 
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al., 2011].  Our analysis of the situation in neonates suggests that this metabolic burden 
may be greater still, because the need for creatine accretion in neonates is larger because 
of the expanding muscle mass.  The current study has shed light on both the provision of 
creatine to neonates via the diet and the impact that creatine synthesis has on amino acid 
metabolism in the neonate.  
 
The role of the mammary gland in the provision of creatine to rat pups was investigated.  
It was found that milk creatine was extracted by the rat mammary gland from the 
circulation, rather than being synthesized within the gland, since there was no apparent 
capacity for creatine synthesis in the rat mammary gland.  During lactation, the increased 
demand for creatine in the lactating mother can be largely supported by hyperphagia 
when creatine is present in the food. 
 
This is the first time it has been shown that neonatal creatine accretion is largely due to de 
novo synthesis in both the human and the rat.  Very little creatine is supplied to the 
neonate from mother’s milk or from commercially available formulas.  Since there is a 
large need for creatine in the neonate due to creatine lost as creatinine and new muscle 
lay-down, creatine biosynthesis places a significant drain on the available amino acids, 
arginine, glycine and methionine.  Of particular importance is the burden that creatine 
synthesis imposes on methionine metabolism and methyl balance.  This study has 
provided a firm foundation for our understanding of the regulation of creatine synthesis 
and the burden that creatine synthesis places on amino acid metabolism, particularly in 
the developing neonate. 
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A.1. INTRODUCTION 
This paper reviews new aspects of the function and synthesis of creatine and creatine 
phosphate. We examine creatine synthesis, which has emerged as a quantitatively major 
pathway in amino acid metabolism. We emphasize the inter-organ aspects of creatine 
synthesis, involving both the kidney and liver. Finally, though interest in creatine has 
traditionally been concerned with its role in muscle, we highlight the critical role that 
creatine plays in brain function, both in the developing brain as well as in the adult. 
 
A.1.1. Creatine Function 
The role of creatine and creatine phosphate in energy metabolism has long been 
recognized. The creatine kinase (EC 2.7.3.2) reaction, (ATP+creatine↔creatine 
phosphate+ADP) provides the basis for this role. However, in recent years, our view of 
the function served by this reaction has changed from one in which the primary role is 
that of buffering ATP levels or the ATP/ADP ratio to one of rapid, intracellular 
translocation of high-energy phosphate compounds from their mitochondrial sites of 
production to their cytosolic sites of utilization. This latter view is supported by the 
subcellular location of different creatine kinase isoenzymes, in the mitochondria as well 
as in myofibrils, sarcoplasmic reticulum and plasma membranes (Schlattner et al., 2006). 
This view of the creatine/creatine phosphate system is illustrated in Figure A.1. It is often 
suggested that the major advantage provided by this energy translocation model over the 
more conventional system, where ATP and ADP are thought to diffuse between sites of 
production and utilization, is the higher diffusivity of creatine phosphate compared to   
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Figure A.1. Mitochondrial–cytoplasmic interactions in creatine function. ATP is 
produced by ATP synthase (AS) on the mitochondrial inner membrane. It exits to the 
intermembrane space, in exchange for ADP, via the adenine nucleotide transporter 
(ANT). This ATP phosphorylates creatine (Cr), catalyzed by the mitochondrial isoform of 
creatine kinase (CK), at contact points between the inner and outer mitochondrial 
membranes. Creatine phosphate (CrP) may be used to buffer ATP levels (or ATP:ADP 
ratios) in the cytosol and to rephosphorylate ADP at sites of ATP utilization (ATPase). 
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ATP, as the molecular weight of creatine phosphate is less than half that of ATP. In fact, 
the diffusion coefficient for creatine phosphate is only about 30% higher than that for 
ATP (Ellington, 2001). It is much more likely that the key difference is in the diffusivity 
of creatine compared to ADP and is provided less by the difference in their molecular 
weights (ADP=427; creatine=131) than by very great differences in their cytosolic 
concentrations (Wallimann et al., 1992). Free cytosolic concentrations of ATP, creatine 
phosphate and creatine in skeletal muscle are, respectively, about 8, 27 and 13 mM 
(Veech et al., 1979).  The free cytosolic ADP concentration is about 20 μM (Nioka et al., 
1992). It should, of course, be emphasized that the two postulated roles of the 
creatine/creatine phosphate system are not mutually exclusive and it is likely that both 
temporal energy buffering and spatial energy translocation occur, to different degrees, in 
different cell types. It appears that temporal buffering is more important in fast-twitch 
muscles whereas the energy translocation function predominates in slow-twitch muscles 
(Wallimann et al., 1992). 
The creatine/creatine phosphate system is not equally important in every cell. Indeed, 
some cells with high rates of oxidative metabolism (e.g. hepatocytes) do not employ this 
system. It is apparent that it is primarily present in cells with high and intermittent energy 
demands, such as skeletal muscle (where energy output can vary by a factor of 100), heart 
(where there are substantial differences in energy demand from systole to diastole) and 
the brain (where certain tasks require some neurons to fire very quickly) (Wallimann et 
al., 1992). 
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In addition to these physiological roles of creatine, this substance is also consumed in 
quite substantial amounts both by athletes, as an ergogenic supplement (Kraemer and 
Volek, 1999) and by patients suffering from a variety of neurological disorders (Baker 
and Tarnopolsky, 2003). Annual consumption of creatine is estimated at about four 
million kilograms per annum with a value, in the United States alone, of more than $200 
million. 
A.1.2. Creatine Loss and Replacement 
The whole body pool of creatine plus creatine phosphate in 70 kg young adults is of the 
order of 120 g. Both creatine and phosphocreatine are non-enzymatically and irreversibly 
degraded to creatinine at a rate of about 1.7% of the total body pool per day (Wyss and 
Kaddurah-Daouk, 2000). This creatinine is lost in the urine. The amount of this loss is 
proportional to muscle mass and is, therefore, greater in males than in females and in 
young adults than in the elderly. Daily creatinine excretion (and creatine loss) varies from 
about 1.7 g to about 0.9 g in 70 kg males of ages 18–29 and 70–79, respectively (Stead et 
al., 2006). In vegetarians, all of this creatine needs to be replaced via synthesis. However, 
for individuals on a typical North American omnivorous diet, we have calculated that 
approximately half of the replacement can be provided via food creatine and the other 
half requires endogenous synthesis. Thus, we have calculated that men, aged 20–39, need 
to synthesize about 1.0 g creatine/day; women of the same age group synthesize about 
0.75 g/day (Stead et al., 2006). 
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A.1.3. Creatine Synthesis and Transport 
Creatine synthesis occurs via an exceedingly simple metabolic pathway, consisting of 
only two enzymes (Figure A.2). The first enzyme, l-arginine:glycine amidinotransferase 
(AGAT) (EC 2.1.4.1) catalyzes the formation of guanidinoacetate and ornithine from 
arginine and glycine. The second enzyme, guanidinoacetate N-methyltransferase (EC 
2.1.1.2), employs S-adenosylmethionine to methylate guanidinoacetate, producing 
creatine and S-adenosylhomocysteine. Although most of the body's creatine is found in 
skeletal muscle, there is very little evidence for appreciable creatine synthesis in this 
tissue. Rather, creatine, whether of dietary origin or synthesized endogenously, is taken 
up from the plasma via a specific transporter (CreaT). CreaT is found in a variety of 
tissues, including skeletal muscle, kidney, heart, forebrain, cerebellum and liver (Snow 
and Murphy, 2001). It transports creatine, together with sodium and chloride ions, against 
a considerable concentration gradient. Additional complexity is provided by the 
occurrence of at least two different isoforms of CreaT, most likely as a result of 
alternative mRNA splicing (Guerrero-Ontiveras and Wallimann, 1998). 
Creatine synthesis represents a considerable metabolic load, in particular with regard to 
amino acid utilization. A comparison of rates of creatine synthesis with the dietary intake 
of glycine, arginine and methionine is revealing. The synthesis of 1.0 g creatine/day 
amounts to 7.6 mmol. This compares to a dietary intake of about 78 mmol glycine, 
37 mmol of arginine and 19 mmol of methionine (these figures are based on an intake of 
80 g protein/day with the amino acid composition of beef protein). Therefore, creatine   
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Figure A.2. Pathway of creatine synthesis. The boxes indicate the groups transferred by 
these transferase reactions. Abbreviation: GAA, guanidinoacetate; AdoMet, S-
adenosylmethionine; AdoHcy, S-adenosylhomocysteine. 
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synthesis consumes about 10% of dietary glycine as the entire glycine molecule is 
incorporated into creatine. It is not certain whether similar arguments can be made for 
methionine and arginine since only the methyl group of methionine and the amidino 
group of arginine are incorporated into creatine. In addition to methionine, the diet 
provides labile methyl groups in the form of choline and betaine and new methyl groups 
(methylneogenesis) can be produced via the remethylation of homocysteine (Stead et al., 
2006). Comparison of rates of creatine synthesis with isotopically measured rates of 
transmethylation reveal that the synthesis of this molecule makes very great demands on 
S-adenosylmethionine. Approximately 40% of S-adenosylmethionine's methyl groups are 
consumed by creatine synthesis (Stead et al., 2006). 
The ornithine produced by AGAT could, in theory, be reconverted to arginine by the 
reactions of the urea cycle (Brosnan and Brosnan, 2004). However, there is, at present, no 
compelling evidence that this actually occurs. Therefore, it is possible that creatine 
synthesis could consume as much as 20% of dietary arginine. Regardless of the 
uncertainties inherent in these calculations, it is apparent that creatine synthesis places a 
considerable demand on amino acid metabolism. This demand is even greater in 
vegetarians where creatine synthesis is double that in omnivores and where protein intake 
is, typically, less. 
A.1.4. Inborn Errors of Creatine Synthesis and Transport 
Inborn errors involving mutations in each of the three proteins required for creatine 
synthesis and transport are now known. Perhaps the most remarkable feature of these 
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disorders is that they present, in children, with a very similar constellation of neurological 
symptoms, i.e. mental retardation, epilepsy and difficulties in language development. The 
symptoms are invariably more severe in the GAMT-deficient children and this has been 
attributed to the accumulation of guandinoacetate, which is thought to exert specific 
neurotoxic actions. Because of its methyl group, creatine is readily detected non-
invasively by 
1
H-MRS. Children who present with these inborn errors display a massive 
depletion of brain creatine. In addition, those with AGAT deficiency have decreased 
plasma creatine and guanidinoacetate while those with GAMT deficiency have markedly 
increased plasma guanidinoacetate and lowered creatine. In the case of patients with 
creatine transporter deficiency, plasma guanidinoacetate is in the normal range while 
creatine is elevated (Stromberger et al., 2003). 
Treatment of children with these enzyme defects with creatine largely or completely 
restores brain creatine over time and results in a marked clinical improvement. The 
general experience with creatine supplementation, however, has been that the children 
never fully recover; learning and language functions remain impaired. However, until 
recently, it has never been clear whether the neurological deficits could have been 
avoided if creatine supplementation had begun at birth. One recent case-study gives 
encouraging information on this point. The affected child was homozygous for the 
W149X mutation in AGAT that also affected two older siblings. A very early diagnosis 
could, therefore, be made. Treatment with creatine monohydrate was begun at 4 months, 
upon weaning. This child's growth and development was entirely normal at the age of 18 
months (Battini et al., 2006). In contrast to the improvement found upon creatine 
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supplementation of children with the enzyme deficiencies, the transporter-deficient 
patients are refractory to treatment with creatine. There is no accumulation of creatine in 
the brain and no clinical improvement (Stromberger et al., 2003). 
A.1.5. Creatine Synthesis in the Rat 
The creatine-deficiency syndromes clearly emphasize the importance of creatine 
synthesis. We have, therefore, conducted a series of studies on creatine synthesis, 
employing the rat as a model. Previous work has indicated that the two enzymes of 
creatine synthesis occur in a variety of tissues. In particular, AGAT is most highly active 
in the rat kidney but this enzyme is also found in pancreas, spleen, brain, testis and 
thymus (Wyss and Kaddurah-Daouk, 2000). A particularly vexing question concerns the 
possible occurrence of AGAT in the liver. McGuire et al. (1986) using 
immunofluorescence microscopy reported AGAT protein in hepatocytes. However, we 
have been unable to detect enzyme activity in the liver. The highest activity of GAMT is 
found in the rat liver but activity is also reported in pancreas, spleen and testis (Wyss and 
Kaddurah-Daouk, 2000). Based on the fact that the highest abundance of AGAT is in the 
kidney whereas that of GAMT is in the liver, we have postulated the occurrence of an 
inter-organ pathway for creatine synthesis (Figure A.3) by which guanidinoacetate is 
released by the kidney, taken up by the liver and methylated there to produce creatine. 
We have tested this inter-organ hypothesis in a variety of ways. Direct measurements of 
arterio-venous (A-V) differences across rat kidneys reveal guanidinoacetate production 
(arterial concentration 5 μM, renal venous concentration 9 μM, p<0.01). When these  
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Figure A.3. Inter-organ pathway for creatine synthesis in the rat. Abbreviations: 
AGAT, l-arginine:glycine amidinotransferase; GAA, guanidinoacetate; GAMT, 
guanidinoacetate N-methyltransferase; AdoMet, S-adenosylmethionine; AdoHcy, S-
adenosylhomocysteine. 
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studies are carried out on rats fed purified diets (i.e. no dietary creatine), we found that 
guanidinoacetate production by the kidney was not significantly different from creatinine 
loss across the same kidney. This implies that the kidney is the organ responsible for the 
great bulk of guanidinoacetate production in the rat. We have also examined the 
production of creatine, from guanidinoacetate in isolated hepatocytes. These cells 
produced creatine from guanidinoacetate (half maximal rates at 
[guanidinoacetate]=14 μM). The rate of creatine production was doubled by the provision 
of a source of methyl groups (e.g. methionine or betaine in the presence of 
homocysteine). Maximal rates of creatine synthesis by rat hepatocytes are about 
25 nmol/h/mg dry weight. 
We have also examined the regulation of creatine synthesis. It is known that renal AGAT 
activity is down-regulated by dietary creatine (McGuire et al., 1984). We have confirmed 
this in rats that were fed a diet containing 0.4% creatine for 2 weeks—renal AGAT 
activity was decreased by 85%; renal AGAT mRNA abundance also fell, though not as 
much. In turn, this decreased renal AGAT activity translated into a reduced A-V 
difference for guanidinoacetate across the kidney (1 vs. 4 μM) and a markedly reduced 
circulating guanidinoacetate concentration (1.5 vs. 5 μM). We suggest that the primary 
regulation of creatine synthesis occurs at the level of renal AGAT expression and its 
modulation by dietary creatine. We suggest that little active regulation occurs in the liver. 
Half-maximal creatine production by hepatocytes is found at about 14 μM 
guanidinoacetate, which is appreciably higher than circulating levels (about 5 μM). 
Therefore, we suggest that hepatic creatine synthesis can respond to increased or 
 154 
 
decreased renal guanidinoacetate production in a simple concentration-dependent manner. 
This is not to suggest, however, that our knowledge of the hepatic aspect of creatine 
synthesis is complete. In particular, we need to understand the transport mechanisms 
whereby guanidinoacetate enters hepatocytes and by which creatine exits. There is the 
well-described creatine transporter in tissues such as muscle, which takes up creatine 
against a considerable gradient. However, creatine transport in hepatocytes occurs in the 
opposite direction and may require a unique transporter. 
A.1.6. Creatine Synthesis and Homocysteine 
Creatine synthesis accounts for approximately 40% of all S-adenosylmethionine-derived 
methyl groups (Stead et al., 2006). This, in turn, implies that it is responsible for the 
production of about 40% of the body's homocysteine. Elevated plasma homocysteine has 
been implicated as a risk-factor for a number of chronic illnesses, including 
cardiovascular disease (Stampfer et al., 1992), Alzheimer's disease (Seshadri et al., 2002) 
and fractures (van Meurs et al., 2004). There is, therefore, considerable interest in ways 
of reducing plasma homocysteine levels. Given that we have shown that dietary creatine 
down-regulates endogenous creatine synthesis, it was important to determine whether 
dietary creatine could decrease plasma homocysteine levels. We, therefore, measured 
plasma homocysteine in rats that had been fed a diet containing 0.4% creatine for 2 weeks 
(Stead et al., 2001). Figure A.4 shows that plasma homocysteine decreased by 
approximately 25%. There was no effect on methionine levels. 
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Figure A.4. Effect of dietary GAA and creatine supplementation on total plasma 
homocysteine and methionine levels. Rats were fed the diets for 2 weeks. From Stead et 
al. (2001), with permission. Abbreviation: GAA, guanidinoacetate. 
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Does dietary creatine decrease plasma homocysteine in humans? Certainly, there is 
evidence that it down-regulates guanidinoacetate production as the plasma concentration 
of this compound decreases in subjects who ingested creatine (Derave et al., 2004). Two 
groups have examined plasma homocysteine with discordant results. Steenge et al. (2001) 
found no decrease in plasma homocysteine in subjects who ingested 3 g creatine 
monohydrate/day for 61 days. On the other hand, Korzun (2004) found a 10% decrease in 
subjects who, each day, ingested an amount of creatine equal to twice their daily 
creatinine excretion for 28 weeks. We consider it likely that the decrease in homocysteine 
that we observed in rats also occurs in humans although its magnitude may be somewhat 
less. 
A.1.7. Perspective 
As the great bulk of the body's total creatine is found in muscle, attention has primarily 
centered on its function in this tissue. However, the fact that children with inborn errors in 
creatine synthesis or transport present with profound neurological impairments obliges us 
to focus both on how the brain acquires its creatine as well as its function in this organ. 
The occurrence of the neurological symptoms implies that dietary creatine is insufficient 
in these children. However, the almost complete absence of brain creatine is somewhat 
puzzling since infant formulas that are based on cow's milk contain substantial quantities 
of creatine. However, our own analyses show that soy-based formulas are devoid of 
creatine. It is possible, therefore, that these children's diet may play some role in the 
severity of their symptoms. The fact that creatine supplements are effective in restoring 
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brain creatine in these children indicates that the brain can take up blood-borne creatine. 
Nevertheless, both AGAT and GAMT have been reported to be ubiquitously located, in 
neuronal and glial cells, throughout the rat brain (Braissant et al., 2001). The possible role 
of brain creatine synthesis, vis-à-vis creatine uptake from the circulation, needs to be 
clarified. 
What role(s) might creatine play in the brain? At the moment, we have no reason not to 
suppose that the traditional roles of creatine phosphate and creatine kinase are paramount. 
The brain has a very high rate of oxygen consumption; the adult human brain weighs less 
than 1% of body weight but accounts for about 10% of the total oxygen consumption 
(Burton, 1966). In addition, individual rapidly firing neurons have very high energy 
requirements. 
An intriguing study from Australia examined the effect of creatine supplementation on 
performance in a number of cognitive tests (Rae et al., 2003). The subjects, students from 
the University of Sydney, were either vegetarians or vegans because it was reasoned that 
their creatine status might be impaired due to little or no dietary creatine ingestion. A 
double-blind, placebo-controlled, cross-over trial was carried out in which subjects 
ingested a daily dose of either 5 g of creatine monohydrate or placebo for 6 weeks, Then, 
after a 6-week wash-out period, the doses were reversed. A number of cognitive tests that 
require speed of processing were administered at the beginning and after each 6-week 
period. Creatine ingestion resulted in remarkably improved performance in these tests. 
This remarkable result emphasizes the importance of creatine in non-muscle tissues and 
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suggests that brain creatine acquisition and function is an important field for future 
research. 
 
A.2. SUMMARY 
The text-book view of the role of the creatine/creatine phosphate system as an energy 
buffer has been expanded to include functions such as energy shuttling, proton buffering 
and regulating cytosolic ADP levels. There is continuous need for creatine replacement 
due to creatinine formation. Replacement involves a combination of diet and de novo 
synthesis. Creatine synthesis makes very significant demands on amino acid metabolism, 
in particular that of glycine, arginine and methionine. It uses about 40% of all methyl 
groups transferred from S-adenosylmethionine. Although the traditional view of the 
function of the creatine/creatine phosphate system is largely concerned with its role in 
skeletal and cardiac muscle, recent work obliges us to take a broader view. In particular, 
its role in the brain is brought into sharp focus by the neurological symptoms displayed 
by children suffering from inborn errors of creatine synthesis and transport, as well as by 
suggestions that brain creatine status may play a role in cognitive performance in adults. 
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APPENDIX B 
 
MATERIALS AND METHODS 
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B.1. CHEMICALS 
Only chemicals of the highest quality available were used in the following experiments. 
All chemicals were purchased from Sigma (Oakville, ON, Canada), except where 
mentioned in the text. 
 
B.2. ANIMAL HANDLING 
Male Sprague-Dawley rats weighing between 200-300g were purchased from Memorial 
University of Newfoundland’s breeding colony and were exposed to a 12-hour light: 12-
hour dark cycle.  The light cycle commenced at 0800 h.  All experiments were performed 
during the light cycle.  Rats were fed ad libitum either laboratory chow, AIN-93 growth 
diet, or 0.4% creatine-supplemented AIN-93 growth diet.  All rats had free access to 
water.  All procedures were conducted in accordance with the guidelines and principles of 
the Canadian Council on Animal Care and were approved by Memorial University of 
Newfoundland’s Institutional Animal Care Committee. 
 
B.2.1. Urine and Feces Collection 
Urine and feces were collected from animals placed on the recommended AIN-93G diet 
for 24 hours prior to sacrifice.  Urine and feces were collected approximately every 2 
hours (except overnight it was left at room temp for about 8 hours) and frozen at -20C 
until analysis. 
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B.3. EXPERIMENTAL DIETS 
When animals were fed purified diets instead of laboratory chow, the diets were based 
upon the American Institute of Nutrition AIN-93G diet for growth.  Prior to the initiation 
of each experimental period, animals were allowed to become accustomed to the AIN-
93G powdered diet for a period of 3 days.  Some experiments involved the feeding of a 
0.4% creatine diet for a period of 2 weeks.  When creatine was fed, an equivalent mass of 
cornstarch was omitted.  The control diet was the recommended AIN-93G diet (20% 
casein).  For experimental diet composition, refer to Table B-1.  
 
B.4. TISSUE PREPARATION 
Animals were anaesthetized with 65 mg/kg sodium pentobarbital (i.p.).  Following a 
midline abdominal incision and opening of the abdominal cavity, the renal vein was 
cleaned and blood flow was measured using a T206 small animal blood flow meter by 
Transonic Systems Inc. (Ithaca, NY, USA).  Arterial and venous blood was taken across 
the kidney.  Kidneys were removed and immediately placed in ice-cold 50 mM potassium 
phosphate buffer (pH 7.4), except for a small sample which was retained for RT-PCR 
analysis. 
 
For infusion experiments, before opening of the abdominal cavity, the femoral vein was 
cleaned to allow delivery of the 0.8 mL prime injection and the jugular vein was 
cannulated with PE50 tubing to allow delivery of infusate.  A restrainer was placed in the 
animal’s mouth to prevent suffocation by the tongue.  Once the abdominal cavity was 
opened and the T206 probe placed on the renal vein, the prime was given and the infusion
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Table B.1: Experimental diet composition.  All quantities are listed as g/kg diet.  Diet conditions are written in the text.  
Vitamin Mix and Mineral Mix were purchased from MP Biomedicals (Irving, California, USA). 
Component 
Amount in g/kg 
 
  20% Protein 0.4% Creatine 
Cornstarch 397.486 393.486 
Casein 200.000 200.000 
Dextrinized Cornstarch 132.000 132.000 
Sucrose 100.000 100.000 
Soybean Oil 70.000 70.000 
Alphacel 50.000 50.000 
Mineral Mix 35.000 35.000 
Vitamin Mix 10.000 10.000 
L-cystine 3.000 3.000 
Choline Bitartrate 2.500 2.500 
t-Butylhydroquinone 0.014 0.014 
Creatine 0.000 4.000 
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pump was set to deliver 0.037 mL/minute into the jugular vein for 20 minutes.  Blood 
flow was measured during the entire 20 minute infusion.  After infusion, both arterial and 
renal venous blood was sampled.  For prime and infusate concentrations, refer to Table 
B-2. 
 
B.4.1. Plasma Preparation 
Arterial and renal venous blood samples were centrifuged for 10 minutes at 6000 x g for 
plasma separation.  Plasma samples were frozen at -20C for later analyses. 
 
B.4.2. Kidney Preparation 
Upon removal, kidneys were immediately placed in 50 mM potassium phosphate buffer 
as previously described (Section B.4).  After being rinsed of blood, kidneys were diluted 
4 mL phosphate buffer/g kidney, chopped with scissors and homogenized with a Polytron 
homogenizer (Brinkman Instruments, Toronto, ON, Canada) for 25 seconds at 50% 
output.  The homogenate was diluted 19:1 vol/vol with phosphate buffer to prepare a 1% 
kidney homogenate for AGAT analysis, as described in Section B.6.1.  
 
B.5. PLASMA ANALYSES 
Frozen plasma samples were prepared as described above and used for all analyses.  To 
calculate arteriovenous (A-V) differences, analyses were performed on both the arterial 
and renal venous plasma samples and the values obtained for renal venous samples were 
subtracted from those values obtained for arterial samples.  A positive value 
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Table B.2: Prime and infusate concentrations.  Infusion conditions are found in 
Section B.4.  All solutions were made isotonic with sodium chloride.  0.9% sodium 
chloride served as a control. 
Amino Acid Prime Infusate 
Glycine 200 mM 60 mM 
Arginine 200 mM 60 mM 
Citrulline 100 mM 30 mM 
Alanine 200 mM 60 mM 
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for an A-V difference is indicative of an uptake of the given metabolite by the kidney 
while a negative value for an A-V difference would indicate that there was an output of 
the given metabolite by the kidney.  If the A-V difference is zero, this would imply that 
the kidney does not take-up nor release the given metabolite unless the uptake rate is the 
same as the output rate. 
 
B.5.1. Plasma Guanidinoacetate Analysis 
Plasma was diluted  3:1 vol/vol with PBS (Dulbecco’s phosphate buffered saline, 
Invitrogen Canada Inc., Burlington, Ontario, Canada) and placed in a Centricon 3000 
molecular weight cutoff spin column (Millipore, Barrerica, Massachusetts, USA) to 
remove large proteins.  The spin columns were centrifuged at 10 000 x g for 30 minutes.  
Filtered plasma was used for GAA analysis via HPLC according to the method of 
Carducci et al. (2001).  Plasma samples were derivatized with benzoin under basic 
conditions at 100ºC for 15 minutes, neutralized and loaded onto a Hypersil ODS 5 µm 
150 mm x 4.6 mm C18 reverse-phase HPLC column.  Buffer A consisted of 20 mM 
sodium acetate, pH 7.35 and Buffer B was 20% vol/vol 100 mM sodium acetate buffer, 
pH 7.35 and 80% vol/vol methanol.  Both solutions were filtered through a 0.45 µm 
Millipore filter (Millipore, Barrerica, Massachusetts, USA) prior to use.  Separation of 
GAA was obtained at approximately 22 minutes using a flow rate of 0.8 mL/minute under 
the following gradient conditions: a linear increase in Buffer B from 40% to 70% over 15 
minutes, maintained constant at 70% for 10 minutes, increased to 100% over 5 minutes, 
maintained at 100% for 5 minutes, decreased to 40% over 1 minute, and maintained at 
40% for 9 minutes.  The column was maintained at 38ºC.  Excitation at 325 nm and 
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emission detection at 435 nm allowed fluorescence detection of the benzoin-derivatized 
guanidino compounds.  An example chromatogram for standards and plasma samples is 
shown in Figure B-1.  The peaks obtained before 3.5 minutes and at approximately 23.5 
minutes are common to all chromatograms regardless of the sample being derivatized.  A 
standard curve for GAA is shown in Figure B-2.   
 
B.5.2. Plasma Creatine Analysis 
Before creatine analysis, plasma was deproteinized by adding 50% vol/vol 0.6 M 
perchloric acid, kept on ice for 20 minutes, and centrifuged at 20 000 x g for 5 minutes to 
sediment proteins.  To 1.5 mL supernatant, 25 µL 50% potassium carbonate, and 20 µL 
universal indicator were added before neutralization with 20% potassium hydroxide.  The 
deproteinized, neutralized plasma was used for the creatine assay following the 
spectrophotometric method as described by Lowry & Passonneau [1972].  The reaction 
mixture consisted of imidazole cocktail, pH 8.0 (50 mM imidazole, 5 mM magnesium 
chloride, 30 mM potassium chloride), 0.17 mM NADH, 0.2 mM PEP, 1 mM ATP, 
pyruvate kinase (rabbit muscle), 5 µg/mL (0.75 U/mL), lactate dehydrogenase (beef 
heart), 1 µg/mL (0.2 U/mL), and 0.1 mL of neutralized plasma to a final volume of 3.0 
mL.  The optical density (OD) was read at 340 nm every 2 minutes until steady (about 10 
minutes).  The reaction was started by the addition of 5 µL creatine kinase (rabbit 
muscle), 10 mg/mL (Roche, Quebec, Canada).  The OD was read every 2 minutes until 
steady and the difference in OD (from before the creatine kinase was added until it 
leveled out) was used to calculate the amount of creatine present in the sample as  
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A       B 
 
Figure B.1: Sample chromatogram of GAA as measured via HPLC.  The peak at 
21.7 minutes corresponds to GAA.  A. Known standard derivatized with benzoin.  B.  
Plasma sample derivatized with benzoin.  See text for preparation, HPLC apparatus, and 
run conditions (Section B.5.1). 
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Figure B.2: Standard curve of GAA detection via HPLC.  Linearity was shown by 
derivatization of known concentrations of GAA with benzoin as described in Section 
B.5.1.  Areas obtained for the plasma samples were within this linear range. 
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compared to a known standard concentration.  A creatine standard curve is shown in 
Figure B-3. 
 
B.5.3. Plasma Creatinine Analysis 
Plasma creatinine was determined in one of three ways.  First, a creatinine kit from Sigma 
Diagnostics was used, procedure number 555.  The Sigma kit became discontinued so 
samples were sent to Dr. Edward Randell who determined creatinine levels using a 
Synchron LX System (Beckman Coulter Inc., Buckinghamshire, UK).  Finally, another 
creatinine assay kit (500701) became available from Cayman Chemical (Michigan, USA).  
All kits/methods employed the Jaffé reaction [Jaffé, 1886].  When creatinine is added to a 
mixture of picric acid and subjected to alkali conditions, a creatinine-picrate complex 
forms which is red in color and can be measured at 495 nm.  A standard curve for 
creatinine via the Cayman Chemical kit number 500701 is shown in Figure B-4.  
 
B.5.4. Plasma Amino Acid Analysis 
For amino acid analysis, plasma samples were deproteinized by mixing 200 µL plasma, 
200 µL internal standard (norleucine), and 1.0 mL 5% trifluoroacetic acid in methanol.  
Samples were frozen in liquid nitrogen and placed on a freeze-dryer overnight.  Dried 
plasma samples were used for amino acid analysis via HPLC according to a modified 
method by Bidlingmeyer et al. [1984].  Plasma samples were derivatized with phenyl 
isothiocyanate (PITC) under basic conditions (10% triethanolamine (TEA), 70% 
methanol and 10% PITC) for 35 minutes at room temperature, frozen in liquid nitrogen  
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Figure B.3:  
Standard curve of creatine detection via spectrophotometry.  Linearity was shown by 
spectrophotometric detection of known concentrations of creatine at 340 nm as described 
in Section B.5.2.  Changes in optical density for each of the samples were within this 
linear range.  
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Figure B.4:  Standard curve of creatinine detection via Cayman Chemical kit.  
Linearity was shown by spectrophotometric detection of known concentrations of 
creatinine at 495 nm as described in Section B.5.3.  Changes in optical density for each of 
the samples were within this linear range.  
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and placed on a freeze dryer overnight.  Dried amino acids were resuspended in 2.65 mM 
sodium phosphate (pH 7.4) in 5% acetonitrile and loaded onto a Waters Pico-Tag® 3.9 x 
300 mm C18 column (Millipore Corporation, Waters Chromatography Division, Milford, 
Massachusetts).  Buffer A consisted of 70 mM sodium acetate in 2.5% acetonitrile, pH 
6.55, and Buffer B was 45% vol/vol acetonitrile, 15% vol/vol methanol.  All solutions 
and samples were filtered through a 0.45 um Millipore filter (Millipore, Barrerica, 
Massachusetts, USA) prior to use.  Separations of various amino acids were obtained 
using a flow rate of 1.0 mL/min under the following gradient conditions: a hyperbolic 
increase (curve 11) in Buffer B from 0% to 3% over 13.5 minutes, increased to 6% over 
10 minutes (curve 8), increased to 9% over 6 minutes (curve 5), a linear increase to 34% 
over 20 minutes, maintained at 34% for 12 minutes, increased linearly to 100% over 30 
seconds, maintained at 100% for 12 minutes, decreased to 0% over 30 seconds, and 
maintained at 0% for 12 minutes.  The column was maintained at 46ºC and the samples 
were stored at 4ºC prior to loading.  Detection of the various amino acids occurred at 254 
nm using a Waters Lambda Max LC Spectrophotometer model 481 (Millipore 
Corporation, Waters Chromatography Division, Milford, Massachusetts).  An example 
chromatogram for standards and plasma samples is shown in Figure B.5.  A standard 
curve for each measured amino acid is shown in Figure B.6. 
 
B.6. KIDNEY ANALYSES 
All analyses were performed on kidney samples prepared as previously described 
(Section B.4.2). 
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Figure B.5:  Sample chromatograms of amino acids as measured via HPLC.  Glycine 
separates at 9 minutes, citrulline at 14, alanine at 15.8, arginine at 17.6, methionine at 
47.7, norleucine (internal standard) at 56.7 and ornithine at 60.7 minutes.  A. Known 
standards derivatized with PITC.  B.  Plasma sample derivatized with PITC.  See text for 
preparation, HPLC apparatus, and run conditions (Section B.5.4). 
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Figure B.6:  Amino acid standard curves.  Linearity was shown by derivatization of 
known concentrations of amino acids with PITC as described in Section B.5.4.  Areas 
obtained for the plasma samples were within these linear ranges.  A.  Glycine standard 
curve.  B.  Citrulline standard curve.  C.  Alanine standard curve.  D.  Arginine standard 
curve.  E.  Methionine standard curve.  F.  Ornithine standard curve. 
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B.6.1. L-Arginine:Glycine Amidinotransferase  (AGAT) Activity 
L-Arginine:glycine amidinotransferase (AGAT) was assayed in the 1% kidney 
homogenate (prepared as described previously; Section B.4.2) using a modified method 
of Van Pilsum et al. [1970], in which ornithine is detected by ninhydrin.  The reaction 
mixture consisted of 100 mM potassium phosphate (pH 7.4) with 33 mM sodium fluoride 
(an arginase inhibitor), and 30 mM L-arginine and 45 mM glycine, as appropriate.  
Blanks for the assay involved omitting arginine and glycine separately and concurrently 
from the potassium phosphate-sodium fluoride reaction mixture.  0.5 mL of the 
appropriate incubation mixture was added to each flask and maintained at 37ºC in a 
shaking water bath (Precision Scientific, Winchester, Virginia, USA).  To start the 
reaction, 0.5 mL of the 1% kidney homogenate was added to each flask and incubated at 
37ºC for 60 minutes.  The reaction was terminated by the addition of 1.5 mL 0.6 M 
perchloric acid (PCA).  Tissue blanks for 0 time incubations had PCA added before the 
addition of homogenate.  After addition of PCA, a portion of the resulting mixture was 
added to a microfuge tube and centrifuged at 10 000 x g for 5 minutes to sediment the 
precipitated proteins.  To assay for ornithine, 0.5 mL of the resulting supernatant was 
added to 1.5 mL of the ninhydrin color reagent (6 grams of ninhydrin in 100 mL of 
ethylene glycol monomethyl ether) and incubated at 100ºC for 15 minutes.  Tubes were 
cooled to room temperature and the optical density recorded at 505 nm.  The blank for 
this assay consisted of 100 µL water, 300 µL PCA and 100 µL of the potassium 
phosphate-sodium fluoride buffer incubated with 1.5 mL of the ninhydrin color reagent 
under the same assay conditions.  To determine the amount of ornithine produced by 
AGAT, the optical density of each of the blanks (arginine alone, glycine alone, and the 
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colorimetric blank) was subtracted from the optical density of the arginine-glycine 
incubation and compared with the optical density of a known concentration of ornithine. 
AGAT activity was shown to be directly proportional to the amount of kidney in the 
incubation mixture and to the incubation time (Figure B-7).  Also, the optical density 
values from the assay were all within the linear portion of the ornithine standard curve 
(Figure B-8). 
 
B.6.2. RT-PCR Analysis of L-Arginine:Glycine Amidinotransferase (AGAT) 
mRNA 
RNA was prepared from the kidney samples using a rapid guanidinium thiocyanate 
method as described by Chomczynski & Sacchi [1987].  RT-PCR analysis of AGAT 
mRNA was performed by Dr. Shobhitha Ratnam using a one-step reverse transcription kit 
from Qiagen (Mississauga, Ontario, Canada).  2 µg of RNA was reverse transcribed for 
30 minutes at 50ºC and denatured at 95ºC for 10 minutes.  PCR amplification consisted of 
21 cycles of 3 steps: denaturation (1 minute at 95ºC), annealing (1 minute 30 seconds at 
56ºC), and elongation (2 minutes at 72ºC).  An upstream primer (5’-
ATGCTACGGGTGCGGTGT-3’) and a downstream primer (5’-
ATAATTGACCTGTATGCGCG-3’) were designed from a rat kidney AGAT sequence 
(Genbank #U07971).  The primers were used to amplify a 599-basepair (bp) PCR 
fragment.  A 768-bp fragment of the rat ß-actin gene was coamplified using amplimer set 
primers from BD Biosciences Clontec (Palo Alto, California, USA).  PCR products were 
separated on a 1.5% agarose gel.  Ethidium bromide stains were visualized by UV 
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Figure B.7:  Dependence of L-arginine:glycine amidinotransferase activity on 
amount of kidney and incubation time.  Linearity with respect to protein was 
determined using a 60 minute incubation.  The time curve was obtained using 5 mg of 
kidney.     
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Figure B.8:  
Standard curve of ornithine detection by 6% ninhydrin.  Linearity was shown by 
spectrophotometric detection of known concentrations of ornithine at 505 nm as 
described in Section B.6.1.  Changes in optical density for each of the samples were 
within this linear range.  
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illumination and quantified by densitometry.   
 
B.7. URINE ANALYSIS 
Urine creatine levels were measured in previously frozen urine samples (collected as 
previously described; Section B.2.2) using a spectrophotometric method as described by 
Lowry & Passonneau [1972] (see Section B.5.2).  Urine creatinine levels were measured 
by Dr. Edward Randell as previously described for plasma (Section B.5.3). 
 
B.8. INFANT FORMULA ANALYSES 
Eight different types of infant formula were purchased from various Wal-Mart stores (St. 
John’s, Newfoundland and Labrador, Canada).  Six different lot numbers of each type 
were purchased, except for Isomil for which only five different lot numbers were 
available.  For details on each type of formula see Table B-3. 
 
A fraction of each infant formula was centrifuged at 150 000 x g for 60 minutes to 
separate the aqueous phase.  The aqueous phase was taken for creatinine analysis using a 
kit from Cayman Chemical (see Section B.5.3 for kit details). 
 
A separate fraction of the various formulas was deproteinized and neutralized as 
described for plasma in Section B.5.2.  The deproteinized, neutralized formula was used 
for creatine and GAA determination as described in Sections B.5.2 and B.5.1, 
respectively.   
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Table B.3: Infant Formula Information.  There were 6 different lot numbers purchased for each formula type, 
except for Similac Advance Isomil (only 5 lot numbers were available).  Preparation and analyses are explained in the 
text.  
Formula Name 
Number of 
Samples 
Type of Formula Mixing Directions 
Similac Advance Concentrate 6 
Cow's milk-based, Iron 
fortified 
Equal amounts of formula and cooled, 
previously boiled, water 
Similac Advance Ready to Use 6 
Cow's milk-based, Iron 
fortified Do not dilute with water 
Similac Advance Isomil 5 Soy-based, Lactose-free Do not dilute with water 
Nestle Goodstart 6 
Cow's milk-based, Iron 
fortified 
Equal amounts of formula and cooled, 
previously boiled, water 
Nestle Alsoy 1 6 
Soy-based, Iron fortified, 
lactose-free 
Equal amounts of formula and cooled, 
previously boiled, water 
Enfalac with Iron 6 
Cow's milk-based, Iron 
fortified Do not dilute with water 
Enfamil A+ 6 
Cow's milk-based, DHA, 
ARA and iron fortified 
Equal amounts of formula and cooled, 
previously boiled, water 
Enfalac Lactofree 6 Soy-based, Lactose-free 
Equal amounts of formula and cooled, 
previously boiled, water 
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B.9. HUMAN MILK COLLECTION AND ANALYSIS 
Twenty healthy subjects were studied after the protocol had been approved by Memorial 
University of Newfoundland Human Investigation Committee and the Research Approval 
Committee for The Health Care Corporation of St. John’s.  Informed written consent was 
obtained before collecting 5 mL of milk at either 1-2 weeks or 5-6 weeks postpartum (10 
subjects for each time-period).  Milk was collected at the Janeway Children’s Health and 
Rehabilitation Centre’s breastfeeding clinic using an electronic breast pump.  2 mL of 
blood was also collected from the subjects by nurses at the Janeway Children’s Health 
and Rehabilitation Centre Blood Collection at these times (1-2 weeks and 5-6 weeks 
postpartum; consent and time permitting) to obtain about 1 mL of plasma by 
centrifugation as previously described in Section B.4.1.  Milk samples were centrifuged 
at 100 000 x g for 60 minutes to separate the aqueous phase.  Both the aqueous phase of 
the milk samples and the plasma samples were analyzed for GAA, creatine and creatinine 
as described in Section B.5.1, Section B.5.2 and Section B.5.3, respectively. 
 
B.10. HUMAN UMBILICAL CORD BLOOD COLLECTION AND ANALYSIS 
Eighteen healthy subjects were studied after the protocol had been approved by Memorial 
University of Newfoundland Human Investigation Committee and the Research Approval 
Committee for The Health Care Corporation of St. John’s.  Informed written consent was 
obtained before collecting 2 mL of arterial and 2 mL of venous umbilical cord blood from 
discarded placentas after elective Caesarian birth.  2 mL of arterial blood was obtained 
from each mother from samples already drawn and stored for other purposes at the blood 
bank at the Health Science Centre.  Blood samples were centrifuged as described in 
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Section B.4.1 to obtain about 1 mL of plasma.  Plasma samples were analyzed for GAA, 
creatine and creatinine as described in Section B.5.1, Section B.5.2 and Section B.5.3, 
respectively. 
 
B.11. LACTATING RAT STUDIES 
HPLC-grade methanol, Hypercarb HPLC columns and Scintiverse E were purchased 
from Fisher Scientific (Ottawa, ON, Canada).  
14
C-creatine (creatine [4-
14
C], with a 
specific radioactivity of 1.96 GBq·mmol
-1
) was obtained from American Radiolabeled 
Chemicals (St. Louis, MO, USA).  Oxytocin was obtained from Hospira Healthcare 
Corporation (Montréal, QC, Canada).  Ion exchange resin (AG 50W-X8 200-400 mesh) 
was obtained from Biorad (Mississauga, ON, Canada).   
 
Lactating Sprague-Dawley rats (337.4 ± 16.5 g) with their pups were provided by 
Memorial University’s breeding colony.  At day 10 postpartum, each litter was 
standardized to 8 pups; extra pups were randomly selected and killed by inhalation of 
halothane (Isoflo, Abbott Laboratories, Saint-Laurent, QC, Canada).  Each litter was 
individually housed on a 12:12-hour light-dark cycle and consumed Purina Rat Diet 5012 
ad libitum.  Milk, blood and various tissue samplings were conducted 14 days after 
parturition which coincides with the peak of lactation [Rodgers, 1995].  When required, 
size-matched virgin females were used as controls.  One hour prior to milk collection, the 
pups were removed from the dam who was anaesthetized with an i.p. injection of 6 mg of 
sodium pentobarbital per 100 g body weight and injected i.p. with oxytocin (4 IU·kg body 
wt
-1
) to stimulate milk release.  The nipples and surrounding fur were then thoroughly 
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cleaned by rinsing with distilled water.  Milk was collected using a vacuum milking 
system adapted from Rodgers [1995].  Typically, 3-4 mL of milk were collected from 
each dam in less than 10 minutes.  The collected milk was immediately frozen in liquid 
nitrogen and kept at -80ºC until further analysis.  Immediately following milk collection, 
arterial blood was drawn from the dam’s abdominal aorta into a heparinised syringe and 
centrifuged at 6000 X g at 4ºC for 10 minutes.  Plasma was removed and stored at -80ºC 
until further analysis. 
 
B.11.1. In vivo GAA production, milk and plasma creatine concentration, and renal 
AGAT activity  
The renal GAA output was measured in plasma from lactating and virgin rats (n=7) as 
described previously in Section B.4 and Section B.5.1.  Kidney samples were 
immediately freeze-clamped and stored at -80°C.  AGAT was assayed in kidney samples 
that were frozen for less than a week, as previously described in Section B.6.1.  
 
B.11.2. Hepatic GAMT activity 
GAMT was measured on fresh liver samples using the method of Ogawa et al. [1983], 
except that creatine production was quantified by HPLC [Buchberger & Ferdig, 2004]. 
Fresh rat liver was homogenized in 4 volumes of a buffer solution consisting of 0.25 M 
sucrose, 10 mM HEPES and 1 mM EDTA.  Homogenates were centrifuged at 100,000 x 
g at 4ºC for 1 hour and supernatant assayed for GAMT activity.  Basically, the 
supernatant was incubated at 37ºC for 10 minutes in 35 mM Tris buffer (pH 7.4), 7 mM 
2-mercaptoethanol and 50 µM S-adenosylmethionine.  The assay was started by addition 
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of 0.2 mM GAA.  Blanks for the assay did not contain GAA.  After incubation, the assay 
was stopped by addition of 75 µL of 15% (w/v) TCA.  The assay mixture was 
immediately neutralized by the addition of 72 µL of 1 M Tris (pH 7.4) and centrifuged at 
10,000 x g for 5 minutes at room temperature to pellet the precipitated protein.  
Supernatant samples were derivatized by mixing 400 uL of the ultra-filtrated sample 
solution with 300 uL of 1.3 M potassium hydroxide and 150 uL of 0.9% aqueous 
ninhydrin solution.  The samples were allowed to sit for 15 minutes at room temperature 
and then 100 uL of 5% ascorbic acid and 100 uL of 5 M phosphoric acid were added.  
Ascorbic acid was added to the reaction solution prior to the acidification with phosphoric 
acid to act as an antioxidant and minimize oxidative decomposition.  The closed vials 
were then incubated at 90ºC for 30 minutes.  Samples were allowed to cool at room 
temperature for 5 minutes, filtered, and 50 uL was injected into the HPLC column 
(Hypercarb YMC 150 mm X 4.6 mm from Fisher Scientific, Ottawa, ON, Canada).  The 
mobile phases consisted of 50 mM formic acid (Buffer A) and 100% methanol (Buffer 
B).  At time 0, Buffer A was 95% and Buffer B was 5%.  Over 15 minutes Buffer A 
changed to 10% and Buffer B, 90%.  This remained constant for 5 minutes.  Over 2 
minutes Buffer A went back to 95% and Buffer B, 5%.  This was maintained for 10 
minutes.  The flow rate was 1 mL per minute.  Excitation was at 390 nm and emission 
was at 470 nm.  Dependence of GAMT activity on both the amount of protein and on 
time is shown in Figure B.9.  Total protein was measured using the Biuret method.   
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Figure B.9:  Dependence of guanidinoacetate methyltransferase activity on amount 
of protein and incubation time.  Linearity with respect to protein was determined using 
a 20 minute incubation.  The time curve was obtained using 5 mg of liver.  Both curves 
were produced from work completed by Dr. Simon LaMarre.  
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B.11.3. Determination of creatine specific radioactivity  
This involved the determination of both the creatine concentration and its associated 
radioactivity.  Lactating rats were administered 740.9 kBq 
14
C-creatine (prepared in 0.5 
mL saline) via the caudal vein on day 11 postpartum and immediately returned to their 
pups.  After a 3 day equilibration period, milk and blood samples were drawn.   
 
We used a modification of the HPLC method of Gu & Lim [1990] to measure the creatine 
concentration; the eluate from the HPLC column was collected by fraction collection and 
the creatine peak counted in a liquid scintillation spectrometer.  Milk and plasma samples 
(1 mL) were deproteinized by the addition of 100 µL of ice-cold trifluoroacetic acid 
(TFA), placed on ice for 10 minutes and the precipitated protein pelleted at 10,000 X g 
for 10 minutes at 4 °C.  The supernatant was immediately applied to a Bond-Elut C18 
solid-phase extraction cartridge (100 mg, 1 mL; Varian Inc., Paulo Alto, CA, USA) and 
the eluate collected.  The cartridge was washed with 1 mL dH2O and eluate was again 
collected.  The pooled eluate was applied to a disposable chromatography column 
containing 2 mL of cation-exchange resin using sodium as a counterion.  It was followed 
by two 3 mL water washes and this eluate was discarded.  Creatine bound to the resin was 
eluted with 1 mL of 2 M ammonium hydroxide.  This eluate was freeze-dried and 
dissolved in 250 µL of the mobile phase immediately prior to HPLC analysis.  A 100 µL 
volume of the dissolved eluate was injected onto a porous graphitized carbon column 
(Hypercarb, 100.0 x 4.6 mm).  The column was eluted isocratically with 1% TFA and 2% 
methanol; the absorbance was monitored at 210 nm.  Fractions were collected every 30 
seconds for 15 minutes.  All fractions were mixed with 10 mL of Scintiverse E and 
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counted for 10 minutes on a LKB 1214 Rackbeta liquid scintillation counter (LKB, 
Gaithersburg, MD, USA).  Creatine eluted at approximately 4 minutes and the 
corresponding fractions were the only ones containing substantial quantities of 
radioactivity.  The creatine concentration was referenced to a set of creatine standards (0 
to 1 mM) that was processed in parallel to the samples (including solid phase extraction 
and ion exchange chromatography).  The creatine specific radioactivity was expressed as 
mBq·nmol
-1
. 
 
B.11.4.  Creatine content of adult tissues and pups 
To determine whether rats’ total creatine pool becomes depleted during lactation, we 
measured the creatine concentration of muscle and brain (2 major pools of creatine) in 
lactating and virgin females (n=4).  Tissues were homogenized in 150 mM sodium 
phosphate (pH 7.4).  Rat pups were killed at days 10, 15, and 20 (n=6) by halothane 
inhalation and each pup was homogenized.  The homogenates were allowed to stand for 
30 minutes at room temperature to allow for the conversion of creatine-phosphate to 
creatine.  The total creatine content was measured by HPLC as described in Section 
B.11.2. and Section B.11.3. and was reported as nmol·g
-1
 for adult tissues and µmol·g
-1
 
for the pups. 
 
B.12. STATISTICAL ANALYSES 
In studies with only two groups, a student’s unpaired t-test was used to determine 
significant differences.  When variances were heterogeneous, the Mann-Whitney U test 
was used.  One-way ANOVA followed by Newman-Keuls post-hoc tests were used in 
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studies involving three or more experimental groups.  Tukey’s post hoc test was used for 
the lactating rat experiments.  A P value of <0.05 was taken as significant. 
 
 
 
 
